US20110195064A1 - Survival predictor for diffuse large b cell lymphoma - Google Patents

Survival predictor for diffuse large b cell lymphoma Download PDF

Info

Publication number
US20110195064A1
US20110195064A1 US12/996,489 US99648909A US2011195064A1 US 20110195064 A1 US20110195064 A1 US 20110195064A1 US 99648909 A US99648909 A US 99648909A US 2011195064 A1 US2011195064 A1 US 2011195064A1
Authority
US
United States
Prior art keywords
stromal
signature
survival
gene expression
signature value
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US12/996,489
Inventor
Lisa Rimsza
Andrew T. Lister
Dennis Weisenburger
Jan Delabie
Erlend B. Smeland
Harald Holte
Stein Kvaloy
Rita M. Braziel
Richard I. Fisher
Pedro Jares
Armando Lopez-Guillermo
Elias Campo Guerri
Elaine S. Jaffe
Georg Lenz
Wyndham H. Wilson
George Wright
Sandeep S. Dave
Louis M. Staudt
Randy D. Gascoyne
Joseph M. Connors
Hans-Konrad Muller-Hermelink
Andreas Rosenwald
German Ott
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
British Columbia Cancer Agency BCCA
Julius Maximilians Universitaet Wuerzburg
Universitat de Barcelona UB
Hospital Clinic de Barcelona
Queen Mary University of London
Oslo Universitetssykehus hf
Arizona Board of Regents of University of Arizona
US Department of Health and Human Services
Oregon Health Science University
University of Nebraska
University of Rochester
Original Assignee
British Columbia Cancer Agency BCCA
Julius Maximilians Universitaet Wuerzburg
Universitat de Barcelona UB
Hospital Clinic de Barcelona
Queen Mary and Westfiled College University of London
Oslo Universitetssykehus hf
Arizona Board of Regents of University of Arizona
US Department of Health and Human Services
Oregon Health Science University
University of Nebraska
University of Rochester
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by British Columbia Cancer Agency BCCA, Julius Maximilians Universitaet Wuerzburg, Universitat de Barcelona UB, Hospital Clinic de Barcelona, Queen Mary and Westfiled College University of London, Oslo Universitetssykehus hf, Arizona Board of Regents of University of Arizona, US Department of Health and Human Services, Oregon Health Science University, University of Nebraska, University of Rochester filed Critical British Columbia Cancer Agency BCCA
Priority to US12/996,489 priority Critical patent/US20110195064A1/en
Assigned to THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES reassignment THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: STAUDT, LOUIS M.
Assigned to OREGON HEALTH & SCIENCE UNIVERSITY, QUEEN MARY AND WESTFIELD COLLEGE, UNIVERSITY OF LONDON, HOSPITAL CLINIC, UNIVERSITAT DE BARCELONA, BRITISH COLOMBIA CANCER AGENCY BRANCH, OSLO UNIVERSITY HOSPITAL HF, BOARD OF REGENTS OF THE UNIVERSITY OF NEBRASKA, JULIUS-MAXIMILIANS-UNIVERSITY OF WUERZBURG, UNIVERSITY OF ROCHESTER, ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA, THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES reassignment OREGON HEALTH & SCIENCE UNIVERSITY ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: DAVE, SANDEEP S., BRAZIEL, RITA M., JAFFE, ELAINE S., WRIGHT, GEORGE, DELABIE, JAN, HOLTE, HARALD, KVALOY, STEIN, SMELAND, ERLEND B., WILSON, WYNDHAM H., MULLER-HERMELINK, HANS-KONRAD, OTT, GERMAN, CONNORS, JOSEPH M., LISTER, ANDREW T., CAMPO GUERRI, ELIAS, GASCOYNE, RANDY D., JARES, PEDRO, LENZ, GEORG, LOPEZ-GUILLERMO, ARMANDO, WEISENBURGER, DENNIS, RIMSZA, LISA, ROSENWALD, ANDREAS, FISHER, RICHARD I.
Publication of US20110195064A1 publication Critical patent/US20110195064A1/en
Assigned to THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES reassignment THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: CHAN, WING C.
Abandoned legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/112—Disease subtyping, staging or classification
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/56—Staging of a disease; Further complications associated with the disease

Definitions

  • the current standard of care for the treatment of diffuse large B cell lymphoma includes anthracycline-based chemotherapy regimens such as CHOP in combination with the administration of the anti-CD20 monoclonal antibody Rituximab.
  • This combination regimen R-CHOP
  • R-CHOP can cure about 60% of patients and has improved the overall survival of DLBCL patients by 10-15% (Coiffier et al., N. Engl. J. Med., 346: 235-42 (2002)). Nonetheless, the molecular basis of response or resistance to this therapy is unknown.
  • DLBCL is a molecularly heterogeneous disease (Staudt et al., Adv. Immunol., 87: 163-208 (2005)), and different molecular subtypes of DLBCL can have very different prognoses following treatment.
  • gene expression profiling has identified two molecular subtypes of DLBCL that are biologically and clinically distinct (Rosenwald et al., N. Engl. J. Med., 346: 1937-47 (2002); Alizadeh et al., Nature, 403: 503-11 (2000)).
  • the germinal center B cell-like (GCB) DLBCL subtype likely arises from normal germinal center B cells, whereas the activated B cell-like (ABC) DLBCL subtype may arise from a post-germinal center B cell that is blocked during plasmacytic differentiation.
  • GCB DLBCLs have recurrent t(14,18) translocations
  • ABC DLBCLs have recurrent trisomy 3 and deletion of the INK4a/ARF locus as well as constitutive activation of the anti-apoptotic NF-kB signalling pathway (Rosenwald et al., N. Engl. J.
  • a separate analytical approach identified four gene expression signatures that reflect distinct DLBCL tumor attributes and that were associated with distinct survival profiles in CHOP-treated DLBCL patients (Rosenwald et al., N. Engl. J. Med., 346: 1937-47 (2002)).
  • a “germinal center B cell” (GCB) signature was associated with a favorable prognosis and paralleled the distinction between ABC and GCB DLBCL.
  • the “proliferation” signature was associated with an adverse prognosis and included MYC and its target genes.
  • the “MHC class II” signature was silenced in the malignant cells in a subset of DLBCL cases, an event that was associated with inferior survival (Rosenwald et al., N. Engl. J.
  • a fourth prognostic signature termed “lymph node” signature was associated with favorable prognosis and included components of the extracellular matrix, suggesting that it reflects the nature of the tumor-infiltrating non-malignant cells. These signatures predicted survival in a statistically independent fashion, indicating that multiple biological variables dictate the response to CHOP chemotherapy in DLBCL.
  • the invention provides methods and arrays related to a gene expression-based survival predictor for DLBCL patients, including patients treated with the current standard of care, which includes chemotherapy and the administration of Rituximab.
  • the invention provides a method of predicting the survival outcome of a subject suffering from diffuse large B cell lymphoma (DLBCL) that includes obtaining a gene expression profile from one or more DLBCL biopsy samples from the subject.
  • the gene expression profile which can be derived from gene expression product isolated from the one or more biopsy samples, includes an expression level for each gene in a germinal center B cell (GCB) gene expression signature and each gene in a stromal-1 gene expression signature. From the gene expression profile, a GCB signature value and a stromal-1 signature value are derived. From these values, a survival predictor score can be calculated using an equation that includes subtracting [(x)*(the GCB signature value)] and subtracting [(y)*(the stromal-1 signature value)]. In the equation, (x) and (y) are scale factors. A lower survival predictor score indicates a more favorable survival outcome, and a higher survival predictor score indicates a less favorable survival outcome for the subject.
  • the invention also provides a method of generating a survival estimate curve for subjects suffering from DLBCL.
  • the method includes obtaining a gene expression profile from one or more DLBCL biopsy samples taken from each member of a plurality of subjects.
  • Each gene expression profile which can be derived from gene expression product isolated from the one or more biopsy samples taken from each subject, includes an expression level for each gene in a GCB expression signature, a stromal-1 gene expression signature, and a stromal-2 gene expression signature.
  • the GCB signature value, the stromal-1 signature value, and the stromal-2 signature value are determined from the subject's gene expression profile, and, for each subject, a survival predictor score is generated.
  • Each subject's survival outcome following treatment for DLBCL is tracked.
  • a survival estimate curve is generated which correlates the probability of the tracked survival outcome with time following treatment for DLBCL and which also correlates the tracked outcome over time with the survival predictor score for the subjects.
  • the invention additionally provides a method of predicting the survival outcome of a subject suffering from DLBCL.
  • the method includes obtaining a gene expression profile from one or more DLBCL biopsy samples from the subject.
  • the gene expression profile which can be derived from gene expression product isolated from the one or more biopsy samples, includes an expression level for each gene in a GCB gene expression signature, each gene in a stromal-1 gene expression signature, and each gene in a stromal-2 gene expression signature.
  • the GCB signature value, the stromal-1 signature value, and the stromal-2 signature value are determined from the gene expression profile.
  • the method then includes calculating a survival predictor score using the equation:
  • survival predictor score A ⁇ [( x )*(the GCB signature value)] ⁇ [( y )*(the stromal-1 signature value)]+[( z )*(the stromal-2 signature value)].
  • A is an offset term
  • (x), (y), and (z) are scale factors.
  • the method further includes calculating the probability of a survival outcome for the subject beyond an amount of time t following treatment for DLBCL, wherein the subject's probability of the survival outcome P(SO) is calculated using the equation:
  • SO 0 (t) is the probability of the survival outcome, which corresponds to the largest time value smaller than t in a survival outcome curve, and wherein (s) is a scale factor.
  • the invention provides a method of evaluating a subject for antiangiogenic therapy of DLBCL.
  • the method includes obtaining a gene expression profile from one or more DLBCL biopsy samples from the subject.
  • the gene expression profile which can be derived from gene expression product isolated from the one or more biopsy samples, includes an expression level for each gene in a stromal-2 signature.
  • the subject's stromal-2 signature value is then derived from the gene expression profile and evaluated to determine whether the subject's stromal-2 signature value is higher or lower than a standard stromal-2 value. If the subject's stromal-2 signature value is higher than the standard stromal-2 value, then antiangiogenic therapy is indicated, and the subject can be treated with antiangiogenic therapy. If the subject's stromal-2 signature value is not higher than the standard stromal-2 value, then antiangiogenic therapy is not indicated.
  • the invention also provides a second method of evaluating a subject for antiangiogenic therapy of DLBCL.
  • the method includes obtaining a gene expression profile from one or more DLBCL biopsy samples from the subject.
  • the gene expression profile which can be derived from gene expression product isolated from the one or more biopsy samples, includes an expression level for each gene in a stromal-1 signature and in a stromal-2 signature.
  • the subject's stromal-1 signature value and stromal-2 signature value are then derived from the gene expression profile.
  • the stromal-1 signature value is subtracted from the stomal-2 signature value to thereby obtain the subject's stromal score.
  • the subject's stromal score is evaluated to determine whether it is higher or lower than a standard stromal score.
  • the subject's stromal score is higher than the standard stromal score, then antiangiogenic therapy is indicated, and the subject can be treated with antiangiogenic therapy. If the subject's stromal score is not higher than the standard stromal-score, then antiangiogenic therapy is not indicated.
  • the invention provides a machine-readable medium containing a digitally encoded GCB signature value, a digitally encoded stromal-1 signature value, a digitally encoded stromal-2 signature, or any combination of the foregoing signature values obtained from a subject suffering from DLBCL.
  • the invention provides a machine-readable medium containing the digitally encoded survival predictor score obtained using a method disclosed herein for predicting the survival outcome of a subject suffering from diffuse large B cell lymphoma (DLBCL).
  • the invention provides a machine-readable medium containing the survival estimate curve obtained using a method disclosed herein for generating a survival estimate curve for subjects suffering from DLBCL.
  • the invention provides a machine-readable medium containing the digitally encoded probability of survival calculated according to a method disclosed herein for predicting the survival outcome (e.g., progression-free survival or overall survival) of a subject suffering from DLBCL.
  • the invention provides a machine-readable medium containing the digitally encoded stromal score generated by a method disclosed herein for evaluating a subject for antiangiogenic therapy of DLBCL.
  • the invention also provides a targeted array comprising at least one probe or at least one set of probes for each gene in a germinal center B cell gene (GCB) expression signature, a stromal-1 gene expression signature, and a stromal-2 gene expression signature.
  • the array can include probes for fewer than 20,000 genes or fewer than 10,000 genes.
  • FIG. 1A is a Kaplan-Meier estimates plot depicting the probability of progression-free-survival versus time (in years) of patients with GCB DLBCL and ABC DLBCL. The plot indicates that GCB patients have a more favorable, i.e., higher probability of progression-free survival rate than ABC patients for at least five years following R-CHOP therapy.
  • FIG. 1B a Kaplan-Meier estimates plot depicting the probability of overall survival versus time (in years) of patients with GCB DLBCL and ABC DLBCL. The plot indicates that GCB patients have a more favorable, i.e., higher probability, of overall survival than ABC patients for at least five years following R-CHOP therapy.
  • FIG. 1C is a series of four Kaplan-Meier estimates plots depicting the probabilities of overall survival versus time (in years) in DLBCL patients. Each of the four plots correlates the probability of overall survival with the lymph node/stromal-1, germinal center B cell, proliferation, or MHC class II gene expression signature, respectively. Moreover, in each plot, the average expression of the signature genes in each biopsy sample was used to rank cases and divide the cohort into quartile groups as indicated.
  • FIG. 2A is a pair of Kaplan-Meier estimates plots depicting the probability of progression-free-survival and the probability of overall survival, as indicated, versus time (in years) among DLBCL patients treated with R-CHOP.
  • Patient samples were ranked according to a bivariate model created using the germinal center B cell (GCB) and stromal-1 signatures and divided into quartile groups.
  • GCB germinal center B cell
  • FIG. 2B is a pair of Kaplan-Meier plots depicting the probability of progression-free-survival and the probability of overall survival, as indicated, versus time (in years) among DLBCL patients treated with R-CHOP.
  • Patient samples were ranked according to a survival predictor score derived from a model incorporating the germinal center B cell, stromal-1, and stromal-2 signatures and divided into quartile groups.
  • FIG. 2C is a series of three Kaplan-Meier estimates plots depicting the probability of overall survival versus time (in years) among R-CHOP treated DLBCL patients in the indicated low, intermediate, or high IPI risk groups.
  • Patient samples were stratified according to the same survival predictor score used in FIG. 2B , except that the first and second quartiles were merged, and the third and fourth quartiles were merged.
  • FIG. 3 depicts the expression levels of the indicated GCB cell, stromal-1, and stromal-2 signature genes in ABC, GCB, and unclassified DLBCL biopsy samples. Relative levels of gene expression are depicted according to the scale shown. Shown at the bottom are the signature averages for each patient. Also shown is the stromal score, which is the component of the survival model contributed by the difference between the stromal-2 and stromal-1 signature averages. The survival predictor score is shown for each patient and was used to order the cases, after grouping into ABC DLBCL, GCB DLBCL, and unclassified categories.
  • FIG. 4A depicts the relative gene expression of stromal-1, stromal-2, and germinal center B cell signatures in CD19+ malignant and CD19 ⁇ non-malignant subpopulations of cells isolated from three biopsy specimens from patients with DLBCL.
  • Stromal-1 and stromal-2 signature genes were more highly expressed in the non-malignant cells, whereas the germinal center B cell signature genes were more highly expressed in the malignant cells.
  • the log 2 ratios of gene expression levels in the CD19 ⁇ subpopulation to those in the CD19+ subpopulations are depicted according to the scale shown.
  • FIG. 4B depicts the results of gene enrichment analysis comparing the stromal-1 gene signature with mesenchyme-1 and mesenchyme-2 signatures (from normal mesenchymal origin cells), with a monocyte signature expressed more highly in normal blood monocytes than in blood B, T, and NK cells, and in a pan-T cell signature expressed more highly in blood T cells than in blood B cells, NK cells, and monocytes. While a relationship was seen between stromal-1 signature and mesenchyme-1, mesenchyme-2, and monocyte signatures, no relationship was observed between the stromal-1 signature and a pan-T cell signature expressed more highly in blood T cells than in blood B cells, NK cells, and monocytes. The relative levels of gene expression are depicted according to the scale shown.
  • FIG. 5A is a Kaplan-Meier estimates plot depicting the probability of overall survival versus time (in years) in DLBCL cases segregated according to SPARC protein expression levels, as indicated.
  • FIG. 5B is a pair of images showing the identification of tumor blood vessels by immunohistochemical analysis of CD34+ endothelial cells in representative DLBCL biopsies having low or high blood vessel density (CD34+ objects/ ⁇ M 2 ), as indicated.
  • FIG. 5C is a plot depicting the correlation between the tumor blood vessel density and the stromal score in analyzed DLBCL biopsies.
  • FIG. 6A is a Kaplan-Meier estimates plot depicting the probability of overall survival versus time (in years) for “LLMPP CHOP” patients with DLBCL following therapy. The plot indicates that in this cohort, patients with GCB DLBCL show significantly superior overall survival compared to patients with ABC DLBCL following CHOP therapy.
  • FIG. 6B is a is a Kaplan-Meier estimates plot depicting depicting the probability of overall survival versus time (in years) for “MMMLNP CHOP” patients with DLBCL following therapy.
  • patients with GCB DLBCL show significantly superior overall survival compared to patients with ABC DLBCL following CHOP therapy.
  • FIG. 7 is a set of four Kaplan-Meier estimates plots depicting the probability of overall survival versus time (in years) in a “MMMLNP CHOP” cohort. Each of the four plots correlates the probability of overall survival with the lymph node/stromal-1, germinal center B cell, proliferation, or MHC class II gene expression signature, respectively. Moreover, in each plot, the average expression of the signature genes in each biopsy sample was used to rank cases and divide the cohort into quartile groups as indicated.
  • FIG. 8A is a Kaplan-Meier estimates plot depicting the probability of overall survival versus time (in years) in a “LLMPP CHOP” cohort, which was divided according to MHC class II signature expression levels. Patients with low MHC class II signature expression have significantly inferior overall survival compared to patients with normal MHC class II expression.
  • FIG. 8B is a Kaplan-Meier estimates plot depicting the probability of overall survival versus time (in years) in a “MMMLNP CHOP” cohort, which was divided according to MHC class II signature expression levels. Patients with low MHC class II signature expression have significantly inferior overall survival compared to patients with normal MHC class II expression.
  • FIG. 8C is a Kaplan-Meier estimates plot depicting the probability of overall survival versus time (in years) in a “LLMPP R-CHOP” cohort, which was divided according to MHC class II signature expression levels. There was no significant difference in the overall survival of patients with low MHC class II signature expression as compared to patients with normal MHC class II expression.
  • FIG. 9A is a pair of Kaplan-Meier estimates plots depicting the probabilities of progression-free survival or overall survival, as indicated, versus time (in years) among patients grouped into quartiles according to a gene expression model consisting of stromal-1 signature, GCB signature, and signature 122 following R-CHOP therapy.
  • FIG. 9B is a pair Kaplan-Meier estimates plots depicting the probabilities of overall survival versus time (in years) among “MMMLNP CHOP” cohort patients grouped into quartiles according to a gene expression model consisting of either stromal-1 signature and GCB signature or stromal-1, GCB signature, and signature 122, as indicated, following CHOP therapy.
  • FIG. 9C is a Kaplan-Meier estimates plot depicting the probabilities of overall survival versus time (in years) among “MMMLNP CHOP” cohort patients grouped into quartiles according to a gene expression model consisting of stromal-1 signature, GCB signature, and stromal-2 signature following CHOP therapy.
  • FIG. 10A is a Kaplan-Meier estimates plot depicting the overall survival among low revised International Prognostic Index (IPI) risk group patients stratified according to the gene expression-based outcome predictor score. After grouping patients into quartiles according to gene expression-based outcome predictor score, quartiles 1 and 2 were merged (Low Model Score), and quartiles 3 and 4 were merged (High Model Score).
  • IPI International Prognostic Index
  • FIG. 10B is a Kaplan-Meier estimates plot depicting the overall survival among intermediate revised International Prognostic Index (IPI) risk group patients stratified according to the gene expression-based outcome predictor. After grouping patients into quartiles according to gene expression-based outcome predictor score, quartiles 1 and 2 were merged (Low Model Score), and quartiles 3 and 4 were merged (High Model Score).
  • IPI International Prognostic Index
  • FIG. 10C is a Kaplan-Meier estimates plot depicting the overall survival among high revised International Prognostic Index (IPI) risk group patients stratified according to the gene expression-based outcome predictor. After grouping patients into quartiles according to gene expression-based outcome predictor score, quartiles 1 and 2 were merged (Low Model Score), and quartiles 3 and 4 were merged (High Model Score).
  • IPI International Prognostic Index
  • FIG. 11 depicts normal mesenchymal-1 and normal mesenchymal-2 signature gene expression in various normal tissues.
  • the invention provides a gene expression-based survival predictor for DLBCL patients, including those patients receiving the current standard of care, R-CHOP.
  • the survival predictor can be used to determine the relative probability of a survival outcome in a specific subject.
  • the survival predictor can also be used to predict; i.e., determine the expected probability that a survival outcome will occur by a defined period following treatment for DLBCL.
  • prognostic information can be very useful to both the patient and the physician.
  • Patients with survival predictor scores that indicate inferior outcome with R-CHOP therapy could be candidates for a different therapeutic regimen, if, for example, they relapse from R-CHOP treatment.
  • the survival predictor can also be used in the design of clinical studies and analysis of clinical data to provide a quantitative survey of the types of DLBCL patients from which clinical data was gathered.
  • the predictor can be used to improve one or more comparisons between data from different sources (e.g., from different clinical trials), by enabling comparisons with respect to patient characteristics, which are manifested in the gene expression levels that determine and, thus, are embodied in the predictor.
  • the invention provides information that can be very valuable to a DLBCL patient, since the patient may be inclined to order his or her life quite differently, depending on whether the patient has a high or low probability of surviving and/or remaining progression-free for a period of time following treatment.
  • ABC activated B cell-like diffuse large B cell lymphoma
  • CHOP cyclophosphamide, doxorubicine, vincristine, and prednisone
  • CI confidence interval
  • COP cyclophosphamide, vincristine, and prednisone
  • DLBCL diffuse large B cell lymphoma
  • DOD dead of disease
  • ECOG Eastern Cooperative Oncology Group
  • FACS fluorescence-activated cell sorting
  • FH follicular hyperplasia
  • FISH fluorescence in situ hybridization
  • FL follicular lymphoma
  • GC germinal center
  • GCB germinal center B cell-like diffuse large B cell lymphoma
  • IPI International Prognostic Index
  • LPC lymphoplasmacytic lymphoma
  • MHC major histocompatibility complex
  • NA not available or not applicable
  • NK natural killer
  • PCR polymerase chain reaction
  • RQ-PCR polymerase chain reaction
  • R-CHOP refers generally to any therapeutic regimen that includes chemotherapy and the administration of Rituximab. Accordingly, while the term can refer to a Rituximab combination therapy that includes a CHOP regimen of cyclophosphamide, doxorubicine, vincristine, and prednisone, the term R-CHOP can also refer to therapy that includes Rituximab in combination with a chemotherapeutic regimen other than CHOP.
  • gene expression data refers to information regarding the relative or absolute level of expression of a gene or set of genes in a cell or group of cells.
  • the level of expression of a gene may be determined based on the level of RNA, such as mRNA, encoded by the gene. Alternatively, the level of expression may be determined based on the level of a polypeptide or fragment thereof encoded by the gene.
  • Gene expression data may be acquired for an individual cell, or for a group of cells such as a tumor or biopsy sample.
  • Gene expression data and gene expression levels can be stored on computer readable media, e.g., the computer readable medium used in conjunction with a microarray or chip reading device. Such gene expression data can be manipulated to generate gene expression signatures.
  • microarray refers to a plurality of nucleic acid probes coupled to the surface of a substrate in different known locations.
  • the substrate is preferably solid.
  • Microarrays have been generally described in the art in, for example, U.S. Pat. No. 5,143,854 (Pirrung), U.S. Pat. No. 5,424,186 (Fodor), U.S. Pat. No. 5,445,934 (Fodor), U.S. Pat. No. 5,677,195 (Winkler), U.S. Pat. No. 5,744,305 (Fodor), U.S. Pat. No. 5,800,992 (Fodor), and U.S. Pat. No. 6,040,193 (Winkler), and Fodor et al., Science, 251: 767-777 (1991).
  • gene expression signature refers to a group of coordinately expressed genes.
  • the genes making up this signature may be expressed in a specific cell lineage, stage of differentiation, or during a particular biological response.
  • the genes can reflect biological aspects of the tumors in which they are expressed, such as the cell of origin of the cancer, the nature of the non-malignant cells in the biopsy, and the oncogenic mechanisms responsible for the cancer (Shaffer et al., Immunity, 15: 375-385 (2001)).
  • Examples of gene expression signatures include lymph node, proliferation (Rosenwald et al., New Engl. J.
  • signature value corresponds to a mathematical combination of measurements from expression levels of the genes in a gene expression signature.
  • An exemplary signature value is a signature average which corresponds to the average or mean of the individual expression levels in a gene expression signature.
  • survival predictor score refers to a score generated by a multivariate model used to predict survival based on gene expression. A subject with a higher survival predictor score is predicted to have poorer survival than a subject with a lower survival predictor score.
  • survival may refer to the probability or likelihood of a subject surviving for a particular period of time. Alternatively, it may refer to the likely term of survival for a subject, such as expected mean or median survival time for a subject with a particular gene expression pattern.
  • progression free survival can refer to the probability or likelihood of a subject surviving without significant progression or worsening of disease for a particular period of time. Alternatively, it may refer to the likely term for a subject of survival without significant progression or worsening of disease, such as expected mean or median survival time for a subject with a particular gene expression pattern without significant progression or worsening of disease.
  • survival outcome may refer to survival, overall survival, or progression free survival.
  • scale factor refers to a factor that relates change in gene expression to prognosis.
  • An example of a scale factor is a factor obtained by maximizing the partial likelihoods of the Cox proportional hazards model.
  • the gene expression signatures, signature values, survival predictor scores, stromal scores, survival estimate curves, and probabilities of survival disclosed herein may be stored in digitally encoded format on computer readable media, e.g., computer readable media used in conjunction with microarray or chip reading devices or computer readable media used to store patient data during treatment for DLBCL.
  • computer readable media e.g., computer readable media used in conjunction with microarray or chip reading devices or computer readable media used to store patient data during treatment for DLBCL.
  • Such media and the specialized devices that use them, e.g., for diagnostic and clinical applications, are known in the art.
  • the invention provides a method for predicting a survival outcome in a subject diagnosed with DLBCL using gene expression data.
  • data may be gathered using any effective method of quantifying gene expression.
  • gene expression data may be measured or estimated using one or more microarrays.
  • the microarrays may be of any effective type, including, but not limited to, nucleic acid based or antibody based.
  • Gene expression may also be measured by a variety of other techniques, including, but not limited to, PCR, quantitative RT-PCR, real-time PCR, RNA amplification, in situ hybridization, immunohistochemistry, immunocytochemistry, FACS, serial analysis of gene expression (SAGE) (Velculescu et al., Science, 270: 484-87 (1995)), Northern blot hybridization, or western blot hybridization.
  • Nucleic acid microarrays generally comprise nucleic acid probes derived from individual genes and placed in an ordered array on a support.
  • This support may be, for example, a glass slide, a nylon membrane, or a silicon wafer.
  • Gene expression patterns in a sample are obtained by hybridizing the microarray with the gene expression product from the sample.
  • This gene expression product may be, for example, total cellular mRNA, rRNA, or cDNA obtained by reverse transcription of total cellular mRNA.
  • the gene expression product from a sample is labeled with a radioactive, fluorescent, or other label to allow for detection.
  • the microarray is washed, and hybridization of the gene expression product to each nucleic acid probe on the microarray is detected and quantified using a detection device such as a phosphorimager or scanning confocal microscope.
  • cDNA arrays consist of hundreds or thousands of cDNA probes immobilized on a solid support. These cDNA probes are usually 100 nucleotides or greater in size. There are two commonly used designs for cDNA arrays.
  • the first is the nitrocellulose filter array, which is generally prepared by robotic spotting of purified DNA fragments or lysates of bacteria containing cDNA clones onto a nitrocellulose filter (Southern et al., Genomics, 13: 1008-17 (1992); Southern et al., Nucl Acids Res 22: 1368-73 (1994); Gress et al., Oncogene, 13: 1819-30 (1996); Pietu et al., Genome Res., 6: 492-503 (1996)).
  • the other commonly used cDNA arrays is fabricated by robotic spotting of PCR fragments from cDNA clones onto glass microscope slides (Schena et al., Science, 270: 467-70 (1995); DeRisi et al., Nature Genet., 14: 457-60 (1996); Schena et al., Proc. Nat'l. Acad. Sci. USA, 93: 10614-19 (1996); Shalon et al., Genome Res., 6: 639-45 (1996); DeRisi et al., Science, 278: 680-86 (1997); Heller et al., Proc. Nat'l. Acad. Sci.
  • cDNA microarrays are simultaneously hybridized with two fluorescent cDNA probes, each labeled with a different fluorescent dye (typically Cy3 or Cy5). In this format, the relative mRNA expression in two samples is directly compared for each gene on the microarray.
  • Oligonucleotide arrays differ from cDNA arrays in that the probes are 20- to 25-mer oligonucleotides.
  • Oligonucleotide arrays are generally produced by in situ oligonucleotide synthesis in conjunction with photolithographic masking techniques (Pease et al., Proc. Nat'l. Acad. Sci. USA, 91: 5022-26 (1994); Lipshutz et al., Biotechniques 19: 442-47 (1995); Chee et al., Science, 274: 610-14 (1996); Lockhart et al., Nature Biotechnol., 14: 1675-80 (1996); Wodicka et al., Nature Biotechnol., 15: 1359-6714 (1997)).
  • the solid support for oligonucleotide arrays is typically a glass or silicon surface.
  • Microarrays may generally be produced using a variety of techniques, such as mechanical or light directed synthesis methods that incorporate a combination of photolithographic methods and solid phase synthesis methods. Techniques for the synthesis of microarrays using mechanical synthesis methods are described in, for example, U.S. Pat. No. 5,384,261 (Winkler) and U.S. Pat. No. 6,040,193 (Winkler). Although a planar array surface is preferred, the microarray may be fabricated on a surface of virtually any shape, or even on a multiplicity of surfaces. Microarrays may be nucleic acids on beads, gels, polymeric surfaces, fibers such as fiber optics, glass, or any other appropriate substrate. See, for example, U.S. Pat. No.
  • Microarrays can be packaged in such a manner as to allow for diagnostic use, or they can be all-inclusive devices. See, for example, U.S. Pat. No. 5,856,174 (Lipshutz) and U.S. Pat. No. 5,922,591 (Anderson).
  • Microarrays directed to a variety of purposes are commercially available from Affymetrix (Santa Clara, Calif.). For instance, these microarrays may be used for genotyping and gene expression monitoring.
  • Gene expression data can be used to identify genes that are coordinately regulated. Genes that encode components of the same multi-subunit protein complex are often coordinately regulated. Coordinate regulation is also observed among genes whose products function in a common differentiation program or in the same physiological response pathway. Recent application of gene expression profiling to the immune system has shown that lymphocyte differentiation and activation are accompanied by parallel changes in expression among hundreds of genes. Gene expression databases may be used to interpret the pathological changes in gene expression that accompany autoimmunity, immune deficiencies, cancers of immune cells and of normal immune responses.
  • microarray gene expression data for the prediction of survival in DLBCL patients, there is a need for new algorithms to be developed, which can identify important information and convert it to a more manageable format.
  • microarrays used to generate this data can be streamlined to incorporate probe sets that are useful for survival outcome prediction.
  • Mathematical analysis of gene expression data is a rapidly evolving science based on a rich mathematics of pattern recognition developed in other contexts (Kohonen, Self - Organizing Maps, Springer Press (Berlin 1997)).
  • Mathematical analysis of gene expression data can be used, for example, to identify groups of genes that are coordinately regulated within a biological system, to recognize and interpret similarities between biological samples on the basis of similarities in gene expression patterns, and/or to recognize and identify those features of a gene expression pattern that are related to distinct biological processes or phenotypes.
  • Mathematical analysis of gene expression data often begins by establishing the expression pattern for each gene on an array across a number (n) of experimental samples.
  • the expression pattern of each gene can be represented by a point in n-dimensional space, with each coordinate specified by an expression measurement in one of the n samples (Eisen et al., Proc. Nat'l. Acad. Sci. USA, 95: 14863-68 (1998)).
  • a clustering algorithm that uses distance metrics can then be applied to locate clusters of genes in this n-dimensional space. These clusters indicate genes with similar patterns of variation in expression over a series of experiments.
  • Clustering methods that have been applied to microarray data in the past include hierarchical clustering (Eisen et al., supra), self-organizing maps (SOMs) (Tamayo et al., Proc. Nat'l. Acad. Sci. USA, 96: 2907-12 (1999)), k-means (Tavazoie et al., Nature Genet., 22: 281-85 (1999)), and deterministic annealing (Alon et al., Proc. Nat'l. Acad. Sci. USA, 96: 6745-50 (1999)).
  • Hierarchical clustering begins by determining the gene expression correlation coefficients for each pair of the n genes studied. Genes with similar gene expression correlation coefficients are grouped next to one another in a hierarchical fashion. Generally, genes with similar expression patterns under a particular set of conditions can encode protein products with related roles in the physiological adaptation to those conditions. Novel genes of unknown function that are clustered with a large group of functionally related genes likely participate in similar or related biological process. Likewise, other clustering methods mentioned herein can also group genes together that encode proteins with related biological function.
  • genes that are clustered together reflect a particular biological function, and are termed gene expression signatures (Shaffer et al., Immunity 15: 375-85 (2001)).
  • gene expression signatures include genes that are characteristically expressed in a particular cell type or at a particular stage of cellular differentiation or activation.
  • Another general type of gene expression signature includes genes that are regulated in their expression by a particular biological process such as proliferation, or by the activity of a particular transcription factor or signaling pathway.
  • the pattern of gene expression in a biological sample can provide a distinctive and accessible molecular picture of its functional state and identity (DeRisi et al., Science, 278: 680-86 (1997); Cho et al., Mol. Cell., 2: 65-73 (1998); Chu et al., Science, 282: 699-705 (1998); Holstege et al., Cell., 95: 717-728 (1998); Spellman et al., Mol. Biol. Cell, 9: 3273-97 (1998)).
  • Each cell transduces variations in its environment, internal state, and developmental state into readily measured and recognizable variations in its gene expression patterns. Two different samples with related gene expression patterns are therefore likely to be biologically and functionally similar to one another.
  • a specific gene expression signature in a sample can provide important biological insights into its cellular composition and the function of various intracellular pathways within those cells.
  • the expression pattern of genes in the germinal center B cell signature in a lymphoma biopsy indicates that the lymphoma includes cells derived from the germinal center stage of differentiation.
  • the expression of genes from the T cell signature can be used to estimate the degree of infiltration of the tumor by host T cells, while the expression of genes from the proliferation signature can be used to quantitate the tumor cell proliferation rate.
  • gene expression signatures provide an “executive summary” of the biological properties of a tumor specimen. Gene expression signatures can also be helpful in interpreting the results of a supervised analysis of gene expression data.
  • a supervised analysis generates a list of genes with expression patterns that correlate with survival. Gene expression signatures can be useful in assigning these “predictive” genes to functional categories. In building a multivariate model of survival based on gene expression data, this functional categorization helps to limit the inclusion of multiple genes in the model that measure the same aspect of tumor biology.
  • the model of the invention generates a survival predictor score, with a higher score being associated with worse clinical outcome.
  • the resulting model can be used separately to predict a survival outcome.
  • the model can be used in conjunction with one or more other models, disclosed herein or in other references, to predict a survival outcome.
  • the present invention discloses several gene expression signatures related to the clinical outcome of DLBCL patients.
  • the signatures were identified using the clinical data and methods described below in Examples 1 and 2.
  • Three of these gene expression signatures are the germinal center B cell (GCB) signature, the stromal-1 signature, and the stromal-2 signature.
  • GCB germinal center B cell
  • Each component gene of these signatures is identified in Table 1 according to its GenBank accession number, its GeneID assigned by Entrez Gene, a common gene symbol, and a descriptive gene title.
  • Table 1 also provides the Affymetrix Probe Set ID, which can be used (e.g., on the Affymetrix U133+ (Affymetrix, Santa Clara, Calif.) microarray) to determine the gene expression level for the indicated gene.
  • the computer-readable sequence listing filed herewith includes a representative fragment sequence (of about 100 by or greater) for each genomic target sequence listed in Table 1, followed by the sequence for each probe in the corresponding Affymetrix probe set listed in Table 1.
  • the DLBCL survival predictors of the invention were generated using expression data and methods described in Examples 1 and 2, below.
  • the first bivariate survival predictor incorporates the GCB and stromal-1 gene expression signatures. Fitting the Cox proportional hazards model to the gene expression data obtained from these two signatures resulted in a bivariate model survival predictor score calculated using the following generalized equation:
  • Bivariate DLBCL survival predictor score A ⁇ [( x )*(GCB signature value)] ⁇ [( y )*(stromal-1 signature value)].
  • A is an offset term, while (x) and (y) are scale factors.
  • the GCB signature value and the stromal-1 signature value can correspond to the average of the expression levels of all genes in the GCB signature and the stromal-1 signature, respectively.
  • a lower survival predictor score indicates a more favorable survival outcome, and a higher survival predictor score indicates a less favorable survival outcome for the subject.
  • the bivariate survival predictor was refined into a multivariate survival predictor that incorporates GCB, stromal-1, and stomal-2 gene expression signatures. Fitting the Cox proportional hazards model to the gene expression data obtained from these three signatures resulted in a multivariate model survival predictor score calculated using the following generalized equation:
  • A is an offset term, while (x), (y), and (z) are scale factors.
  • the GCB signature value, the stromal-1 signature value, and the stromal-2 signature value can correspond to the average of the expression levels of all genes in the GCB signature, the stromal-1 signature, and the stromal-2 signature, respectively.
  • a lower survival predictor score indicates a more favorable survival outcome and a higher survival predictor score indicates a less favorable survival outcome for the subject.
  • the invention provides the following multivariate survival predictor equation:
  • Multivariate DLBCL survival predictor score 8.11 ⁇ [0.419*(GCB signature value)] ⁇ [1.015*(stromal-1 signature value)]+[0.675*(stromal-2 signature value)]
  • a lower survival predictor score indicates a more favorable survival outcome
  • a higher survival predictor score indicates a poorer survival outcome for the subject.
  • the offset term (A) or (8.11) can be varied without affecting the equation's usefulness in predicting clinical outcome.
  • Scale factors (x), (y), and (z) can also be varied, individually or in combination.
  • scale factor (x) can be from about 0.200 or more, from about 0.225 or more, from about 0.250 or more, from about 0.275 or more, from about 0.300, from about 0.325 or more, from about 0.350 or more, from about 0.375 or more, or from about 0.400 or more.
  • scale factor (x) can be about 0.625 or less, about 0.600 or less, about 0.575 or less, about 0.550 or less, about 0.525 or less, about 0.500 or less, about 0.475 or less, about 0.450 or less, or about 0.425 or less.
  • scale factor (z) can be one that is bounded by any two of the previous endpoints.
  • scale factor (x) can be a value from 0.200-0.625, from 0.350-0.550, from 0.350-0.475, or from 0.400-0.425.
  • scale factor (y) can be from about 0.800 or more, from about 0.825 or more, from about 0.850 or more, from about 0.875 or more, from about 0.900 or more, from about 0.925 or more, from about 0.950 or more, from about 0.975 or more, or from about 1.000 or more.
  • scale factor (y) can be, e.g., about 1.250 or less, e.g., about 1.225 or less, about 1.200, about 1.175 or less, about 1.150 or less, about 1.125 or less, about 1.100 or less, about 1.075 or less, about 1.050 or less, or about 1.025 or less.
  • scale factor (y) can be one that is bounded by any two of the previous endpoints.
  • scale factor (y) can be a value from 0.800-1.250, a value from 0.950-1.1025, a value from 0.950-1.200 or a value from 1.000-1.025.
  • scale factor (z) can be from about 0.450 or more, about 0.475 or more, about 0.500 or more, about 0.525 or more, about 0.550 or more, about 0.575 or more, about 0.600 or more, about 0.625 or more, or about 0.650 or more.
  • scale factor (z) can be, e.g., about 0.900 or less, e.g., about 0.875 or less, about 0.850, about 0.825 or less, about 0.800 or less, about 0.775 or less, about 0.750 or less, or about 0.725 or less.
  • scale factor (z) can be one that is bounded by any two of the previous endpoints.
  • scale factor (z) can be a value from 0.450-0.900, any value from 0.650-0.725, any value from 0.625-0.775 or any value from 0.650-0.700.
  • the invention includes any set of scale factors (x), (y), and (z) in conjunction in the general multivariate DLBCL survival predictor score that creates a function that is monotonically related to a multivariate DLBCL survival predictor score equation using any combination of the foregoing specified scale factor (x), (y), and (z) values.
  • a survival predictor score can be calculated using fewer than all of the gene components of the GCB signature, the stromal-1 signature, and/or the stromal-2 signature listed in Table 1.
  • the survival prediction equations disclosed herein can be calculated using mathematical combinations of the expressions of 98% (38), 95% (37), 93% (36), or 90% (35) of the genes listed in Table 1 for the GCB signature, about 99% (about 280), about 98% (about 277), 97% (about 275), about 96% (about 272), about 95% (about 270), about 94% (about 266), about 93% (about 263), about 92% (about 260), about 91% (about 257), or about 90% (about 255) of the genes listed in Table 1 for the stromal-1 signature, and/or 99% (71), 97% (70), 96% (69), 95% (68) 93% (67), 92% (66), or 90% (65) of the genes listed in Table 1 for the stromal-2 signature (instead
  • the survival prediction equations disclosed herein can be calculated using mathematical combinations of the expressions of 88% (34 genes), 85% (33 genes), 82% (32 genes), 80% (31 genes) of the genes listed in Table 1 for the GCB signature, about 89% (about 252), about 88% (about 249), about 87% (about 246), about 86% (about 243), about 85% (about 241), about 84% (about 238), about 83% (about 235), about 82% (about 232), about 81% (about 229), or about 80% (about 226) of the genes listed in Table 1 for the stromal-1 signature, and/or 89% (64), 88% (63), 86% (62), 85% (61), 83% (60), 82% (59) or 80% (58) of the genes listed in Table 1 for the stromal-2 signature (instead of using all of the genes corresponding to a gene signature in Table 1 to calculate the GCB signature value, the stromal-1 signature value, and/or stromal-2 signature value
  • the invention also provides a method of using a DLBCL survival predictor score to predict the probability of a survival outcome beyond an amount of time t following treatment for DLBCL.
  • the method includes calculating the probability of a survival outcome for a subject using the following general equation:
  • P(SO) is the subject's probability of the survival outcome beyond time t following treatment for DLBCL
  • SO 0 (t) is the probability of survival outcome, which corresponds to the largest time value smaller than t in a survival outcome curve
  • (s) is a scale factor.
  • Treatment for DLBCL can include chemotherapy and the administration of Rituximab.
  • a survival curve can be calculated using statistical methods, such as the Cox Proportional Hazard Model. Additional information regarding survival outcome curves is set forth in Lawless, Statistical Models and Methods for Lifetime Data, John Wiley and Sons (New York 1982) and Kalbyak et al., Biometrika, 60: 267-79 (1973).
  • the method of the invention includes calculating the probability of overall survival for a subject beyond an amount of time t following treatment for DLBCL.
  • the method includes calculating the probability of a survival outcome for a subject using the following general equation:
  • P(OS) is the subject's probability of overall survival beyond time t following treatment for DLBCL
  • SO 0 (t) is the curve probability of survival outcome, which corresponds to the largest time value in a survival curve which is smaller than t
  • scale factor (s) 1
  • Treatment for DLBCL can include chemotherapy alone or in combination with the administration of Rituximab (R-CHOP).
  • the method of the invention includes calculating the probability of progression-free survival for a subject beyond an amount of time t following treatment for DLBCL.
  • the method includes calculating the probability of a survival outcome for a subject using the following general equation:
  • P(PFS) is the subject's probability of progression-free survival beyond time t following treatment for DLBCL
  • SO 0 (t) is the curve probability of progression-free survival, which corresponds to the largest time value in a survival curve which is smaller than t
  • scale factor (s) 0.976.
  • the treatment for DLBCL can include chemotherapy alone or in combination with the administration of Rituximab (R-CHOP).
  • the scale factor in the foregoing P(PFS) can be varied such that (instead of 0.976) scale factor (s) is a value between 0.970 and 0.980, e.g. 0.971, 0.972, 0.973, 0.973, 0.974, 0.975, 0.977, 0.978, and 0.979.
  • the invention also provides a method of selecting a subject for antiangiogenic therapy of DLBCL based on the subject's high relative expression of stromal-2 signature genes.
  • the stromal-2 signature includes a number of genes whose expression or gene products are related to angiogenesis.
  • high relative expression of stromal-2 signature genes in DLBCL can be indicative of high angiogenic activity.
  • high relative expression of stromal-2 signature genes can be related to the heavy infiltration of some DLBCL tumors with myeloid lineage cells. Accordingly, subjects with high relative expression of stromal-2 signature genes are good candidates for treatment with antiangiogenic therapy, either alone or in combination with other anti-oncogenic therapies.
  • a stromal score which was obtained by subtracting the stromal-1 signature value from the stromal-2 signature value, was observed to correlate with high tumor blood vessel density.
  • antiangiogenic monoclonal antibody to vascular endothelial growth factor bevacizumab has been clinically tested in patients with DLBCL (Ganjoo et al., Leuk. Lymphoma, 47: 998-1005 (2006)).
  • Other antiangiogenic therapies can include small molecule inhibitors of SDF-1 receptor, such as CXCR4 (Petit et al., Trends Immunol., 28: 299-307 (2007).
  • Still another example of an antiangiogenic therapy can include blocking antibodies to the myeloid lineage cell marker CTGF, which has been implicated in angiogenesis.
  • anti-CTGF antibodies have been shown to have anti-cancer activity in pre-clinical models of cancer (Aikawa et al., Mol. Cancer Ther., 5: 1108-16 (2006)).
  • the method of the invention for selecting a subject for antiangiogenic therapy includes obtaining a gene expression profile from a DLBCL biopsy from the subject.
  • the subject's stromal-2 signature value is determined.
  • the subject's stromal-2 signature value is then compared to a standard stromal-2 value.
  • a standard stromal-2 value corresponds to the average of multiple stromal-2 signature values in DLBCL biopsy samples from a plurality of randomly selected subjects with DLBCL, e.g., more than 10, 20, 30, 40, 50, 60, 70, 80, 90, 100, 150, 200, or 250 randomly selected subjects with DLBCL. If the subject's stromal-2 signature value is significantly higher than the standard stromal-2 value, then the subject can be treated with anti-angiogenic therapy.
  • the method of the invention for selecting a subject for anti-angiogenic therapy includes obtaining a gene expression profile from a DLBCL biopsy from the subject.
  • the subject's stromal 1 signature value and stromal-2 signature value are determined.
  • the stromal-1 signature value is then subtracted from the stromal-2 signature value to obtain a stomal score.
  • the subject's stromal score is then compared to a standard stromal score.
  • the invention further provides a targeted array that can be used to detect the expression levels of all or most of the genes in a germinal center B cell gene (GCB) expression signature, a stromal-1 gene expression signature, and/or a stromal-2 gene expression signature.
  • a targeted array is an array directed to a limited set of genes and thus differs from a whole genome array.
  • the targeted array of the invention can include probes for fewer than 20,000 genes, fewer than 15,000 genes, fewer than 10,000 genes, fewer than 8,000 genes, fewer than 7,000 genes, fewer than 6,000 genes, fewer than 5,000 genes, or fewer than 4,000 genes.
  • the targeted array includes probes for at least 80% of the genes in a germinal center B cell gene (GCB) expression signature, a stromal-1 gene expression signature, and/or a stromal-2 gene expression signature.
  • GCB germinal center B cell gene
  • the targeted arrays of the invention can be used, for example, to detect expression levels for use in the methods described herein.
  • the invention provides a targeted array that includes probes for all of the genes in the stromal-1 gene expression signature.
  • the invention also provides a targeted array that includes probes for all of the genes in the stromal-2 gene expression signature.
  • the invention provides a targeted array that includes probes for all of the genes in the stromal-1 gene expression signature and all of the genes in the stromal-2 gene expression signature.
  • the invention provides a targeted array that includes probes for all of the genes in the stromal-1 gene expression signature, all of the genes in the stromal-2 gene expression signature, and all of the genes in the GCB signature.
  • the arrays of the invention can include 98% (38), 95% (37), 93% (36), or 90% (35) of the genes listed in Table 1 for the GCB signature, about 99% (about 280), about 98% (about 277), 97% (about 275), about 96% (about 272), about 95% (about 270), about 94% (about 266), about 93% (about 263), about 92% (about 260), about 91% (about 257), or about 90% (about 255) of the genes listed in Table 1 for the stromal-1 signature, and/or 99% (71), 97% (70), 96% (69), 95% (68) 93% (67), 92% (66), or 90% (65) of the genes listed in Table 1 for the stromal-2 signature (instead of all of the genes listed in Table 1 for the GCB signature average, the stromal-1 signature average, and/or stromal-2 signature average, respectively).
  • the arrays of the invention can include 88% (34 genes), 85% (33 genes), 82% (32 genes), 80% (31 genes) of the genes listed in Table 1 for the GCB signature, about 89% (about 252), about 88% (about 249), about 87% (about 246), about 86% (about 243), about 85% (about 241), about 84% (about 238), about 83% (about 235), about 82% (about 232), about 81% (about 229), or about 80% (about 226) of the genes listed in Table 1 for the stromal-1 signature, and/or 89% (64), 88% (63), 86% (62), 85% (61), 83% (60), 82% (59) or 80% (58) of the genes listed in Table 1 for the stromal-2 signature (instead of all of the genes listed in Table 1 for the GCB signature average, the stromal-1 signature average, and/or stromal-2 signature average, respectively).
  • Pre-treatment tumor biopsy specimens and clinical data were obtained from 414 patients with de novo DLBCL treated at 10 institutions in North America and Europe and studied according to a protocol approved by the National Cancer Institute's Institutional Review Board.
  • Patients included in a “LLMP CHOP cohort” of 181 patients were treated with anthracycline-based combinations, most often cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) or similar regimens, as previously described (Rosenwald et al., N. Engl. J. Med., 346: 1937-47 (2002)).
  • the remaining 233 patients constituted an R-CHOP cohort that received similar chemotherapy plus Rituximab.
  • the median follow-up in the R-CHOP cohort was 2.1 years (2.8 years for survivors).
  • a panel of expert hematopathologists confirmed the diagnosis of DLBCL using current WHO criteria. Additional clinical patient characteristics for the R-CHOP cohort are described in Table 2. Additional analysis used a second “MMMNLP CHOP” cohort of 177 patients studied by the Molecular Mechanisms of Non-Hodgkin's Lymphoma Network Project (Hummel et al., N. Engl. J. Med., 354: 2419-30 (2006)).
  • Gene expression profiling was performed using Affymetrix U133+2.0 microarrays. Gene expression profiling data are available through the National Center for Biotechnology Information web site as described in Lenz et al., New Engl. J. Med, 359: 2313-23 (2008), at page 2314. All gene expression array data were normalized using MAS 5.0 software, and were log 2 transformed. To account for technical differences in the microarray processing between the R-CHOP cohort data and the LLMPP CHOP cohort data, the expression values of each gene in the R-CHOP cohort data were adjusted so that its median matched the median of the LLMPP CHOP data.
  • Gene expression profiles were determined for pre-treatment biopsy samples from a “training set” of 181 patients treated with CHOP or CHOP-like chemotherapy alone and from a “test set” of 233 patients treated with R-CHOP.
  • the patients in these two cohorts were comparable with respect to age range and distribution of the clinical prognostic variables that constitute the International Prognostic Index (IPI) (Table 2).
  • IPI International Prognostic Index
  • patients with GCB DLBCL had better survival rates than those with ABC DLBCL.
  • R-CHOP treated GCB DLBCL and ABC DLBCL patients had 3-year overall survival rates of 84% and 56%, respectively, and 3-year progression-free survival rates of 74% and 40%, respectively ( FIGS. 1A and 1B ).
  • the remaining fourth gene expression signature was not associated with survival in the R-CHOP cohort (see MHC class II signature panel in FIG. 1C ).
  • tumors with extremely low “outlier” expression of this signature were associated with inferior survival in both CHOP cohorts (see FIGS. 8A and 8B ), but not in the R-CHOP cohort (see FIG. 8C ).
  • future clinical trials in DLBCL should incorporate quantitative methods to discern these biological differences so that patient cohorts in different trials can be compared and treatment responses can be related to defined tumor phenotypes.
  • This example demonstrates the development of GCB, stromal-1, and stromal-2 survival signatures and a related multivariate model of survival for R-CHOP-treated DLBCL.
  • LLMPP CHOP CHOP cohort data 936 genes were identified as associated with poor prognosis p ⁇ 0.01 (1-sided). For genes having multiple array probe sets associated with survival, only the probe set with the strongest association with survival was used. The expression values of the probe sets in the LLMPP CHOP cohort data were then clustered. The largest cluster with an average correlation of >0.6 and containing myc was identified as the proliferation survival signature. 1396 genes were identified as associated with favorable outcome. The largest cluster with average correlation of >0.6 and containing BCL6 was identified as the germinal center B cell (GCB) survival signature.
  • GCB germinal center B cell
  • a cluster with average correlation of >0.6 and containing FM was identified as the stromal-1 survival signature, whereas another cluster with average correlation of >0.6 containing HLADRA was identified as the MHC class II survival signature.
  • the expression levels of genes within each signature were then averaged to create a “signature average” for each biopsy specimen. For the MMMLNP CHOP data set, the average was calculated for those array elements represented on the Affymetrix U133A microarray.
  • the CHOP training set was used to discover and refine signatures that added to the prognostic significance of this bivariate model, and the resulting multivariate models were tested in the R-CHOP cohort.
  • 563 genes were identified as adding to the model in the direction of adverse prognosis. These genes were clustered by hierarchical clustering, and three clusters of more than 10 genes with an average correlation of >0.6 were identified.
  • 542 genes were identified which added to the stromal-1 and GCB signature model in the direction of favorable prognosis. These genes were clustered, and two clusters of more than 10 genes with an average correlation of >0.6 were identified.
  • Signature averages were determined for these clusters, and three variable models containing the stromal-1 and GCB signature and each of the cluster averages were formed on the MMMLNP CHOP and R-CHOP data sets. Of the five cluster averages, two were found to add statistical significance (p ⁇ 0.02) in the MMMLNP CHOP data as compared to a model containing the stromal-1 and GCB signatures alone. By contrast, in the R-CHOP data, three of the five cluster averages were found to add significance (p ⁇ 0.02) to the bivariate model. One of these cluster averages added significantly to the bivariate model in both the MMMLNP CHOP and R-CHOP data. This signature, designated Signature 122, was also found to add to the stromal-1 and GCB signature far more significantly than any of the four other signatures on the LLMPP CHOP data and, thus, was retained for further analysis.
  • This Signature 122 positively correlated with the stromal-1 signature, although it was associated with adverse survival when added to the bivariate model.
  • we identified genes that were more correlated with Signature 122 than with the stromal-1 signature (p ⁇ 0.02). These genes were organized by hierarchical clustering, and three sets of correlated genes (r>0.6) were observed. One of these clusters, the stromal-2 signature, added to the significance of the bivariate model in both the MMMLNP CHOP cohort (p 0.002) and the R-CHOP cohort (p ⁇ 0.001) ( FIGS. 2B and 9D ).
  • a multivariate survival model was formed by fitting a Cox model with the GCB, stromal-1, and stomal-2 signatures to the LLMPP CHOP cohort data shown in Table 3. This final multivariate model with its associated scaling coefficients was then evaluated on the MMLLMPP CHOP and R-CHOP cohort data sets. Survival predictor scores from the final model were used to divide the R-CHOP cohort into quartile groups with 3-year overall survival rates of 89%, 82%, 74%, and 48%, and 3-year progression-free survival rates of 84%, 69%, 61% and 33% ( FIG. 2B ). The survival predictor scores from the final model are illustrated in FIG. 3 along with the three component signatures and representative genes of each signature.
  • the inventive gene expression-based survival model retained its prognostic significance among R-CHOP-treated patients segregated according to IPI into high, intermediate and low IPI risk groups, both as originally defined (Shipp et al., supra) (p ⁇ 0.001) ( FIG. 2C ) and as recently modified for R-CHOP-treated DLBCL (Sehn et al., supra) (p ⁇ 0.001) ( FIG. 10 ).
  • the gene expression-based multivariate model can be used to identify large disparities in survival among patients with different DLBCL gene signature profiles.
  • survival predictor scores were used to divide patients into least and most favorable quartile groups having 3-year progression-free survival rates of 33% and 84%, respectively.
  • the gene expression-based survival predictor provides a complementary view of DLBCL variation that can be considered when analyzing data from DLBCL clinical trials.
  • whole-genome gene expression profiles in conjunction with the survival model described herein can be used to provide optimal predictions of expected survival outcomes for subjects suffering from DLBCL.
  • This example demonstrates the use of a survival predictor score to predict the probability of progression free and overall survival outcomes at a period of time t following R-CHOP treatment in accordance with the invention.
  • RNA is isolated from a patient's DLBCL biopsy and hybridized to a U133+ array from Affymetrix (Santa Clara, Calif.). The array is scanned, and MAS 5.0 algorithm is applied to obtain signal values normalized to a target intensity of 500. Signal values are log 2 transformed to intensity values. For genes of interest with multiple probe sets, the intensity value of the multiple probe sets are averaged to obtain a single intensity value for each gene. The single intensity values of genes in the GCB signature are averaged to obtain a GCB signature average of 9.2. The single intensity values of genes in the stromal-1 signature are averaged to obtain a stromal-1 signature average of 8.5. The single intensity values of genes in the stromal-2 signature are averaged to obtain a stromal-2 signature average of 7.2.
  • Table 4 includes values from a progression free survival curve generated using baseline hazard functions calculated from the R-CHOP patient data described in Table 3. The curve was generated in accordance with the methods of Kalbées and Prentice, Biometrika, 60: 267-279 (1973), which involves maximizing the full likelihood, under the assumption that the true scaling coefficients were equal to prior estimates.
  • F 0 (t) is the probability of progression free survival for each indicated time period following R-CHOP treatment (t-RCHOP).
  • F 0 (t) is the F 0 (t) value that corresponds to the largest time value smaller than 2 years in the progression free survival curve.
  • the largest time value smaller than 2 is 1.919, and the corresponding PF 0 (t) value is 0.705.
  • Table 5 includes values from an overall survival curve generated using baseline hazard functions calculated from the R-CHOP patient data described in Table 3. The curve was made according to the method of Kalbées and Prentice, Biometrika, 60: 267-279 (1973), which involves maximizing the full likelihood, under the assumption that the true scaling coefficients were equal to our estimates.
  • OS 0 (t) is the probability of overall survival for each indicated time period following R-CHOP treatment (t-RCHOP).
  • OS 0 (t) is the value that corresponds to the largest time value in the overall survival curve which is smaller than 2 years.
  • the largest time value smaller than 2 is 1.889
  • the corresponding OS 0 (t) value is 0.791.
  • This example demonstrates the biological basis for DLBCL prognostic signatures.
  • Example 2 To assess whether the gene expression signatures in the final survival model of Example 2 were derived from the malignant lymphoma cells or from the host microenvironment, three DLBCL biopsy samples were fractionated into CD19+ malignant cells and CD19 ⁇ non-malignant cells by flow sorting. Most germinal center B cell signature genes were more highly expressed in the malignant fraction, whereas genes from the stromal-1 and stromal-2 signatures were more highly expressed in the non-malignant stromal fraction ( FIG. 4A ), hence their name. Since these two signatures were synergistic in predicting survival, they were combined into a “stromal score” ( FIG. 3 ), high values of which were associated with adverse outcome.
  • the germinal center B cell signature relates to the distinction between the ABC and GCB DLBCL subtypes ( FIG. 3 ).
  • the genes defining the stromal-1 signature encodes components of the extracellular matrix, including fibronectin, osteonectin, various collagen and laminin isoforms, and the anti-angiogenic factor thrombospondin ( FIG. 3 and Table 1).
  • This signature also encodes modifiers of collagen synthesis (LOXL1, SERPINHI), proteins that remodel the extracellular matrix (MMP2, MMP9, MMP14, PLAU, TIMP2), and CTGF, a secreted protein that can initiate fibrotic responses (Frazier et al., J. Invest. Dermatol., 107(3): 404-11 (1996)).
  • the stromal-1 signature includes genes characteristically expressed in cells of the monocytic lineage, such as CEBPA and CSF2RA.
  • the stromal-1 signature is significantly related to several previously curated gene expression signatures (Shaffer et al., Immunol. Rev., 210: 67-85 (2006)) based on gene set enrichment analysis (Subramanian et al., Proc. Nat'l. Acad. Sci. USA, 102(43): 15545-50 (2005)).
  • Two of these signatures include genes that are coordinately expressed in normal mesenchymal tissues but not in hematopoietic subsets, many of which encode extracellular matrix proteins (false discovery rate (FDR) ⁇ 0.001) ( FIGS. 4B and 11 ) (Su et al., Proc. Nat'l. Acad. Sci. USA, 101: 6062-7 (2004)).
  • a pan-T cell signature was not related to the stromal-1 signature ( FIG. 4B ).
  • the stromal-1 signature gene product fibronectin was prominently localized by immunohistochemistry to fibrous strands running between the malignant cells in DLBCL biopsy samples, in keeping with its role in extracellular matrix formation.
  • MMP9, SPARC, and CTGF colocalized with CD68, which is a marker for cells in the monocytic lineage.
  • SPARC protein levels were associated with favorable overall survival ( FIG. 5A ).
  • the stromal-1 signature includes genes that are coordinately expressed in many normal mesenchymal tissues, most of which encode proteins that form or modify the extracellular matrix.
  • the localization of fibronectin to fibrous strands insinuated between the malignant lymphoma cells suggests that the stromal-1 signature reflects the fibrotic nature of many DLBCL tumors.
  • This fibrotic reaction may be related to another stromal-1 signature component, CTGF, which participates in many fibrotic responses and diseases, and promotes tumor growth and metastasis of epithelial cancers (Shi-Wen et al., Cytokine Growth Factor Rev., 19: 133-44 (2008)).
  • the stromal-1 signature reflects a monocyte-rich host reaction to the lymphoma that is associated with the abundant deposition of extracellular matrix.
  • Tumors with high expression of the stromal-1 signature were infiltrated by cells of the myeloid lineage, which include cells that have been implicated in the pathogenesis of epithelial cancers, including tumor-associated macrophages, myeloid-derived suppressor cells, and Tie2-expressing monocytes (reviewed in Wels et al., Genes Dev., 22: 559-74 (2008)).
  • these myeloid lineage cells promote tumor cell invasion by secreting matrix metalloproteinases such as MMP9, suppress T cell immune responses, and initiate angiogenesis.
  • VWF von-Willebrand factor
  • PECAM1 CD31
  • This signature also includes genes encoding key regulators of angiogenesis, such as, for example, KDR (VEGF receptor-2); Grb10, which mediates KDR signaling; integrin alpha 9, which enhances VEGF signaling; TEK, the receptor tyrosine kinase for the cytokine angiopoietin; ROBO4, an endothelial-specific molecular guidance molecule that regulates angiogenesis; and ERG, a transcription factor required for endothelial tube formation.
  • KDR VEGF receptor-2
  • Grb10 which mediates KDR signaling
  • integrin alpha 9 which enhances VEGF signaling
  • TEK the receptor tyrosine kinase for the cytokine angiopoietin
  • ROBO4 an endothelial-specific molecular guidance molecule that regulates angiogenesis
  • ERG a transcription factor required for endothelial tube formation.
  • the stromal-2 signature genes CAV1, CAV2, and EHD2 encode components of caveolae, which are specialized plasma membrane structures that are abundant in endothelial cells and required for angiogenesis (Frank et al., Arterioscler. Thromb. Vasc. Biol., 23: 1161-8 (2003); Woodman et al., Am. J. Pathol., 162: 2059-68 (2003)).
  • the stromal-2 signature includes a large number of genes expressed in endothelial cells, other genes are expressed exclusively in adipocytes, including ADIPOQ, FABP4, RBP4, and PLIN.
  • the stromal-1 and stromal-2 gene expression signatures reflect the character of the non-malignant cells in DLBCL tumors, and the stromal-2 signature may represent an “angiogenic switch” in which the progression of a hyperplastic lesion to a fully malignant tumor is accompanied by new blood vessel formation (Hanahan et al., Cell, 86: 353-64 (1996)).
  • DLBCL tumors with high relative expression of the stomal-2 signature were associated with increased tumor blood vessel density and adverse survival.
  • CXCL12 SDF-1
  • stromal-2 signature component is a chemokine secreted either by fibroblasts or endothelial cells that can promote angiogenesis by recruiting CXCR4+ endothelial precursor cells from the bone marrow (Orimo et al., Cell, 121: 335-48 (2005)).
  • an antagonist of angiogenesis is a stromal-1 signature component, which may explain why tumors with low relative expression of this signature had an elevated blood vessel density.
  • adipocyte-associated genes in DLBCL tumors with high stromal-2 signature expression may play a role in angiogenesis since some cells in adipose tissue may have the potential to differentiate into endothelial cells (Planat-Benard et al., Circulation, 109: 656-63 (2004)).
  • adipose-associated genes may reflect the recruitment of bone marrow-derived mesenchymal stem cells, which home efficiently to tumors (Karnoub et al., Nature, 449: 557-63 (2007)) and can stabilize newly formed blood vessels (Au et al., Blood, 111: 4551-4558 (2008)).
  • the stromal-1 and stromal-2 gene signatures can be used to generate a stromal score that correlates with increased blood vessel density.
  • the stromal score can be used to determine if a DLBCL patient is likely to benefit from administration of antiangiogenic therapy (alone, or in conjunction with another DLBCL therapeutic regimen).

Abstract

The invention provides methods and materials related to a gene expression-based survival predictor for diffuse large B cell lymphoma (DLBCL) patients.

Description

    CROSS-REFERENCE TO RELATED APPLICATION
  • This application claims the benefit of U.S. Provisional Patent Application No. 61/059,678, filed on Jun. 6, 2008, the disclosure of which is incorporated by reference.
    • INCORPORATION-BY-REFERENCE OF MATERIAL SUBMITTED ELECTRONICALLY
  • Incorporated by reference in its entirety herein is a computer-readable nucleotide sequence listing submitted concurrently herewith and identified as follows: One 1,231,630 Byte ASCII (Text) file named “704777_ST25.TXT,” created on Jun. 5, 2009.
    • BACKGROUND OF THE INVENTION
  • The current standard of care for the treatment of diffuse large B cell lymphoma (DLBCL) includes anthracycline-based chemotherapy regimens such as CHOP in combination with the administration of the anti-CD20 monoclonal antibody Rituximab. This combination regimen (R-CHOP) can cure about 60% of patients and has improved the overall survival of DLBCL patients by 10-15% (Coiffier et al., N. Engl. J. Med., 346: 235-42 (2002)). Nonetheless, the molecular basis of response or resistance to this therapy is unknown.
  • DLBCL is a molecularly heterogeneous disease (Staudt et al., Adv. Immunol., 87: 163-208 (2005)), and different molecular subtypes of DLBCL can have very different prognoses following treatment. For example, gene expression profiling has identified two molecular subtypes of DLBCL that are biologically and clinically distinct (Rosenwald et al., N. Engl. J. Med., 346: 1937-47 (2002); Alizadeh et al., Nature, 403: 503-11 (2000)). The germinal center B cell-like (GCB) DLBCL subtype likely arises from normal germinal center B cells, whereas the activated B cell-like (ABC) DLBCL subtype may arise from a post-germinal center B cell that is blocked during plasmacytic differentiation. Many oncogenic mechanisms distinguish these subtypes: GCB DLBCLs have recurrent t(14,18) translocations, whereas ABC DLBCLs have recurrent trisomy 3 and deletion of the INK4a/ARF locus as well as constitutive activation of the anti-apoptotic NF-kB signalling pathway (Rosenwald et al., N. Engl. J. Med., 346: 1937-47 (2002); Bea et al., Blood, 106: 3183-90 (2005); Tagawa et al., Blood, 106: 1770-77 (2005); Davis et al., J. Exp. Med., 194:1861-74 (2001); Ngo et al., Nature, 441: 106-10 (2006); Lenz et al., Science, 319: 1676-79 (2008)). When treated with CHOP-like chemotherapy, the overall survival rates of patients with GCB DLBCL and ABC DLBCL were 60% and 30%, respectively (Wright et al., Proc. Nat'l. Acad. Sci. USA, 100: 9991-96 (2003)). Thus, the prognosis for different DLBCL can vary widely.
  • A separate analytical approach identified four gene expression signatures that reflect distinct DLBCL tumor attributes and that were associated with distinct survival profiles in CHOP-treated DLBCL patients (Rosenwald et al., N. Engl. J. Med., 346: 1937-47 (2002)). A “germinal center B cell” (GCB) signature was associated with a favorable prognosis and paralleled the distinction between ABC and GCB DLBCL. The “proliferation” signature was associated with an adverse prognosis and included MYC and its target genes. The “MHC class II” signature was silenced in the malignant cells in a subset of DLBCL cases, an event that was associated with inferior survival (Rosenwald et al., N. Engl. J. Med., 346: 1937-47 (2002); Rimsza et al., Blood, 103: 4251-58 (2004)). A fourth prognostic signature, termed “lymph node” signature was associated with favorable prognosis and included components of the extracellular matrix, suggesting that it reflects the nature of the tumor-infiltrating non-malignant cells. These signatures predicted survival in a statistically independent fashion, indicating that multiple biological variables dictate the response to CHOP chemotherapy in DLBCL.
  • Reports have suggested that the benefit of Rituximab immunotherapy might be restricted to certain molecular subtypes of DLBCL. High expression of BCL-2 or low expression of BCL-6 was associated with inferior survival with CHOP therapy. However, this distinction disappeared with R-CHOP therapy (Mounier et al., Blood, 101: 4279-84 (2003); Winter et al., Blood, 107: 4207-13 (2006)). Immunohistochemistry has also been used to distinguish DLBCLs with a germinal center versus post-germinal center phenotype. Although such immunohistochemical phenotypes were prognostically significant in CHOP-treated cases, they were not prognostic for R-CHOP-treated cases (Nyman et al., Blood, 109: 4930-35 (2007)).
  • Accordingly, there is a need for new methods of distinguishing among DLBCL subtypes that is prognostically significant for R-CHOP-treated patients.
    • BRIEF SUMMARY OF THE INVENTION
  • The invention provides methods and arrays related to a gene expression-based survival predictor for DLBCL patients, including patients treated with the current standard of care, which includes chemotherapy and the administration of Rituximab.
  • The invention provides a method of predicting the survival outcome of a subject suffering from diffuse large B cell lymphoma (DLBCL) that includes obtaining a gene expression profile from one or more DLBCL biopsy samples from the subject. The gene expression profile, which can be derived from gene expression product isolated from the one or more biopsy samples, includes an expression level for each gene in a germinal center B cell (GCB) gene expression signature and each gene in a stromal-1 gene expression signature. From the gene expression profile, a GCB signature value and a stromal-1 signature value are derived. From these values, a survival predictor score can be calculated using an equation that includes subtracting [(x)*(the GCB signature value)] and subtracting [(y)*(the stromal-1 signature value)]. In the equation, (x) and (y) are scale factors. A lower survival predictor score indicates a more favorable survival outcome, and a higher survival predictor score indicates a less favorable survival outcome for the subject.
  • The invention also provides a method of generating a survival estimate curve for subjects suffering from DLBCL. Generally the method includes obtaining a gene expression profile from one or more DLBCL biopsy samples taken from each member of a plurality of subjects. Each gene expression profile, which can be derived from gene expression product isolated from the one or more biopsy samples taken from each subject, includes an expression level for each gene in a GCB expression signature, a stromal-1 gene expression signature, and a stromal-2 gene expression signature. For each subject, the GCB signature value, the stromal-1 signature value, and the stromal-2 signature value are determined from the subject's gene expression profile, and, for each subject, a survival predictor score is generated. Each subject's survival outcome following treatment for DLBCL is tracked. A survival estimate curve is generated which correlates the probability of the tracked survival outcome with time following treatment for DLBCL and which also correlates the tracked outcome over time with the survival predictor score for the subjects.
  • The invention additionally provides a method of predicting the survival outcome of a subject suffering from DLBCL. Generally, the method includes obtaining a gene expression profile from one or more DLBCL biopsy samples from the subject. The gene expression profile, which can be derived from gene expression product isolated from the one or more biopsy samples, includes an expression level for each gene in a GCB gene expression signature, each gene in a stromal-1 gene expression signature, and each gene in a stromal-2 gene expression signature. The GCB signature value, the stromal-1 signature value, and the stromal-2 signature value are determined from the gene expression profile. The method then includes calculating a survival predictor score using the equation:

  • survival predictor score=A−[(x)*(the GCB signature value)]−[(y)*(the stromal-1 signature value)]+[(z)*(the stromal-2 signature value)].
  • In this equation, A is an offset term, and (x), (y), and (z) are scale factors. The method further includes calculating the probability of a survival outcome for the subject beyond an amount of time t following treatment for DLBCL, wherein the subject's probability of the survival outcome P(SO) is calculated using the equation:

  • P(SO)=SO0(t)(exp((s)*survival predictor score))
  • In this equation, SO0(t) is the probability of the survival outcome, which corresponds to the largest time value smaller than t in a survival outcome curve, and wherein (s) is a scale factor.
  • Furthermore, the invention provides a method of evaluating a subject for antiangiogenic therapy of DLBCL. The method includes obtaining a gene expression profile from one or more DLBCL biopsy samples from the subject. The gene expression profile, which can be derived from gene expression product isolated from the one or more biopsy samples, includes an expression level for each gene in a stromal-2 signature. The subject's stromal-2 signature value is then derived from the gene expression profile and evaluated to determine whether the subject's stromal-2 signature value is higher or lower than a standard stromal-2 value. If the subject's stromal-2 signature value is higher than the standard stromal-2 value, then antiangiogenic therapy is indicated, and the subject can be treated with antiangiogenic therapy. If the subject's stromal-2 signature value is not higher than the standard stromal-2 value, then antiangiogenic therapy is not indicated.
  • The invention also provides a second method of evaluating a subject for antiangiogenic therapy of DLBCL. The method includes obtaining a gene expression profile from one or more DLBCL biopsy samples from the subject. The gene expression profile, which can be derived from gene expression product isolated from the one or more biopsy samples, includes an expression level for each gene in a stromal-1 signature and in a stromal-2 signature. The subject's stromal-1 signature value and stromal-2 signature value are then derived from the gene expression profile. The stromal-1 signature value is subtracted from the stomal-2 signature value to thereby obtain the subject's stromal score. The subject's stromal score is evaluated to determine whether it is higher or lower than a standard stromal score. If the subject's stromal score is higher than the standard stromal score, then antiangiogenic therapy is indicated, and the subject can be treated with antiangiogenic therapy. If the subject's stromal score is not higher than the standard stromal-score, then antiangiogenic therapy is not indicated.
  • Additionally, the invention provides a machine-readable medium containing a digitally encoded GCB signature value, a digitally encoded stromal-1 signature value, a digitally encoded stromal-2 signature, or any combination of the foregoing signature values obtained from a subject suffering from DLBCL.
  • In another embodiment the invention provides a machine-readable medium containing the digitally encoded survival predictor score obtained using a method disclosed herein for predicting the survival outcome of a subject suffering from diffuse large B cell lymphoma (DLBCL). In yet another embodiment, the invention provides a machine-readable medium containing the survival estimate curve obtained using a method disclosed herein for generating a survival estimate curve for subjects suffering from DLBCL. In still another embodiment, the invention provides a machine-readable medium containing the digitally encoded probability of survival calculated according to a method disclosed herein for predicting the survival outcome (e.g., progression-free survival or overall survival) of a subject suffering from DLBCL. Furthermore, the invention provides a machine-readable medium containing the digitally encoded stromal score generated by a method disclosed herein for evaluating a subject for antiangiogenic therapy of DLBCL.
  • The invention also provides a targeted array comprising at least one probe or at least one set of probes for each gene in a germinal center B cell gene (GCB) expression signature, a stromal-1 gene expression signature, and a stromal-2 gene expression signature. The array can include probes for fewer than 20,000 genes or fewer than 10,000 genes.
    • BRIEF DESCRIPTION OF THE DRAWINGS
  • FIG. 1A is a Kaplan-Meier estimates plot depicting the probability of progression-free-survival versus time (in years) of patients with GCB DLBCL and ABC DLBCL. The plot indicates that GCB patients have a more favorable, i.e., higher probability of progression-free survival rate than ABC patients for at least five years following R-CHOP therapy.
  • FIG. 1B a Kaplan-Meier estimates plot depicting the probability of overall survival versus time (in years) of patients with GCB DLBCL and ABC DLBCL. The plot indicates that GCB patients have a more favorable, i.e., higher probability, of overall survival than ABC patients for at least five years following R-CHOP therapy.
  • FIG. 1C is a series of four Kaplan-Meier estimates plots depicting the probabilities of overall survival versus time (in years) in DLBCL patients. Each of the four plots correlates the probability of overall survival with the lymph node/stromal-1, germinal center B cell, proliferation, or MHC class II gene expression signature, respectively. Moreover, in each plot, the average expression of the signature genes in each biopsy sample was used to rank cases and divide the cohort into quartile groups as indicated.
  • FIG. 2A is a pair of Kaplan-Meier estimates plots depicting the probability of progression-free-survival and the probability of overall survival, as indicated, versus time (in years) among DLBCL patients treated with R-CHOP. Patient samples were ranked according to a bivariate model created using the germinal center B cell (GCB) and stromal-1 signatures and divided into quartile groups.
  • FIG. 2B is a pair of Kaplan-Meier plots depicting the probability of progression-free-survival and the probability of overall survival, as indicated, versus time (in years) among DLBCL patients treated with R-CHOP. Patient samples were ranked according to a survival predictor score derived from a model incorporating the germinal center B cell, stromal-1, and stromal-2 signatures and divided into quartile groups.
  • FIG. 2C is a series of three Kaplan-Meier estimates plots depicting the probability of overall survival versus time (in years) among R-CHOP treated DLBCL patients in the indicated low, intermediate, or high IPI risk groups. Patient samples were stratified according to the same survival predictor score used in FIG. 2B, except that the first and second quartiles were merged, and the third and fourth quartiles were merged.
  • FIG. 3 depicts the expression levels of the indicated GCB cell, stromal-1, and stromal-2 signature genes in ABC, GCB, and unclassified DLBCL biopsy samples. Relative levels of gene expression are depicted according to the scale shown. Shown at the bottom are the signature averages for each patient. Also shown is the stromal score, which is the component of the survival model contributed by the difference between the stromal-2 and stromal-1 signature averages. The survival predictor score is shown for each patient and was used to order the cases, after grouping into ABC DLBCL, GCB DLBCL, and unclassified categories.
  • FIG. 4A depicts the relative gene expression of stromal-1, stromal-2, and germinal center B cell signatures in CD19+ malignant and CD19− non-malignant subpopulations of cells isolated from three biopsy specimens from patients with DLBCL. Stromal-1 and stromal-2 signature genes were more highly expressed in the non-malignant cells, whereas the germinal center B cell signature genes were more highly expressed in the malignant cells. The log 2 ratios of gene expression levels in the CD19− subpopulation to those in the CD19+ subpopulations are depicted according to the scale shown.
  • FIG. 4B depicts the results of gene enrichment analysis comparing the stromal-1 gene signature with mesenchyme-1 and mesenchyme-2 signatures (from normal mesenchymal origin cells), with a monocyte signature expressed more highly in normal blood monocytes than in blood B, T, and NK cells, and in a pan-T cell signature expressed more highly in blood T cells than in blood B cells, NK cells, and monocytes. While a relationship was seen between stromal-1 signature and mesenchyme-1, mesenchyme-2, and monocyte signatures, no relationship was observed between the stromal-1 signature and a pan-T cell signature expressed more highly in blood T cells than in blood B cells, NK cells, and monocytes. The relative levels of gene expression are depicted according to the scale shown.
  • FIG. 5A is a Kaplan-Meier estimates plot depicting the probability of overall survival versus time (in years) in DLBCL cases segregated according to SPARC protein expression levels, as indicated.
  • FIG. 5B is a pair of images showing the identification of tumor blood vessels by immunohistochemical analysis of CD34+ endothelial cells in representative DLBCL biopsies having low or high blood vessel density (CD34+ objects/μM2), as indicated.
  • FIG. 5C is a plot depicting the correlation between the tumor blood vessel density and the stromal score in analyzed DLBCL biopsies.
  • FIG. 6A is a Kaplan-Meier estimates plot depicting the probability of overall survival versus time (in years) for “LLMPP CHOP” patients with DLBCL following therapy. The plot indicates that in this cohort, patients with GCB DLBCL show significantly superior overall survival compared to patients with ABC DLBCL following CHOP therapy.
  • FIG. 6B is a is a Kaplan-Meier estimates plot depicting depicting the probability of overall survival versus time (in years) for “MMMLNP CHOP” patients with DLBCL following therapy. In this cohort, patients with GCB DLBCL show significantly superior overall survival compared to patients with ABC DLBCL following CHOP therapy.
  • FIG. 7 is a set of four Kaplan-Meier estimates plots depicting the probability of overall survival versus time (in years) in a “MMMLNP CHOP” cohort. Each of the four plots correlates the probability of overall survival with the lymph node/stromal-1, germinal center B cell, proliferation, or MHC class II gene expression signature, respectively. Moreover, in each plot, the average expression of the signature genes in each biopsy sample was used to rank cases and divide the cohort into quartile groups as indicated.
  • FIG. 8A is a Kaplan-Meier estimates plot depicting the probability of overall survival versus time (in years) in a “LLMPP CHOP” cohort, which was divided according to MHC class II signature expression levels. Patients with low MHC class II signature expression have significantly inferior overall survival compared to patients with normal MHC class II expression.
  • FIG. 8B is a Kaplan-Meier estimates plot depicting the probability of overall survival versus time (in years) in a “MMMLNP CHOP” cohort, which was divided according to MHC class II signature expression levels. Patients with low MHC class II signature expression have significantly inferior overall survival compared to patients with normal MHC class II expression.
  • FIG. 8C is a Kaplan-Meier estimates plot depicting the probability of overall survival versus time (in years) in a “LLMPP R-CHOP” cohort, which was divided according to MHC class II signature expression levels. There was no significant difference in the overall survival of patients with low MHC class II signature expression as compared to patients with normal MHC class II expression.
  • FIG. 9A is a pair of Kaplan-Meier estimates plots depicting the probabilities of progression-free survival or overall survival, as indicated, versus time (in years) among patients grouped into quartiles according to a gene expression model consisting of stromal-1 signature, GCB signature, and signature 122 following R-CHOP therapy.
  • FIG. 9B is a pair Kaplan-Meier estimates plots depicting the probabilities of overall survival versus time (in years) among “MMMLNP CHOP” cohort patients grouped into quartiles according to a gene expression model consisting of either stromal-1 signature and GCB signature or stromal-1, GCB signature, and signature 122, as indicated, following CHOP therapy.
  • FIG. 9C is a Kaplan-Meier estimates plot depicting the probabilities of overall survival versus time (in years) among “MMMLNP CHOP” cohort patients grouped into quartiles according to a gene expression model consisting of stromal-1 signature, GCB signature, and stromal-2 signature following CHOP therapy.
  • FIG. 10A is a Kaplan-Meier estimates plot depicting the overall survival among low revised International Prognostic Index (IPI) risk group patients stratified according to the gene expression-based outcome predictor score. After grouping patients into quartiles according to gene expression-based outcome predictor score, quartiles 1 and 2 were merged (Low Model Score), and quartiles 3 and 4 were merged (High Model Score).
  • FIG. 10B is a Kaplan-Meier estimates plot depicting the overall survival among intermediate revised International Prognostic Index (IPI) risk group patients stratified according to the gene expression-based outcome predictor. After grouping patients into quartiles according to gene expression-based outcome predictor score, quartiles 1 and 2 were merged (Low Model Score), and quartiles 3 and 4 were merged (High Model Score).
  • FIG. 10C is a Kaplan-Meier estimates plot depicting the overall survival among high revised International Prognostic Index (IPI) risk group patients stratified according to the gene expression-based outcome predictor. After grouping patients into quartiles according to gene expression-based outcome predictor score, quartiles 1 and 2 were merged (Low Model Score), and quartiles 3 and 4 were merged (High Model Score).
  • FIG. 11 depicts normal mesenchymal-1 and normal mesenchymal-2 signature gene expression in various normal tissues.
    •  DETAILED DESCRIPTION OF THE INVENTION
  • The invention provides a gene expression-based survival predictor for DLBCL patients, including those patients receiving the current standard of care, R-CHOP. The survival predictor can be used to determine the relative probability of a survival outcome in a specific subject. The survival predictor can also be used to predict; i.e., determine the expected probability that a survival outcome will occur by a defined period following treatment for DLBCL. Such prognostic information can be very useful to both the patient and the physician. Patients with survival predictor scores that indicate inferior outcome with R-CHOP therapy could be candidates for a different therapeutic regimen, if, for example, they relapse from R-CHOP treatment. The survival predictor can also be used in the design of clinical studies and analysis of clinical data to provide a quantitative survey of the types of DLBCL patients from which clinical data was gathered. The predictor can be used to improve one or more comparisons between data from different sources (e.g., from different clinical trials), by enabling comparisons with respect to patient characteristics, which are manifested in the gene expression levels that determine and, thus, are embodied in the predictor. Furthermore, the invention provides information that can be very valuable to a DLBCL patient, since the patient may be inclined to order his or her life quite differently, depending on whether the patient has a high or low probability of surviving and/or remaining progression-free for a period of time following treatment.
  • The following abbreviations are used herein: ABC, activated B cell-like diffuse large B cell lymphoma; CHOP, cyclophosphamide, doxorubicine, vincristine, and prednisone; CI, confidence interval; COP, cyclophosphamide, vincristine, and prednisone; DLBCL, diffuse large B cell lymphoma; DOD, dead of disease; ECOG, Eastern Cooperative Oncology Group; FACS, fluorescence-activated cell sorting; FH, follicular hyperplasia; FISH, fluorescence in situ hybridization; FL, follicular lymphoma; GC, germinal center; GCB, germinal center B cell-like diffuse large B cell lymphoma; IPI, International Prognostic Index; LPC, lymphoplasmacytic lymphoma; MHC, major histocompatibility complex; NA, not available or not applicable; NK, natural killer; PCR, polymerase chain reaction; RQ-PCR, real-time quantitative PCR; RT-PCR, reverse transcriptase polymerase chain reaction; SAGE, serial analysis of gene expression; WHO, World Health Organization.
  • The term “R-CHOP” as used herein refers generally to any therapeutic regimen that includes chemotherapy and the administration of Rituximab. Accordingly, while the term can refer to a Rituximab combination therapy that includes a CHOP regimen of cyclophosphamide, doxorubicine, vincristine, and prednisone, the term R-CHOP can also refer to therapy that includes Rituximab in combination with a chemotherapeutic regimen other than CHOP.
  • The phrase “gene expression data” as well as “gene expression level” as used herein refers to information regarding the relative or absolute level of expression of a gene or set of genes in a cell or group of cells. The level of expression of a gene may be determined based on the level of RNA, such as mRNA, encoded by the gene. Alternatively, the level of expression may be determined based on the level of a polypeptide or fragment thereof encoded by the gene. Gene expression data may be acquired for an individual cell, or for a group of cells such as a tumor or biopsy sample. Gene expression data and gene expression levels can be stored on computer readable media, e.g., the computer readable medium used in conjunction with a microarray or chip reading device. Such gene expression data can be manipulated to generate gene expression signatures.
  • The term “microarray,” “array,” or “chip” refers to a plurality of nucleic acid probes coupled to the surface of a substrate in different known locations. The substrate is preferably solid. Microarrays have been generally described in the art in, for example, U.S. Pat. No. 5,143,854 (Pirrung), U.S. Pat. No. 5,424,186 (Fodor), U.S. Pat. No. 5,445,934 (Fodor), U.S. Pat. No. 5,677,195 (Winkler), U.S. Pat. No. 5,744,305 (Fodor), U.S. Pat. No. 5,800,992 (Fodor), and U.S. Pat. No. 6,040,193 (Winkler), and Fodor et al., Science, 251: 767-777 (1991).
  • The term “gene expression signature” or “signature” as used herein refers to a group of coordinately expressed genes. The genes making up this signature may be expressed in a specific cell lineage, stage of differentiation, or during a particular biological response. The genes can reflect biological aspects of the tumors in which they are expressed, such as the cell of origin of the cancer, the nature of the non-malignant cells in the biopsy, and the oncogenic mechanisms responsible for the cancer (Shaffer et al., Immunity, 15: 375-385 (2001)). Examples of gene expression signatures include lymph node, proliferation (Rosenwald et al., New Engl. J. Med., 346: 1937-1947 (2002)), MHC class II, ABC DLBCL high, B cell differentiation, T-cell, macrophage, immune response-1, and immune response-2 signatures (U.S. Patent Application Publication No. 2007/0105136 (Staudt)).
  • The term “signature value” as used herein corresponds to a mathematical combination of measurements from expression levels of the genes in a gene expression signature. An exemplary signature value is a signature average which corresponds to the average or mean of the individual expression levels in a gene expression signature.
  • The phrase “survival predictor score” as used herein refers to a score generated by a multivariate model used to predict survival based on gene expression. A subject with a higher survival predictor score is predicted to have poorer survival than a subject with a lower survival predictor score.
  • The term “survival” or “overall survival” as used herein may refer to the probability or likelihood of a subject surviving for a particular period of time. Alternatively, it may refer to the likely term of survival for a subject, such as expected mean or median survival time for a subject with a particular gene expression pattern.
  • The term “progression free survival” as used herein can refer to the probability or likelihood of a subject surviving without significant progression or worsening of disease for a particular period of time. Alternatively, it may refer to the likely term for a subject of survival without significant progression or worsening of disease, such as expected mean or median survival time for a subject with a particular gene expression pattern without significant progression or worsening of disease.
  • The term “survival outcome” as used herein may refer to survival, overall survival, or progression free survival.
  • The phrase “scale factor” as used herein refers to a factor that relates change in gene expression to prognosis. An example of a scale factor is a factor obtained by maximizing the partial likelihoods of the Cox proportional hazards model.
  • The gene expression signatures, signature values, survival predictor scores, stromal scores, survival estimate curves, and probabilities of survival disclosed herein may be stored in digitally encoded format on computer readable media, e.g., computer readable media used in conjunction with microarray or chip reading devices or computer readable media used to store patient data during treatment for DLBCL. Such media and the specialized devices that use them, e.g., for diagnostic and clinical applications, are known in the art.
  • The invention provides a method for predicting a survival outcome in a subject diagnosed with DLBCL using gene expression data. Such data may be gathered using any effective method of quantifying gene expression. For example, gene expression data may be measured or estimated using one or more microarrays. The microarrays may be of any effective type, including, but not limited to, nucleic acid based or antibody based. Gene expression may also be measured by a variety of other techniques, including, but not limited to, PCR, quantitative RT-PCR, real-time PCR, RNA amplification, in situ hybridization, immunohistochemistry, immunocytochemistry, FACS, serial analysis of gene expression (SAGE) (Velculescu et al., Science, 270: 484-87 (1995)), Northern blot hybridization, or western blot hybridization.
  • Nucleic acid microarrays generally comprise nucleic acid probes derived from individual genes and placed in an ordered array on a support. This support may be, for example, a glass slide, a nylon membrane, or a silicon wafer. Gene expression patterns in a sample are obtained by hybridizing the microarray with the gene expression product from the sample. This gene expression product may be, for example, total cellular mRNA, rRNA, or cDNA obtained by reverse transcription of total cellular mRNA. The gene expression product from a sample is labeled with a radioactive, fluorescent, or other label to allow for detection. Following hybridization, the microarray is washed, and hybridization of the gene expression product to each nucleic acid probe on the microarray is detected and quantified using a detection device such as a phosphorimager or scanning confocal microscope.
  • There are two broad classes of microarrays: cDNA and oligonucleotide arrays. cDNA arrays consist of hundreds or thousands of cDNA probes immobilized on a solid support. These cDNA probes are usually 100 nucleotides or greater in size. There are two commonly used designs for cDNA arrays. The first is the nitrocellulose filter array, which is generally prepared by robotic spotting of purified DNA fragments or lysates of bacteria containing cDNA clones onto a nitrocellulose filter (Southern et al., Genomics, 13: 1008-17 (1992); Southern et al., Nucl Acids Res 22: 1368-73 (1994); Gress et al., Oncogene, 13: 1819-30 (1996); Pietu et al., Genome Res., 6: 492-503 (1996)). The other commonly used cDNA arrays is fabricated by robotic spotting of PCR fragments from cDNA clones onto glass microscope slides (Schena et al., Science, 270: 467-70 (1995); DeRisi et al., Nature Genet., 14: 457-60 (1996); Schena et al., Proc. Nat'l. Acad. Sci. USA, 93: 10614-19 (1996); Shalon et al., Genome Res., 6: 639-45 (1996); DeRisi et al., Science, 278: 680-86 (1997); Heller et al., Proc. Nat'l. Acad. Sci. USA, 94: 2150-55 (1997); Lashkari et al., Proc. Nat'l. Acad. Sci. USA, 94: 13057-62 (1997)). These cDNA microarrays are simultaneously hybridized with two fluorescent cDNA probes, each labeled with a different fluorescent dye (typically Cy3 or Cy5). In this format, the relative mRNA expression in two samples is directly compared for each gene on the microarray. Oligonucleotide arrays differ from cDNA arrays in that the probes are 20- to 25-mer oligonucleotides. Oligonucleotide arrays are generally produced by in situ oligonucleotide synthesis in conjunction with photolithographic masking techniques (Pease et al., Proc. Nat'l. Acad. Sci. USA, 91: 5022-26 (1994); Lipshutz et al., Biotechniques 19: 442-47 (1995); Chee et al., Science, 274: 610-14 (1996); Lockhart et al., Nature Biotechnol., 14: 1675-80 (1996); Wodicka et al., Nature Biotechnol., 15: 1359-6714 (1997)). The solid support for oligonucleotide arrays is typically a glass or silicon surface.
  • Methods and techniques applicable to array synthesis and use have been described in, for example, U.S. Pat. No. 5,143,854 (Pirrung), U.S. Pat. No. 5,242,974 (Holmes), U.S. Pat. No. 5,252,743 (Barrett), U.S. Pat. No. 5,324,633 (Fodor), U.S. Pat. No. 5,384,261 (Winkler), U.S. Pat. No. 5,424,186 (Fodor), U.S. Pat. No. 5,445,934 (Fodor), U.S. Pat. No. 5,451,683 (Barrett), U.S. Pat. No. 5,482,867 (Barrett), U.S. Pat. No. 5,491,074 (Aldwin), U.S. Pat. No. 5,527,681 (Holmes), U.S. Pat. No. 5,550,215 (Holmes), U.S. Pat. No. 5,571,639 (Hubbell), U.S. Pat. No. 5,578,832 (Trulson), U.S. Pat. No. 5,593,839 (Hubbell), U.S. Pat. No. 5,599,695 (Pease), U.S. Pat. No. 5,624,711 (Sundberg), U.S. Pat. No. 5,631,734 (Stern), U.S. Pat. No. 5,795,716 (Chee), U.S. Pat. No. 5,831,070 (Pease), U.S. Pat. No. 5,837,832 (Chee), U.S. Pat. No. 5,856,101 (Hubbell), U.S. Pat. No. 5,858,659 (Sapolsky), U.S. Pat. No. 5,936,324 (Montagu), U.S. Pat. No. 5,968,740 (Fodor), U.S. Pat. No. 5,974,164 (Chee), U.S. Pat. No. 5,981,185 (Matson), U.S. Pat. No. 5,981,956 (Stern), U.S. Pat. No. 6,025,601 (Trulson), U.S. Pat. No. 6,033,860 (Lockhart), U.S. Pat. No. 6,040,193 (Winkler), U.S. Pat. No. 6,090,555 (Fiekowsky), and U.S. Pat. No. 6,410,229 (Lockhart), and U.S. Patent Application Publication No. 2003/0104411 (Fodor).
  • Microarrays may generally be produced using a variety of techniques, such as mechanical or light directed synthesis methods that incorporate a combination of photolithographic methods and solid phase synthesis methods. Techniques for the synthesis of microarrays using mechanical synthesis methods are described in, for example, U.S. Pat. No. 5,384,261 (Winkler) and U.S. Pat. No. 6,040,193 (Winkler). Although a planar array surface is preferred, the microarray may be fabricated on a surface of virtually any shape, or even on a multiplicity of surfaces. Microarrays may be nucleic acids on beads, gels, polymeric surfaces, fibers such as fiber optics, glass, or any other appropriate substrate. See, for example, U.S. Pat. No. 5,708,153 (Dower), U.S. Pat. No. 5,770,358 (Dower), U.S. Pat. No. 5,789,162 (Dower), U.S. Pat. No. 5,800,992 (Fodor), and U.S. Pat. No. 6,040,193 (Winkler).
  • Microarrays can be packaged in such a manner as to allow for diagnostic use, or they can be all-inclusive devices. See, for example, U.S. Pat. No. 5,856,174 (Lipshutz) and U.S. Pat. No. 5,922,591 (Anderson).
  • Microarrays directed to a variety of purposes are commercially available from Affymetrix (Santa Clara, Calif.). For instance, these microarrays may be used for genotyping and gene expression monitoring.
  • Gene expression data can be used to identify genes that are coordinately regulated. Genes that encode components of the same multi-subunit protein complex are often coordinately regulated. Coordinate regulation is also observed among genes whose products function in a common differentiation program or in the same physiological response pathway. Recent application of gene expression profiling to the immune system has shown that lymphocyte differentiation and activation are accompanied by parallel changes in expression among hundreds of genes. Gene expression databases may be used to interpret the pathological changes in gene expression that accompany autoimmunity, immune deficiencies, cancers of immune cells and of normal immune responses.
  • Scanning and interpreting large bodies of relative gene expression data is a formidable task. This task is greatly facilitated by algorithms designed to organize the data in a way that highlights systematic features, and by visualization tools that represent the differential expression of each gene as varying intensities and hues of color (Eisen et al., Proc. Nat'l. Acad. Sci. USA, 95: 14863-68 (1998)). The development of microarrays, which are capable of generating massive amounts of expression data in a single experiment, has greatly increased the need for faster and more efficient methods of analyzing large-scale expression data sets. In order to effectively utilize microarray gene expression data for the prediction of survival in DLBCL patients, there is a need for new algorithms to be developed, which can identify important information and convert it to a more manageable format. In addition, the microarrays used to generate this data can be streamlined to incorporate probe sets that are useful for survival outcome prediction.
  • Mathematical analysis of gene expression data is a rapidly evolving science based on a rich mathematics of pattern recognition developed in other contexts (Kohonen, Self-Organizing Maps, Springer Press (Berlin 1997)). Mathematical analysis of gene expression data can be used, for example, to identify groups of genes that are coordinately regulated within a biological system, to recognize and interpret similarities between biological samples on the basis of similarities in gene expression patterns, and/or to recognize and identify those features of a gene expression pattern that are related to distinct biological processes or phenotypes.
  • Mathematical analysis of gene expression data often begins by establishing the expression pattern for each gene on an array across a number (n) of experimental samples. The expression pattern of each gene can be represented by a point in n-dimensional space, with each coordinate specified by an expression measurement in one of the n samples (Eisen et al., Proc. Nat'l. Acad. Sci. USA, 95: 14863-68 (1998)). A clustering algorithm that uses distance metrics can then be applied to locate clusters of genes in this n-dimensional space. These clusters indicate genes with similar patterns of variation in expression over a series of experiments. Clustering methods that have been applied to microarray data in the past include hierarchical clustering (Eisen et al., supra), self-organizing maps (SOMs) (Tamayo et al., Proc. Nat'l. Acad. Sci. USA, 96: 2907-12 (1999)), k-means (Tavazoie et al., Nature Genet., 22: 281-85 (1999)), and deterministic annealing (Alon et al., Proc. Nat'l. Acad. Sci. USA, 96: 6745-50 (1999)).
  • A variety of different algorithms, each emphasizing distinct orderly features of the data, may be required to glean the maximal biological insight from a set of samples (Alizadeh et al., J. Clin. Immunol., 18: 373-79 (1998)). One such algorithm, hierarchical clustering, begins by determining the gene expression correlation coefficients for each pair of the n genes studied. Genes with similar gene expression correlation coefficients are grouped next to one another in a hierarchical fashion. Generally, genes with similar expression patterns under a particular set of conditions can encode protein products with related roles in the physiological adaptation to those conditions. Novel genes of unknown function that are clustered with a large group of functionally related genes likely participate in similar or related biological process. Likewise, other clustering methods mentioned herein can also group genes together that encode proteins with related biological function.
  • In such clustering methods, genes that are clustered together reflect a particular biological function, and are termed gene expression signatures (Shaffer et al., Immunity 15: 375-85 (2001)). One general type of gene expression signature includes genes that are characteristically expressed in a particular cell type or at a particular stage of cellular differentiation or activation. Another general type of gene expression signature includes genes that are regulated in their expression by a particular biological process such as proliferation, or by the activity of a particular transcription factor or signaling pathway.
  • The pattern of gene expression in a biological sample can provide a distinctive and accessible molecular picture of its functional state and identity (DeRisi et al., Science, 278: 680-86 (1997); Cho et al., Mol. Cell., 2: 65-73 (1998); Chu et al., Science, 282: 699-705 (1998); Holstege et al., Cell., 95: 717-728 (1998); Spellman et al., Mol. Biol. Cell, 9: 3273-97 (1998)). Each cell transduces variations in its environment, internal state, and developmental state into readily measured and recognizable variations in its gene expression patterns. Two different samples with related gene expression patterns are therefore likely to be biologically and functionally similar to one another. Thus, a specific gene expression signature in a sample can provide important biological insights into its cellular composition and the function of various intracellular pathways within those cells.
  • Databases of gene expression signatures have proven useful in elucidating the complex gene expression patterns of various cancers. For example, the expression pattern of genes in the germinal center B cell signature in a lymphoma biopsy indicates that the lymphoma includes cells derived from the germinal center stage of differentiation. In the same lymphoma biopsy, the expression of genes from the T cell signature can be used to estimate the degree of infiltration of the tumor by host T cells, while the expression of genes from the proliferation signature can be used to quantitate the tumor cell proliferation rate. In this manner, gene expression signatures provide an “executive summary” of the biological properties of a tumor specimen. Gene expression signatures can also be helpful in interpreting the results of a supervised analysis of gene expression data. A supervised analysis generates a list of genes with expression patterns that correlate with survival. Gene expression signatures can be useful in assigning these “predictive” genes to functional categories. In building a multivariate model of survival based on gene expression data, this functional categorization helps to limit the inclusion of multiple genes in the model that measure the same aspect of tumor biology.
  • This following approach was utilized to create the survival prediction models for DLBCL of the invention. Gene expression profiles were used to create multivariate models for predicting survival. The methods for creating these models were “supervised” in that they used clinical data to guide the selection of genes to be used in the prognostic classification. The method identified genes with expression patterns that correlated with the length of overall survival following chemotherapy. Generally the process for identifying the multivariate model for predicting survival included the following steps:
      • 1. Genes were identified having expression patterns univariately associated with a particular clinical outcome using a Cox proportional hazards model. Generally, a univariate p-value of <0.01 is considered the cut-off for significance (however, another criterion can be used). These genes were termed “predictor” genes.
      • 2. Within a set of predictor genes, gene expression signatures were identified.
      • 3. For each gene expression signature significantly associated with survival, the average expression of each component genes within this signature was used to generate a gene expression signature value.
      • 4. A multivariate Cox model of clinical outcome using the gene expression signature values was built.
      • 5. Additional genes were added to the model, which added to the statistical power of the model.
  • The model of the invention generates a survival predictor score, with a higher score being associated with worse clinical outcome. The resulting model can be used separately to predict a survival outcome. Alternatively, the model can be used in conjunction with one or more other models, disclosed herein or in other references, to predict a survival outcome.
  • The present invention discloses several gene expression signatures related to the clinical outcome of DLBCL patients. The signatures were identified using the clinical data and methods described below in Examples 1 and 2. Three of these gene expression signatures are the germinal center B cell (GCB) signature, the stromal-1 signature, and the stromal-2 signature. Each component gene of these signatures is identified in Table 1 according to its GenBank accession number, its GeneID assigned by Entrez Gene, a common gene symbol, and a descriptive gene title. Table 1 also provides the Affymetrix Probe Set ID, which can be used (e.g., on the Affymetrix U133+ (Affymetrix, Santa Clara, Calif.) microarray) to determine the gene expression level for the indicated gene. The computer-readable sequence listing filed herewith includes a representative fragment sequence (of about 100 by or greater) for each genomic target sequence listed in Table 1, followed by the sequence for each probe in the corresponding Affymetrix probe set listed in Table 1.
  • TABLE 1
    GenBank Entrez Affymetrix
    Signature Accession No. GeneID Gene Symbol Gene Title Probe Set ID
    GCB NM_052932 114908 TMEM123 transmembrane protein 211967_at
    123
    GCB NM_001014380 84056 KATNAL1 katanin p60 subunit A-like 1 227713_at
    GCB NM_004665 8875 VNN2 vanin 2 205922_at
    GCB NM_004760 9263 STK17A serine/threonine kinase 202693_s_at
    17a (apoptosis-inducing)
    GCB CR590554 Full-length cDNA clone 228464_at
    CS0DF007YJ21 of Fetal
    brain of Homo sapiens
    (human)
    GCB NM_017599 55591 VEZT vezatin, adherens 223089_at
    junctions transmembrane
    protein
    GCB NM_018351 55785 FGD6 FYVE, RhoGEF and PH 1555136_at
    domain containing 6
    GCB NM_001007075 51088 KLHL5 kelch-like 5 (Drosophila) 226001_at
    GCB NM_004845 9468 PCYT1B phosphate 228959_at
    cytidylyltransferase 1,
    choline, beta
    GCB AK026881 CDNA: FLJ23228 fis, 226799_at
    clone CAE06654
    GCB NM_018440 55824 PAG1 phosphoprotein 225626_at
    associated with
    glycosphingolipid
    microdomains 1
    GCB NM_004965 3150 HMGN1 high-mobility group 200944_s_at
    nucleosome binding
    domain 1
    GCB NM_001706 604 BCL6 B cell CLL/lymphoma 6 228758_at
    (zinc finger protein 51)
    GCB NM_020747 57507 ZNF608 zinc finger protein 608 229817_at
    GCB NM_001001695 400941 FLJ42418 FLJ42418 protein 231455_at
    GCB NM_015055 23075 SWAP70 SWAP-70 protein 209306_s_at
    GCB NM_005607 5747 PTK2 PTK2 protein tyrosine 208820_at
    kinase 2
    GCB XM_027236 23508 TTC9 tetratricopeptide repeat 213172_at
    domain 9
    GCB BQ213652 440864 LOC440864 hypothetical gene 1569034_a_at
    supported by BC040724
    GCB NM_005574 4005 LMO2 LIM domain only 2 204249_s_at
    (rhombotin-like 1)
    GCB NM_014667 9686 VGLL4 vestigial like 4 212399_s_at
    (Drosophila)
    GCB NM_002221 3707 ITPKB inositol 1,4,5- 203723_at
    trisphosphate 3-kinase B
    GCB NM_000902 4311 MME membrane metallo- 203434_s_at
    endopeptidase (neutral
    endopeptidase,
    enkephalinase)
    GCB NM_012446 23635 SSBP2 single-stranded DNA 203787_at
    binding protein 2
    GCB NM_024613 79666 PLEKHF2 pleckstrin homology 222699_s_at
    domain containing, family
    F (with FYVE domain)
    member 2
    GCB AV705976 Transcribed locus 204681_s_at
    GCB NM_012108 26228 BRDG1 BCR downstream 220059_at
    signaling 1
    GCB NM_014397 10783 NEK6 NIMA (never in mitosis 223158_s_at
    gene a)-related kinase 6
    GCB NM_018981 54431 DNAJC10 DnaJ (Hsp40) homolog, 225174_at
    subfamily C, member 10
    GCB NM_001379 1786 DNMT1 DNA (cytosine-5-)- 227684_at
    methyltransferase 1
    GCB NM_006152 4033 LRMP lymphoid-restricted 35974_at
    membrane protein
    GCB NM_024701 79754 ASB13 ankyrin repeat and SOCS 218862_at
    box-containing 13
    GCB NM_006085 10380 BPNT1 3′(2′), 5′-bisphosphate 232103_at
    nucleotidase 1
    GCB NM_023009 65108 MARCKSL1 MARCKS-like 1 200644_at
    GCB NM_033121 88455 ANKRD13A ankyrin repeat domain 224810_s_at
    13A
    GCB NM_015187 23231 KIAA0746 KIAA0746 protein 235353_at
    GCB NM_175739 327657 SERPINA9 serpin peptidase inhibitor, 1553499_s_at
    clade A (alpha-1
    antiproteinase,
    antitrypsin), member 9
    GCB NM_001012391 400509 RUNDC2B RUN domain containing 1554413_s_at
    2B
    GCB XM_034274 4603 MYBL1 v-myb myeloblastosis 213906_at
    viral oncogene homolog
    (avian)-like 1
    Stromal-1 NM_024579 79630 C1orf54 chromosome 1 open 219506_at
    reading frame 54
    Stromal-1 NM_001645 341 APOC1 apolipoprotein C-I 213553_x_at
    Stromal-1 NM_001562 3606 IL18 interleukin 18 (interferon- 206295_at
    gamma-inducing factor)
    Stromal-1 NM_014479 27299 ADAMDEC1 ADAM-like, decysin 1 206134_at
    Stromal-1 NM_003465 1118 CHIT1 chitinase 1 208168_s_at
    (chitotriosidase)
    Stromal-1 NM_000954 5730 PTGDS prostaglandin D2 211748_x_at
    synthase 21 kDa (brain)
    Stromal-1 NM_001056 6819 SULT1C1 sulfotransferase family, 211470_s_at
    cytosolic, 1C, member 1
    Stromal-1 NM_018000 55686 MREG melanoregulin 219648_at
    Stromal-1 NM_001018058 22797 TFEC transcription factor EC 206715_at
    Stromal-1 NM_000239 4069 LYZ lysozyme (renal 213975_s_at
    amyloidosis)
    Stromal-1 NM_006834 10981 RAB32 RAB32, member RAS 204214_s_at
    oncogene family
    Stromal-1 NM_000416 3459 IFNGR1 interferon gamma 202727_s_at
    receptor 1
    Stromal-1 NM_004666 8876 VNN1 vanin 1 205844_at
    Stromal-1 NM_031491 83758 RBP5 retinol binding protein 5, 223820_at
    cellular
    Stromal-1 NM_001276 1116 CHI3L1 chitinase 3-like 1 209396_s_at
    (cartilage glycoprotein-39)
    Stromal-1 NM_138434 113763 C7orf29 chromosome 7 open 227598_at
    reading frame 29
    Stromal-1 NM_001005340 10457 GPNMB glycoprotein 201141_at
    (transmembrane) nmb
    Stromal-1 NM_002294 3920 LAMP2 lysosomal-associated 203041_s_at
    membrane protein 2
    Stromal-1 NM_002888 5918 RARRES1 retinoic acid receptor 221872_at
    responder (tazarotene
    induced) 1
    Stromal-1 NM_172248 1438 CSF2RA colony stimulating factor 2 210340_s_at
    receptor, alpha, low-
    affinity (granulocyte-
    macrophage)
    Stromal-1 NM_018344 55315 SLC29A3 solute carrier family 29 219344_at
    (nucleoside transporters),
    member 3
    Stromal-1 NM_032413 84419 C15orf48 chromosome 15 open 223484_at
    reading frame 48
    Stromal-1 NM_001001851 80760 ITIH5 inter-alpha (globulin) 1553243_at
    inhibitor H5
    Stromal-1 NM_000211 3689 ITGB2 integrin, beta 2 1555349_a_at
    (complement component
    3 receptor 3 and 4
    subunit)
    Stromal-1 NM_005213 1475 CSTA cystatin A (stefin A) 204971_at
    Stromal-1 NM_003874 8832 CD84 CD84 molecule 205988_at
    Stromal-1 NM_000228 3914 LAMB3 laminin, beta 3 209270_at
    Stromal-1 NM_005651 6999 TDO2 tryptophan 2,3- 205943_at
    dioxygenase
    Stromal-1 NM_001005266 283651 C15orf21 chromosome 15 open 242649_x_at
    reading frame 21
    Stromal-1 AV659177 Transcribed locus 230391_at
    Stromal-1 NM_001747 822 CAPG capping protein (actin 201850_at
    filament), gelsolin-like
    Stromal-1 NM_000784 1593 CYP27A1 cytochrome P450, family 203979_at
    27, subfamily A,
    polypeptide 1
    Stromal-1 NM_052998 113451 ADC arginine decarboxylase 228000_at
    Stromal-1 NM_016240 51435 SCARA3 scavenger receptor class 219416_at
    A, member 3
    Stromal-1 Z74615 COL1A1 Collagen, type I, alpha 1 217430_x_at
    Stromal-1 NM_052947 115701 ALPK2 alpha-kinase 2 228367_at
    Stromal-1 NM_021136 6252 RTN1 reticulon 1 210222_s_at
    Stromal-1 AL049370 Full-length cDNA clone 213100_at
    CL0BB018ZE07 of
    Neuroblastoma of Homo
    sapiens (human)
    Stromal-1 NM_006042 9955 HS3ST3A1 heparan sulfate 219985_at
    (glucosamine) 3-O-
    sulfotransferase 3A1
    Stromal-1 NM_000041 348 APOE apolipoprotein E 203382_s_at
    Stromal-1 NM_004994 4318 MMP9 matrix metallopeptidase 9 203936_s_at
    (gelatinase B, 92 kDa
    gelatinase, 92 kDa type IV
    collagenase)
    Stromal-1 NM_001831 1191 CLU clusterin 222043_at
    Stromal-1 NM_002305 3956 LGALS1 lectin, galactoside- 201105_at
    binding, soluble, 1
    (galectin 1)
    Stromal-1 NM_032024 83938 C10orf11 chromosome 10 open 223703_at
    reading frame 11
    Stromal-1 NM_001025201 1123 CHN1 chimerin (chimaerin) 1 212624_s_at
    Stromal-1 NM_003489 8204 NRIP1 nuclear receptor 202599_s_at
    interacting protein 1
    Stromal-1 NM_032646 94015 TTYH2 tweety homolog 2 223741_s_at
    (Drosophila)
    Stromal-1 NM_001312 1397 CRIP2 cysteine-rich protein 2 208978_at
    Stromal-1 NM_023075 65258 MPPE1 metallophosphoesterase 1 213924_at
    Stromal-1 NM_004364 1050 CEBPA CCAAT/enhancer binding 204039_at
    protein (C/EBP), alpha
    Stromal-1 NM_000248 4286 MITF microphthalmia- 207233_s_at
    associated transcription
    factor
    Stromal-1 NM_002185 3575 IL7R interleukin 7 receptor 226218_at
    Stromal-1 NM_021638 60312 AFAP actin filament associated 203563_at
    protein
    Stromal-1 NM_003786 8714 ABCC3 ATP-binding cassette, 208161_s_at
    sub-family C
    (CFTR/MRP), member 3
    Stromal-1 730351 LOC730351 hypothetical protein 229407_at
    LOC730351
    Stromal-1 NM_012153 26298 EHF ets homologous factor 225645_at
    Stromal-1 NM_004887 9547 CXCL14 chemokine (C—X—C motif) 222484_s_at
    ligand 14
    Stromal-1 NM_002030 2359 FPRL2 formyl peptide receptor- 230422_at
    like 2
    Stromal-1 NM_001321 1466 CSRP2 cysteine and glycine-rich 207030_s_at
    protein 2
    Stromal-1 NM_001945 1839 HBEGF heparin-binding EGF-like 203821_at
    growth factor
    Stromal-1 NM_031412 23710 GABARAPL1 GABA(A) receptor- 208869_s_at
    associated protein like 1
    Stromal-1 NM_006022 8848 TSC22D1 TSC22 domain family, 215111_s_at
    member 1
    Stromal-1 NM_016174 51148 CEECAM1 cerebral endothelial cell 224794_s_at
    adhesion molecule 1
    Stromal-1 NM_015103 23129 PLXND1 plexin D1 212235_at
    Stromal-1 NM_003270 7105 TSPAN6 tetraspanin 6 209109_s_at
    Stromal-1 NM_000887 3687 ITGAX integrin, alpha X 210184_at
    (complement component
    3 receptor 4 subunit)
    Stromal-1 NM_001864 1346 COX7A1 cytochrome c oxidase 204570_at
    subunit VIIa polypeptide 1
    (muscle)
    Stromal-1 CR599008 GPR157 Full-length cDNA clone 227970_at
    CS0DJ007YL22 of T cells
    (Jurkat cell line) Cot 10-
    normalized of Homo
    sapiens (human)
    Stromal-1 NM_198580 376497 SLC27A1 solute carrier family 27 226728_at
    (fatty acid transporter),
    member 1
    Stromal-1 NM_025106 80176 SPSB1 splA/ryanodine receptor 226075_at
    domain and SOCS box
    containing 1
    Stromal-1 NM_020130 56892 C8orf4 chromosome 8 open 218541_s_at
    reading frame 4
    Stromal-1 NM_173833 286133 SCARA5 scavenger receptor class 229839_at
    A, member 5 (putative)
    Stromal-1 NM_007223 11245 GPR176 G protein-coupled 227846_at
    receptor 176
    Stromal-1 NM_013437 29967 LRP12 low density lipoprotein- 219631_at
    related protein 12
    Stromal-1 NM_007332 8989 TRPA1 transient receptor 228438_at
    potential cation channel,
    subfamily A, member 1
    Stromal-1 NM_152744 221935 SDK1 sidekick homolog 1 229912_at
    (chicken)
    Stromal-1 NM_001409 1953 MEGF6 multiple EGF-like- 226869_at
    domains 6
    Stromal-1 NM_012082 23414 ZFPM2 zinc finger protein, 219778_at
    multitype 2
    Stromal-1 NM_080430 140606 SELM selenoprotein M 226051_at
    Stromal-1 NM_030971 81855 SFXN3 sideroflexin 3 217226_s_at
    Stromal-1 NM_003246 7057 THBS1 thrombospondin 1 201109_s_at
    Stromal-1 NM_003882 8840 WISP1 WNT1 inducible signaling 235821_at
    pathway protein 1
    Stromal-1 NM_005202 1296 COL8A2 collagen, type VIII, alpha 2 221900_at
    Stromal-1 NM_003711 8611 PPAP2A phosphatidic acid 210946_at
    phosphatase type 2A
    Stromal-1 NM_004995 4323 MMP14 matrix metallopeptidase 202828_s_at
    14 (membrane-inserted)
    Stromal-1 NM_001005336 1759 DNM1 dynamin 1 215116_s_at
    Stromal-1 NM_153717 2121 EVC Ellis van Creveld 219432_at
    syndrome
    Stromal-1 NM_173462 89932 PAPLN papilin, proteoglycan-like 226435_at
    sulfated glycoprotein
    Stromal-1 XM_496707 441027 FLJ12993 hypothetical LOC441027 229623_at
    Stromal-1 NM_001839 1266 CNN3 calponin 3, acidic 228297_at
    Stromal-1 NM_015429 25890 ABI3BP ABI gene family, member 223395_at
    3 (NESH) binding protein
    Stromal-1 NM_002840 5792 PTPRF protein tyrosine 200636_s_at
    phosphatase, receptor
    type, F
    Stromal-1 NM_001001522 6876 TAGLN transgelin 1555724_s_at
    Stromal-1 NM_017637 54796 BNC2 basonuclin 2 229942_at
    Stromal-1 NM_003391 7472 WNT2 wingless-type MMTV 205648_at
    integration site family
    member 2
    Stromal-1 NM_015461 25925 ZNF521 zinc finger protein 521 226677_at
    Stromal-1 NM_006475 10631 POSTN periostin, osteoblast 210809_s_at
    specific factor
    Stromal-1 NM_005418 6764 ST5 suppression of 202440_s_at
    tumorigenicity 5
    Stromal-1 NM_005203 1305 COL13A1 collagen, type XIII, alpha 1 211343_s_at
    Stromal-1 NM_000681 150 ADRA2A adrenergic, alpha-2A-, 209869_at
    receptor
    Stromal-1 NM_006622 10769 PLK2 polo-like kinase 2 201939_at
    (Drosophila)
    Stromal-1 AL528626 Full-length cDNA clone 228573_at
    CS0DD001YA12 of
    Neuroblastoma Cot 50-
    normalized of Homo
    sapiens (human)
    Stromal-1 AF180519 23766 GABARAPL3 GABA(A) receptors 211458_s_at
    associated protein like 3
    Stromal-1 NM_024723 79778 MICALL2 MICAL-like 2 219332_at
    Stromal-1 NM_057177 117583 PARD3B par-3 partitioning 228411_at
    defective 3 homolog B (C. elegans)
    Stromal-1 NM_004949 1824 DSC2 desmocollin 2 226817_at
    Stromal-1 NM_032784 84870 RSPO3 R-spondin 3 homolog 228186_s_at
    (Xenopus laevis)
    Stromal-1 NM_007039 11099 PTPN21 protein tyrosine 226380_at
    phosphatase, non-
    receptor type 21
    Stromal-1 NM_031935 83872 HMCN1 hemicentin 1 235944_at
    Stromal-1 AK022877 Clone TUA8 Cri-du-chat 213169_at
    region mRNA
    Stromal-1 AK127644 CDNA FLJ45742 fis, 236297_at
    clone KIDNE2016327
    Stromal-1 AK056963 Full length insert cDNA 226282_at
    clone ZE03F06
    Stromal-1 NM_000899 4254 KITLG KIT ligand 226534_at
    Stromal-1 NM_002387 4163 MCC mutated in colorectal 226225_at
    cancers
    Stromal-1 NM_198270 4810 NHS Nance-Horan syndrome 228933_at
    (congenital cataracts and
    dental anomalies)
    Stromal-1 NM_183376 91947 ARRDC4 arrestin domain 225283_at
    containing 4
    Stromal-1 NM_000216 3730 KAL1 Kallmann syndrome 1 205206_at
    sequence
    Stromal-1 NM_001008224 55075 UACA uveal autoantigen with 223279_s_at
    coiled-coil domains and
    ankyrin repeats
    Stromal-1 NM_133493 135228 CD109 CD109 molecule 226545_at
    Stromal-1 NM_005545 3671 ISLR immunoglobulin 207191_s_at
    superfamily containing
    leucine-rich repeat
    Stromal-1 NM_014365 26353 HSPB8 heat shock 22 kDa protein 8 221667_s_at
    Stromal-1 NM_014476 27295 PDLIM3 PDZ and LIM domain 3 209621_s_at
    Stromal-1 NM_020962 57722 NOPE likely ortholog of mouse 227870_at
    neighbor of Punc E11
    Stromal-1 NM_018357 55323 LARP6 La ribonucleoprotein 218651_s_at
    domain family, member 6
    Stromal-1 NM_012323 23764 MAFF v-maf 36711_at
    musculoaponeurotic
    fibrosarcoma oncogene
    homolog F (avian)
    Stromal-1 NM_003713 8613 PPAP2B phosphatidic acid 212230_at
    phosphatase type 2B
    Stromal-1 NM_023016 65124 ANKRD57 ankyrin repeat domain 57 227034_at
    Stromal-1 NM_032777 25960 GPR124 G protein-coupled 65718_at
    receptor 124
    Stromal-1 NM_001554 3491 CYR61 cysteine-rich, angiogenic 201289_at
    inducer, 61
    Stromal-1 NM_145117 89797 NAV2 neuron navigator 2 218330_s_at
    Stromal-1 NM_001002292 79971 GPR177 G protein-coupled 228950_s_at
    receptor 177
    Stromal-1 NM_001401 1902 EDG2 endothelial differentiation, 204036_at
    lysophosphatidic acid G-
    protein-coupled receptor, 2
    Stromal-1 NM_198282 340061 TMEM173 transmembrane protein 224929_at
    173
    Stromal-1 NM_014934 22873 DZIP1 DAZ interacting protein 1 204556_s_at
    Stromal-1 NM_001901 1490 CTGF connective tissue growth 209101_at
    factor
    Stromal-1 NM_024600 79652 C16orf30 chromosome 16 open 219315_s_at
    reading frame 30
    Stromal-1 NM_138370 91461 LOC91461 hypothetical protein 225380_at
    BC007901
    Stromal-1 NM_014632 9645 MICAL2 microtubule associated 212472_at
    monoxygenase, calponin
    and LIM domain
    containing 2
    Stromal-1 NM_032866 84952 CGNL1 cingulin-like 1 225817_at
    Stromal-1 NM_003687 8572 PDLIM4 PDZ and LIM domain 4 211564_s_at
    Stromal-1 BM544548 Transcribed locus 236179_at
    Stromal-1 NM_001856 1307 COL16A1 collagen, type XVI, alpha 1 204345_at
    Stromal-1 XM_087386 57493 HEG1 HEG homolog 1 213069_at
    (zebrafish)
    Stromal-1 NM_003887 8853 DDEF2 development and 206414_s_at
    differentiation enhancing
    factor 2
    Stromal-1 NM_002844 5796 PTPRK protein tyrosine 203038_at
    phosphatase, receptor
    type, K
    Stromal-1 NM_022138 64094 SMOC2 SPARC related modular 223235_s_at
    calcium binding 2
    Stromal-1 NM_001006624 10630 PDPN podoplanin 204879_at
    Stromal-1 NM_003174 6840 SVIL supervillin 202565_s_at
    Stromal-1 NM_002845 5797 PTPRM protein tyrosine 1555579_s_at
    phosphatase, receptor
    type, M
    Stromal-1 NM_002889 5919 RARRES2 retinoic acid receptor 209496_at
    responder (tazarotene
    induced) 2
    Stromal-1 NM_006094 10395 DLC1 deleted in liver cancer 1 210762_s_at
    Stromal-1 NM_022463 64359 NXN nucleoredoxin 219489_s_at
    Stromal-1 AK027294 CDNA FLJ14388 fis, 229802_at
    clone HEMBA1002716
    Stromal-1 NM_005711 10085 EDIL3 EGF-like repeats and 225275_at
    discoidin I-like domains 3
    Stromal-1 NM_000177 2934 GSN gelsolin (amyloidosis, 200696_s_at
    Finnish type)
    Stromal-1 NM_016639 51330 TNFRSF12A tumor necrosis factor 218368_s_at
    receptor superfamily,
    member 12A
    Stromal-1 NM_004460 2191 FAP fibroblast activation 209955_s_at
    protein, alpha
    Stromal-1 NM_000064 718 C3 complement component 3 217767_at
    Stromal-1 NM_016206 389136 VGLL3 vestigial like 3 227399_at
    (Drosophila)
    Stromal-1 NM_004339 754 PTTG1IP pituitary tumor- 200677_at
    transforming 1 interacting
    protein
    Stromal-1 NM_003255 7077 TIMP2 TIMP metallopeptidase 224560_at
    inhibitor 2
    Stromal-1 NM_002998 6383 SDC2 syndecan 2 (heparan 212158_at
    sulfate proteoglycan 1,
    cell surface-associated,
    fibroglycan)
    Stromal-1 NM_012223 4430 MYO1B myosin IB 212364_at
    Stromal-1 NM_020650 57333 RCN3 reticulocalbin 3, EF-hand 61734_at
    calcium binding domain
    Stromal-1 AL573464 Transcribed locus 229554_at
    Stromal-1 AK001903 CDNA FLJ11041 fis, 227140_at
    clone PLACE1004405
    Stromal-1 NM_005928 4240 MFGE8 milk fat globule-EGF 210605_s_at
    factor 8 protein
    Stromal-1 NM_000943 5480 PPIC peptidylprolyl isomerase 204518_s_at
    C (cyclophilin C)
    Stromal-1 NM_001008397 493869 LOC493869 similar to RIKEN cDNA 227628_at
    2310016C16
    Stromal-1 AK025431 768211 RELL1 receptor expressed in 226430_at
    lymphoid tissues like 1
    Stromal-1 NM_000297 5311 PKD2 polycystic kidney disease 203688_at
    2 (autosomal dominant)
    Stromal-1 NM_002975 6320 CLEC11A C-type lectin domain 211709_s_at
    family 11, member A
    Stromal-1 NM_001920 1634 DCN decorin 211813_x_at
    Stromal-1 NM_001723 667 DST dystonin 215016_x_at
    Stromal-1 CR749529 MRNA; cDNA 227554_at
    DKFZp686I18116 (from
    clone DKFZp686I18116)
    Stromal-1 NM_000165 2697 GJA1 gap junction protein, 201667_at
    alpha 1, 43 kDa (connexin
    43)
    Stromal-1 NM_012104 23621 BACE1 beta-site APP-cleaving 217904_s_at
    enzyme 1
    Stromal-1 NM_001957 1909 EDNRA endothelin receptor type A 204464_s_at
    Stromal-1 NM_138455 115908 CTHRC1 collagen triple helix repeat 225681_at
    containing 1
    Stromal-1 NM_001331 1500 CTNND1 catenin (cadherin- 208407_s_at
    associated protein), delta 1
    Stromal-1 NM_001613 59 ACTA2 actin, alpha 2, smooth 200974_at
    muscle, aorta
    Stromal-1 NM_002192 3624 INHBA inhibin, beta A (activin A, 210511_s_at
    activin AB alpha
    polypeptide)
    Stromal-1 NM_000935 5352 PLOD2 procollagen-lysine, 2- 202620_s_at
    oxoglutarate 5-
    dioxygenase 2
    Stromal-1 NM_015170 23213 SULF1 sulfatase 1 212354_at
    Stromal-1 NM_006039 9902 MRC2 mannose receptor, C type 2 37408_at
    Stromal-1 NM_005261 2669 GEM GTP binding protein 204472_at
    overexpressed in skeletal
    muscle
    Stromal-1 NM_001008707 2009 EML1 echinoderm microtubule 204797_s_at
    associated protein like 1
    Stromal-1 NM_001031679 253827 MSRB3 methionine sulfoxide 225782_at
    reductase B3
    Stromal-1 NM_001004125 286319 TUSC1 tumor suppressor 227388_at
    candidate 1
    Stromal-1 NM_005965 4638 MYLK myosin, light chain kinase 202555_s_at
    Stromal-1 NM_016205 56034 PDGFC platelet derived growth 218718_at
    factor C
    Stromal-1 NM_015976 51375 SNX7 sorting nexin 7 205573_s_at
    Stromal-1 NM_130830 131578 LRRC15 leucine rich repeat 213909_at
    containing 15
    Stromal-1 NM_002026 2335 FN1 fibronectin 1 212464_s_at
    Stromal-1 NM_006855 11015 KDELR3 KDEL (Lys-Asp-Glu-Leu) 204017_at
    endoplasmic reticulum
    protein retention receptor 3
    Stromal-1 NM_002292 3913 LAMB2 laminin, beta 2 (laminin S) 216264_s_at
    Stromal-1 NM_002658 5328 PLAU plasminogen activator, 205479_s_at
    urokinase
    Stromal-1 NM_005529 3339 HSPG2 heparan sulfate 201655_s_at
    proteoglycan 2 (perlecan)
    Stromal-1 NM_001235 871 SERPINH1 serpin peptidase inhibitor, 207714_s_at
    clade H (heat shock
    protein 47), member 1,
    (collagen binding protein
    1)
    Stromal-1 AJ318805 CDNA FLJ44429 fis, 227061_at
    clone UTERU2015653
    Stromal-1 NM_000396 1513 CTSK cathepsin K 202450_s_at
    Stromal-1 NM_031302 83468 GLT8D2 glycosyltransferase 8 227070_at
    domain containing 2
    Stromal-1 NM_080821 116151 C20orf108 chromosome 20 open 224690_at
    reading frame 108
    Stromal-1 NM_002345 4060 LUM lumican 201744_s_at
    Stromal-1 NM_005110 9945 GFPT2 glutamine-fructose-6- 205100_at
    phosphate transaminase 2
    Stromal-1 NM_002941 6091 ROBO1 roundabout, axon 213194_at
    guidance receptor,
    homolog 1 (Drosophila)
    Stromal-1 NM_005429 7424 VEGFC vascular endothelial 209946_at
    growth factor C
    Stromal-1 NM_002213 3693 ITGB5 integrin, beta 5 201125_s_at
    Stromal-1 XM_051017 23363 OBSL1 obscurin-like 1 212775_at
    Stromal-1 NM_181724 338773 TMEM119 transmembrane protein 227300_at
    119
    Stromal-1 NM_003474 8038 ADAM12 ADAM metallopeptidase 213790_at
    domain 12 (meltrin alpha)
    Stromal-1 NM_018222 55742 PARVA parvin, alpha 217890_s_at
    Stromal-1 NM_006478 10634 GAS2L1 growth arrest-specific 2 31874_at
    like 1
    Stromal-1 NM_000093 1289 COL5A1 collagen, type V, alpha 1 212489_at
    Stromal-1 NM_006288 7070 THY1 Thy-1 cell surface antigen 208851_s_at
    Stromal-1 CD357685 TIMP2 Transcribed locus, 231579_s_at
    strongly similar to
    XP_511714.1 similar to
    Metalloproteinase
    inhibitor 2 precursor
    (TIMP-2) (Tissue inhibitor
    of metalloproteinases-2)
    (CSC-21K) [Pan
    troglodytes]
    Stromal-1 NM_003247 7058 THBS2 thrombospondin 2 203083_at
    Stromal-1 NM_000088 1277 COL1A1 collagen, type I, alpha 1 1556499_s_at
    Stromal-1 NM_006832 10979 PLEKHC1 pleckstrin homology 209210_s_at
    domain containing, family
    C (with FERM domain)
    member 1
    Stromal-1 NM_021961 7003 TEAD1 TEA domain family 224955_at
    member 1 (SV40
    transcriptional enhancer
    factor)
    Stromal-1 AK128814 CDNA FLJ25106 fis, 213675_at
    clone CBR01467
    Stromal-1 NM_153367 219654 C10orf56 chromosome 10 open 212423_at
    reading frame 56
    Stromal-1 AK092048 MRNA; cDNA 227623_at
    DKFZp313C0240 (from
    clone DKFZp313C0240)
    Stromal-1 NM_005245 2195 FAT FAT tumor suppressor 201579_at
    homolog 1 (Drosophila)
    Stromal-1 NM_001129 165 AEBP1 AE binding protein 1 201792_at
    Stromal-1 NM_002403 4237 MFAP2 microfibrillar-associated 203417_at
    protein 2
    Stromal-1 NM_004342 800 CALD1 caldesmon 1 201616_s_at
    Stromal-1 NM_005576 4016 LOXL1 lysyl oxidase-like 1 203570_at
    Stromal-1 NM_199511 151887 CCDC80 coiled-coil domain 225242_s_at
    containing 80
    Stromal-1 NM_012098 23452 ANGPTL2 angiopoietin-like 2 213001_at
    Stromal-1 NM_002210 3685 ITGAV integrin, alpha V 202351_at
    (vitronectin receptor,
    alpha polypeptide,
    antigen CD51)
    Stromal-1 NM_000366 7168 TPM1 tropomyosin 1 (alpha) 210986_s_at
    Stromal-1 NM_198474 283298 OLFML1 olfactomedin-like 1 217525_at
    Stromal-1 NM_001424 2013 EMP2 epithelial membrane 225078_at
    protein 2
    Stromal-1 NM_032575 84662 GLIS2 GLIS family zinc finger 2 223378_at
    Stromal-1 NM_007173 11098 PRSS23 protease, serine, 23 226279_at
    Stromal-1 NM_001015880 9060 PAPSS2 3′-phosphoadenosine 5′- 203060_s_at
    phosphosulfate synthase 2
    Stromal-1 NM_015645 114902 C1QTNF5 C1q and tumor necrosis 223499_at
    factor related protein 5
    Stromal-1 AK130049 CDNA FLJ26539 fis, 213429_at
    clone KDN09310
    Stromal-1 NM_001849 1292 COL6A2 collagen, type VI, alpha 2 209156_s_at
    Stromal-1 NM_001014796 4921 DDR2 discoidin domain receptor 225442_at
    family, member 2
    Stromal-1 NM_015463 25927 C2orf32 chromosome 2 open 226751_at
    reading frame 32
    Stromal-1 AK055628 ADAM12 CDNA FLJ31066 fis, 226777_at
    clone HSYRA2001153
    Stromal-1 NM_014799 9843 HEPH hephaestin 203903_s_at
    Stromal-1 NM_004385 1462 CSPG2 chondroitin sulfate 221731_x_at
    proteoglycan 2 (versican)
    Stromal-1 NM_152330 122786 FRMD6 FERM domain containing 6 225481_at
    Stromal-1 BQ917964 PPP4R2 Transcribed locus 235733_at
    Stromal-1 NM_002615 5176 SERPINF1 serpin peptidase inhibitor, 202283_at
    clade F (alpha-2
    antiplasmin, pigment
    epithelium derived factor),
    member 1
    Stromal-1 NM_032348 54587 MXRA8 matrix-remodelling 213422_s_at
    associated 8
    Stromal-1 NM_006106 10413 YAP1 Yes-associated protein 1, 224894_at
    65 kDa
    Stromal-1 NM_020182 56937 TMEPAI transmembrane, prostate 222449_at
    androgen induced RNA
    Stromal-1 CB999028 Transcribed locus 226834_at
    Stromal-1 NM_001711 633 BGN biglycan 201261_x_at
    Stromal-1 NM_006902 5396 PRRX1 paired related homeobox 1 226695_at
    Stromal-1 NM_000428 4053 LTBP2 latent transforming growth 204682_at
    factor beta binding protein 2
    Stromal-1 NM_004369 1293 COL6A3 collagen, type VI, alpha 3 201438_at
    Stromal-1 NM_000393 1290 COL5A2 collagen, type V, alpha 2 221730_at
    Stromal-1 NM_015419 25878 MXRA5 matrix-remodelling 209596_at
    associated 5
    Stromal-1 NM_001102 87 ACTN1 actinin, alpha 1 208637_x_at
    Stromal-1 NM_000877 3554 IL1R1 interleukin 1 receptor, 202948_at
    type I
    Stromal-1 NM_015927 7041 TGFB1I1 transforming growth factor 209651_at
    beta 1 induced transcript 1
    Stromal-1 NM_032772 84858 ZNF503 zinc finger protein 503 227195_at
    Stromal-1 NM_020440 5738 PTGFRN prostaglandin F2 receptor 224937_at
    negative regulator
    Stromal-1 NM_000138 2200 FBN1 fibrillin 1 202765_s_at
    Stromal-1 NM_031442 83604 TMEM47 transmembrane protein 209656_s_at
    47
    Stromal-1 NM_001734 716 C1S complement component 208747_s_at
    1, s subcomponent
    Stromal-1 NM_002290 3910 LAMA4 laminin, alpha 4 202202_s_at
    Stromal-1 CN312045 PPP4R2 Transcribed locus, weakly 222288_at
    similar to
    NP_001013658.1 protein
    LOC387873 [Homo
    sapiens]
    Stromal-1 NM_000089 1278 COL1A2 collagen, type I, alpha 2 202403_s_at
    Stromal-1 NM_004530 4313 MMP2 matrix metallopeptidase 2 201069_at
    (gelatinase A, 72 kDa
    gelatinase, 72 kDa type IV
    collagenase)
    Stromal-1 NM_001387 1809 DPYSL3 dihydropyrimidinase-like 3 201431_s_at
    Stromal-1 NM_138389 92689 FAM114A1 family with sequence 213455_at
    similarity 114, member A1
    Stromal-1 NM_006670 7162 TPBG trophoblast glycoprotein 203476_at
    Stromal-1 NM_000304 5376 PMP22 peripheral myelin protein 210139_s_at
    22
    Stromal-1 NM_002775 5654 HTRA1 HtrA serine peptidase 1 201185_at
    Stromal-1 NM_002593 5118 PCOLCE procollagen C- 202465_at
    endopeptidase enhancer
    Stromal-1 NM_003118 6678 SPARC secreted protein, acidic, 212667_at
    cysteine-rich
    (osteonectin)
    Stromal-1 NM_007085 11167 FSTL1 follistatin-like 1 208782_at
    Stromal-1 NM_001080393 727936 predicted glycosyl- 235371_at
    transferase 8 domain
    containing 4
    Stromal-1 NM_018153 84168 ANTXR1 anthrax toxin receptor 1 224694_at
    Stromal-1 NM_001733 715 C1R complement component 212067_s_at
    1, r subcomponent
    Stromal-1 NM_001797 1009 CDH11 cadherin 11, type 2, OB- 207173_x_at
    cadherin (osteoblast)
    Stromal-1 NM_016938 30008 EFEMP2 EGF-containing fibulin- 209356_x_at
    like extracellular matrix
    protein 2
    Stromal-2 NM_014601 30846 EHD2 EH-domain containing 2 45297_at
    Stromal-2 NM_017789 54910 SEMA4C sema domain, 46665_at
    immunoglobulin domain
    (Ig), transmembrane
    domain (TM) and short
    cytoplasmic domain,
    (semaphorin) 4C
    Stromal-2 NM_000484 351 APP amyloid beta (A4) 200602_at
    precursor protein
    (peptidase nexin-II,
    Alzheimer disease)
    Stromal-2 NM_004684 8404 SPARCL1 SPARC-like 1 (mast9, 200795_at
    hevin)
    Stromal-2 NM_002291 3912 LAMB1 laminin, beta 1 201505_at
    Stromal-2 NM_000210 3655 ITGA6 integrin, alpha 6 201656_at
    Stromal-2 NM_000552 7450 VWF von Willebrand factor 202112_at
    Stromal-2 NM_001233 858 CAV2 caveolin 2 203323_at
    Stromal-2 NM_006404 10544 PROCR protein C receptor, 203650_at
    endothelial (EPCR)
    Stromal-2 NM_000609 6387 CXCL12 chemokine (C—X—C motif) 203666_at
    ligand 12 (stromal cell-
    derived factor 1)
    Stromal-2 NM_002253 3791 KDR kinase insert domain 203934_at
    receptor (a type III
    receptor tyrosine kinase)
    Stromal-2 NM_001442 2167 FABP4 fatty acid binding protein 203980_at
    4, adipocyte
    Stromal-2 NM_016315 51454 GULP1 GULP, engulfment 204237_at
    adaptor PTB domain
    containing 1
    Stromal-2 NM_006307 8406 SRPX sushi-repeat-containing 204955_at
    protein, X-linked
    Stromal-2 NM_000163 2690 GHR growth hormone receptor 205498_at
    Stromal-2 NM_000950 5638 PRRG1 proline rich Gla (G- 205618_at
    carboxyglutamic acid) 1
    Stromal-2 NM_002666 5346 PLIN perilipin 205913_at
    Stromal-2 NM_000459 7010 TEK TEK tyrosine kinase, 206702_at
    endothelial (venous
    malformations, multiple
    cutaneous and mucosal)
    Stromal-2 NM_004797 9370 ADIPOQ adiponectin, C1Q and 207175_at
    collagen domain
    containing
    Stromal-2 NM_000442 5175 PECAM1 platelet/endothelial cell 208981_at
    adhesion molecule (CD31
    antigen)
    Stromal-2 NM_198098 358 AQP1 aquaporin 1 (Colton blood 209047_at
    group)
    Stromal-2 NM_021005 7026 NR2F2 nuclear receptor 209120_at
    subfamily 2, group F,
    member 2
    Stromal-2 NM_014220 4071 TM4SF1 transmembrane 4 L six 209386_at
    family member 1
    Stromal-2 NM_001001549 2887 GRB10 growth factor receptor- 209409_at
    bound protein 10
    Stromal-2 NM_006108 10418 SPON1 spondin 1, extracellular 209436_at
    matrix protein
    Stromal-2 NM_001003679 3953 LEPR leptin receptor 209894_at
    Stromal-2 NM_000599 3488 IGFBP5 insulin-like growth factor 211959_at
    binding protein 5
    Stromal-2 NM_001753 857 CAV1 caveolin 1, caveolae 212097_at
    protein, 22 kDa
    Stromal-2 NM_005841 10252 SPRY1 sprouty homolog 1, 212558_at
    antagonist of FGF
    signaling (Drosophila)
    Stromal-2 NM_015345 23500 DAAM2 dishevelled associated 212793_at
    activator of
    morphogenesis 2
    Stromal-2 NM_015234 221395 GPR116 G protein-coupled 212950_at
    receptor 116
    Stromal-2 NM_006108 10418 SPON1 spondin 1, extracellular 213993_at
    matrix protein
    Stromal-2 NM_016215 51162 EGFL7 EGF-like-domain, multiple 7 218825_at
    Stromal-2 NM_022481 64411 CENTD3 centaurin, delta 3 218950_at
    Stromal-2 XM_371262 64123 ELTD1 EGF, latrophilin and 219134_at
    seven transmembrane
    domain containing 1
    Stromal-2 NM_016563 51285 RASL12 RAS-like, family 12 219167_at
    Stromal-2 NM_006094 10395 DLC1 deleted in liver cancer 1 224822_at
    Stromal-2 NM_019035 54510 PCDH18 protocadherin 18 225975_at
    Stromal-2 NM_019055 54538 ROBO4 roundabout homolog 4, 226028_at
    magic roundabout
    (Drosophila)
    Stromal-2 NM_002207 3680 ITGA9 integrin, alpha 9 227297_at
    Stromal-2 XM_930608 641700 ECSM2 endothelial cell-specific 227779_at
    molecule 2
    Stromal-2 XM_037493 85358 SHANK3 SH3 and multiple ankyrin 227923_at
    repeat domains 3
    Stromal-2 NM_052954 116159 CYYR1 cysteine/tyrosine-rich 1 228665_at
    Stromal-2 NM_002837 5787 PTPRB protein tyrosine 230250_at
    phosphatase, receptor
    type, B
    Stromal-2 NM_019558 3234 HOXD8 homeobox D8 231906_at
    Stromal-2 NM_001442 2167 FABP4 fatty acid binding protein 235978_at
    4, adipocyte
    Stromal-2 NM_024756 79812 MMRN2 multimerin 2 236262_at
    Stromal-2 BQ897248 Transcribed locus 242680_at
    Stromal-2 NM_020663 57381 RHOJ ras homolog gene family, 243481_at
    member J
    Stromal-2 AK091419 CDNA FLJ34100 fis, 1558397_at
    clone FCBBF3007597
    Stromal-2 NM_015719 50509 COL5A3 collagen, type V, alpha 3 52255_s_at
    Stromal-2 NM_012072 22918 CD93 CD93 molecule 202878_s_at
    Stromal-2 NM_000300 5320 PLA2G2A phospholipase A2, group 203649_s_at
    IIA (platelets, synovial
    fluid)
    Stromal-2 NM_019105 7148 TNXB tenascin XB 206093_x_at
    Stromal-2 NM_030754 6289 SAA2 serum amyloid A2 208607_s_at
    Stromal-2 NM_019105 7148 TNXB tenascin XB 208609_s_at
    Stromal-2 NM_014220 4071 TM4SF1 transmembrane 4 L six 209387_s_at
    family member 1
    Stromal-2 NM_000668 125 ADH1B alcohol dehydrogenase IB 209612_s_at
    (class I), beta polypeptide
    Stromal-2 NM_000668 125 ADH1B alcohol dehydrogenase IB 209613_s_at
    (class I), beta polypeptide
    Stromal-2 NM_001354 1646 AKR1C2 aldo-keto reductase 209699_x_at
    family 1, member C2
    (dihydrodiol
    dehydrogenase 2; bile
    acid binding protein; 3-
    alpha hydroxysteroid
    dehydrogenase, type III)
    Stromal-2 NM_001032281 7035 TFPI tissue factor pathway 210664_s_at
    inhibitor (lipoprotein-
    associated coagulation
    inhibitor)
    Stromal-2 NM_001001924 57509 MTUS1 mitochondrial tumor 212096_s_at
    suppressor 1
    Stromal-2 NM_019105 7148 TNXB tenascin XB 213451_x_at
    Stromal-2 NM_004449 2078 ERG v-ets erythroblastosis 213541_s_at
    virus E26 oncogene
    homolog (avian)
    Stromal-2 NM_018407 55353 LAPTM4B lysosomal associated 214039_s_at
    protein transmembrane 4
    beta
    Stromal-2 NM_000331 6288 SAA1 serum amyloid A1 214456_x_at
    Stromal-2 NM_019105 7148 TNXB tenascin XB 216333_x_at
    Stromal-2 NM_001034954 10580 SORBS1 sorbin and SH3 domain 218087_s_at
    containing 1
    Stromal-2 NM_017734 54873 PALMD palmdelphin 218736_s_at
    Stromal-2 NM_024756 79812 MMRN2 multimerin 2 219091_s_at
    Stromal-2 NM_006744 5950 RBP4 retinol binding protein 4, 219140_s_at
    plasma
    Stromal-2 NM_001034954 10580 SORBS1 sorbin and SH3 domain 222513_s_at
    containing 1
  • The DLBCL survival predictors of the invention were generated using expression data and methods described in Examples 1 and 2, below. The first bivariate survival predictor incorporates the GCB and stromal-1 gene expression signatures. Fitting the Cox proportional hazards model to the gene expression data obtained from these two signatures resulted in a bivariate model survival predictor score calculated using the following generalized equation:

  • Bivariate DLBCL survival predictor score=A−[(x)*(GCB signature value)]−[(y)*(stromal-1 signature value)].
  • In this equation, A is an offset term, while (x) and (y) are scale factors. The GCB signature value and the stromal-1 signature value can correspond to the average of the expression levels of all genes in the GCB signature and the stromal-1 signature, respectively. A lower survival predictor score indicates a more favorable survival outcome, and a higher survival predictor score indicates a less favorable survival outcome for the subject.
  • The bivariate survival predictor was refined into a multivariate survival predictor that incorporates GCB, stromal-1, and stomal-2 gene expression signatures. Fitting the Cox proportional hazards model to the gene expression data obtained from these three signatures resulted in a multivariate model survival predictor score calculated using the following generalized equation:

  • General multivariate DLBCL survival predictor score=A−[(x)*(GCB signature value)]−[(y)*(stromal-1 signature value)]+[(z)*(stromal-2 signature value)].
  • In this equation, A is an offset term, while (x), (y), and (z) are scale factors. The GCB signature value, the stromal-1 signature value, and the stromal-2 signature value can correspond to the average of the expression levels of all genes in the GCB signature, the stromal-1 signature, and the stromal-2 signature, respectively. A lower survival predictor score indicates a more favorable survival outcome and a higher survival predictor score indicates a less favorable survival outcome for the subject.
  • In one embodiment, the invention provides the following multivariate survival predictor equation:

  • Multivariate DLBCL survival predictor score=8.11−[0.419*(GCB signature value)]−[1.015*(stromal-1 signature value)]+[0.675*(stromal-2 signature value)]
  • In this equation, a lower survival predictor score indicates a more favorable survival outcome, and a higher survival predictor score indicates a poorer survival outcome for the subject.
  • In other embodiments of the multivariate DLBCL survival predictor score equation, the offset term (A) or (8.11) can be varied without affecting the equation's usefulness in predicting clinical outcome. Scale factors (x), (y), and (z) can also be varied, individually or in combination. For example, scale factor (x) can be from about 0.200 or more, from about 0.225 or more, from about 0.250 or more, from about 0.275 or more, from about 0.300, from about 0.325 or more, from about 0.350 or more, from about 0.375 or more, or from about 0.400 or more. Alternatively, or in addition, scale factor (x) can be about 0.625 or less, about 0.600 or less, about 0.575 or less, about 0.550 or less, about 0.525 or less, about 0.500 or less, about 0.475 or less, about 0.450 or less, or about 0.425 or less. Thus, scale factor (z) can be one that is bounded by any two of the previous endpoints. For example scale factor (x) can be a value from 0.200-0.625, from 0.350-0.550, from 0.350-0.475, or from 0.400-0.425. Similarly, scale factor (y) can be from about 0.800 or more, from about 0.825 or more, from about 0.850 or more, from about 0.875 or more, from about 0.900 or more, from about 0.925 or more, from about 0.950 or more, from about 0.975 or more, or from about 1.000 or more. Alternatively, or in addition, scale factor (y) can be, e.g., about 1.250 or less, e.g., about 1.225 or less, about 1.200, about 1.175 or less, about 1.150 or less, about 1.125 or less, about 1.100 or less, about 1.075 or less, about 1.050 or less, or about 1.025 or less. Thus, scale factor (y) can be one that is bounded by any two of the previous endpoints. For example, scale factor (y) can be a value from 0.800-1.250, a value from 0.950-1.1025, a value from 0.950-1.200 or a value from 1.000-1.025. Also similarly, scale factor (z) can be from about 0.450 or more, about 0.475 or more, about 0.500 or more, about 0.525 or more, about 0.550 or more, about 0.575 or more, about 0.600 or more, about 0.625 or more, or about 0.650 or more. Alternatively, or in addition, scale factor (z) can be, e.g., about 0.900 or less, e.g., about 0.875 or less, about 0.850, about 0.825 or less, about 0.800 or less, about 0.775 or less, about 0.750 or less, or about 0.725 or less. Thus, scale factor (z) can be one that is bounded by any two of the previous endpoints. For example, scale factor (z) can be a value from 0.450-0.900, any value from 0.650-0.725, any value from 0.625-0.775 or any value from 0.650-0.700.
  • Furthermore, the invention includes any set of scale factors (x), (y), and (z) in conjunction in the general multivariate DLBCL survival predictor score that creates a function that is monotonically related to a multivariate DLBCL survival predictor score equation using any combination of the foregoing specified scale factor (x), (y), and (z) values.
  • In some embodiments of the invention, a survival predictor score can be calculated using fewer than all of the gene components of the GCB signature, the stromal-1 signature, and/or the stromal-2 signature listed in Table 1. For example, the survival prediction equations disclosed herein can be calculated using mathematical combinations of the expressions of 98% (38), 95% (37), 93% (36), or 90% (35) of the genes listed in Table 1 for the GCB signature, about 99% (about 280), about 98% (about 277), 97% (about 275), about 96% (about 272), about 95% (about 270), about 94% (about 266), about 93% (about 263), about 92% (about 260), about 91% (about 257), or about 90% (about 255) of the genes listed in Table 1 for the stromal-1 signature, and/or 99% (71), 97% (70), 96% (69), 95% (68) 93% (67), 92% (66), or 90% (65) of the genes listed in Table 1 for the stromal-2 signature (instead of using all of the genes corresponding to a gene signature in Table 1 to calculate the GCB signature value, the stromal-1 signature value, and/or stromal-2 signature value, respectively). In other embodiments, the survival prediction equations disclosed herein can be calculated using mathematical combinations of the expressions of 88% (34 genes), 85% (33 genes), 82% (32 genes), 80% (31 genes) of the genes listed in Table 1 for the GCB signature, about 89% (about 252), about 88% (about 249), about 87% (about 246), about 86% (about 243), about 85% (about 241), about 84% (about 238), about 83% (about 235), about 82% (about 232), about 81% (about 229), or about 80% (about 226) of the genes listed in Table 1 for the stromal-1 signature, and/or 89% (64), 88% (63), 86% (62), 85% (61), 83% (60), 82% (59) or 80% (58) of the genes listed in Table 1 for the stromal-2 signature (instead of using all of the genes corresponding to a gene signature in Table 1 to calculate the GCB signature value, the stromal-1 signature value, and/or stromal-2 signature value, respectively).
  • The invention also provides a method of using a DLBCL survival predictor score to predict the probability of a survival outcome beyond an amount of time t following treatment for DLBCL. The method includes calculating the probability of a survival outcome for a subject using the following general equation:

  • P(SO)=SO0(t)(exp((s)*(survival predictor score)))
  • In this equation, P(SO) is the subject's probability of the survival outcome beyond time t following treatment for DLBCL, SO0(t) is the probability of survival outcome, which corresponds to the largest time value smaller than t in a survival outcome curve, and (s) is a scale factor. Treatment for DLBCL can include chemotherapy and the administration of Rituximab. A survival curve can be calculated using statistical methods, such as the Cox Proportional Hazard Model. Additional information regarding survival outcome curves is set forth in Lawless, Statistical Models and Methods for Lifetime Data, John Wiley and Sons (New York 1982) and Kalbfleisch et al., Biometrika, 60: 267-79 (1973).
  • In one embodiment, the method of the invention includes calculating the probability of overall survival for a subject beyond an amount of time t following treatment for DLBCL. The method includes calculating the probability of a survival outcome for a subject using the following general equation:

  • P(OS)=SO0(t)(exp(survival predictor score))
  • In the equation, P(OS) is the subject's probability of overall survival beyond time t following treatment for DLBCL, SO0(t) is the curve probability of survival outcome, which corresponds to the largest time value in a survival curve which is smaller than t, and the general equation scale factor (s)=1. Treatment for DLBCL can include chemotherapy alone or in combination with the administration of Rituximab (R-CHOP).
  • In another embodiment, the method of the invention includes calculating the probability of progression-free survival for a subject beyond an amount of time t following treatment for DLBCL. The method includes calculating the probability of a survival outcome for a subject using the following general equation:

  • P(PFS)=SO0(t)(exp(0.976*(survival predictor score)))
  • In this equation, P(PFS) is the subject's probability of progression-free survival beyond time t following treatment for DLBCL, SO0(t) is the curve probability of progression-free survival, which corresponds to the largest time value in a survival curve which is smaller than t, and the general equation scale factor (s)=0.976. The treatment for DLBCL can include chemotherapy alone or in combination with the administration of Rituximab (R-CHOP).
  • The foregoing equations for P(OS) and P(PFS) were generated by maximizing the partial likelihoods of the Cox proportional hazards model within the LLMPP CHOP data described below in Examples 1 and 2. Separate single variable Cox proportional hazards models were considered for overall survival P(OS) and for progression free survival P(PFS) based on this model score formulation. The single variable scale factor (1.0 for overall survival and 0.997 for progression free survival) were generated for each model by maximization of the partial likelihoods within the R-CHOP patients described below in Examples 1 and 2.
  • In other embodiments, the scale factor in the foregoing P(PFS) can be varied such that (instead of 0.976) scale factor (s) is a value between 0.970 and 0.980, e.g. 0.971, 0.972, 0.973, 0.973, 0.974, 0.975, 0.977, 0.978, and 0.979.
  • The invention also provides a method of selecting a subject for antiangiogenic therapy of DLBCL based on the subject's high relative expression of stromal-2 signature genes. As discussed more fully below in Example 4, the stromal-2 signature includes a number of genes whose expression or gene products are related to angiogenesis. Thus, high relative expression of stromal-2 signature genes in DLBCL can be indicative of high angiogenic activity. Moreover, high relative expression of stromal-2 signature genes can be related to the heavy infiltration of some DLBCL tumors with myeloid lineage cells. Accordingly, subjects with high relative expression of stromal-2 signature genes are good candidates for treatment with antiangiogenic therapy, either alone or in combination with other anti-oncogenic therapies. Furthermore, as also discussed more fully in Example 4, a stromal score, which was obtained by subtracting the stromal-1 signature value from the stromal-2 signature value, was observed to correlate with high tumor blood vessel density.
  • In this regard, the antiangiogenic monoclonal antibody to vascular endothelial growth factor bevacizumab has been clinically tested in patients with DLBCL (Ganjoo et al., Leuk. Lymphoma, 47: 998-1005 (2006)). Other antiangiogenic therapies can include small molecule inhibitors of SDF-1 receptor, such as CXCR4 (Petit et al., Trends Immunol., 28: 299-307 (2007). Still another example of an antiangiogenic therapy can include blocking antibodies to the myeloid lineage cell marker CTGF, which has been implicated in angiogenesis. Moreover, anti-CTGF antibodies have been shown to have anti-cancer activity in pre-clinical models of cancer (Aikawa et al., Mol. Cancer Ther., 5: 1108-16 (2006)).
  • In one embodiment, the method of the invention for selecting a subject for antiangiogenic therapy includes obtaining a gene expression profile from a DLBCL biopsy from the subject. The subject's stromal-2 signature value is determined. The subject's stromal-2 signature value is then compared to a standard stromal-2 value. A standard stromal-2 value corresponds to the average of multiple stromal-2 signature values in DLBCL biopsy samples from a plurality of randomly selected subjects with DLBCL, e.g., more than 10, 20, 30, 40, 50, 60, 70, 80, 90, 100, 150, 200, or 250 randomly selected subjects with DLBCL. If the subject's stromal-2 signature value is significantly higher than the standard stromal-2 value, then the subject can be treated with anti-angiogenic therapy.
  • In another embodiment, the method of the invention for selecting a subject for anti-angiogenic therapy includes obtaining a gene expression profile from a DLBCL biopsy from the subject. The subject's stromal 1 signature value and stromal-2 signature value are determined. The stromal-1 signature value is then subtracted from the stromal-2 signature value to obtain a stomal score. The subject's stromal score is then compared to a standard stromal score. A standard stromal score corresponds to the average of multiple stromal scores (each stromal score=[stromal-2 signature value])−[stromal-1 signature value]) derived from DLBCL biopsy samples from a plurality of randomly selected subjects with DLBCL, e.g., more than 10, 20, 30, 40, 50, 60, 70, 80, 90, 100, 150, 200, or 250 randomly selected subjects with DLBCL. If the subject's stromal score is significantly higher than the standard stromal score, then the subject can be treated with anti-angiogenic therapy.
  • The invention further provides a targeted array that can be used to detect the expression levels of all or most of the genes in a germinal center B cell gene (GCB) expression signature, a stromal-1 gene expression signature, and/or a stromal-2 gene expression signature. A targeted array, as used herein, is an array directed to a limited set of genes and thus differs from a whole genome array. The targeted array of the invention can include probes for fewer than 20,000 genes, fewer than 15,000 genes, fewer than 10,000 genes, fewer than 8,000 genes, fewer than 7,000 genes, fewer than 6,000 genes, fewer than 5,000 genes, or fewer than 4,000 genes. Generally, the targeted array includes probes for at least 80% of the genes in a germinal center B cell gene (GCB) expression signature, a stromal-1 gene expression signature, and/or a stromal-2 gene expression signature. The targeted arrays of the invention can be used, for example, to detect expression levels for use in the methods described herein.
  • The invention provides a targeted array that includes probes for all of the genes in the stromal-1 gene expression signature. The invention also provides a targeted array that includes probes for all of the genes in the stromal-2 gene expression signature. Additionally, the invention provides a targeted array that includes probes for all of the genes in the stromal-1 gene expression signature and all of the genes in the stromal-2 gene expression signature. Moreover, the invention provides a targeted array that includes probes for all of the genes in the stromal-1 gene expression signature, all of the genes in the stromal-2 gene expression signature, and all of the genes in the GCB signature.
  • In certain embodiments, the arrays of the invention can include 98% (38), 95% (37), 93% (36), or 90% (35) of the genes listed in Table 1 for the GCB signature, about 99% (about 280), about 98% (about 277), 97% (about 275), about 96% (about 272), about 95% (about 270), about 94% (about 266), about 93% (about 263), about 92% (about 260), about 91% (about 257), or about 90% (about 255) of the genes listed in Table 1 for the stromal-1 signature, and/or 99% (71), 97% (70), 96% (69), 95% (68) 93% (67), 92% (66), or 90% (65) of the genes listed in Table 1 for the stromal-2 signature (instead of all of the genes listed in Table 1 for the GCB signature average, the stromal-1 signature average, and/or stromal-2 signature average, respectively). In certain embodiments, the arrays of the invention can include 88% (34 genes), 85% (33 genes), 82% (32 genes), 80% (31 genes) of the genes listed in Table 1 for the GCB signature, about 89% (about 252), about 88% (about 249), about 87% (about 246), about 86% (about 243), about 85% (about 241), about 84% (about 238), about 83% (about 235), about 82% (about 232), about 81% (about 229), or about 80% (about 226) of the genes listed in Table 1 for the stromal-1 signature, and/or 89% (64), 88% (63), 86% (62), 85% (61), 83% (60), 82% (59) or 80% (58) of the genes listed in Table 1 for the stromal-2 signature (instead of all of the genes listed in Table 1 for the GCB signature average, the stromal-1 signature average, and/or stromal-2 signature average, respectively).
  • The following examples further illustrate the invention but, of course, should not be construed as in any way limiting its scope.
    • EXAMPLE 1
  • This example demonstrates that significant differences were found between the survival outcomes for R-CHOP treated ABC DLBCL and GCB DLBCL patients and that survival outcome correlated with three prognostic gene expression signatures.
  • Pre-treatment tumor biopsy specimens and clinical data were obtained from 414 patients with de novo DLBCL treated at 10 institutions in North America and Europe and studied according to a protocol approved by the National Cancer Institute's Institutional Review Board. Patients included in a “LLMP CHOP cohort” of 181 patients were treated with anthracycline-based combinations, most often cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) or similar regimens, as previously described (Rosenwald et al., N. Engl. J. Med., 346: 1937-47 (2002)). The remaining 233 patients constituted an R-CHOP cohort that received similar chemotherapy plus Rituximab. The median follow-up in the R-CHOP cohort was 2.1 years (2.8 years for survivors). A panel of expert hematopathologists confirmed the diagnosis of DLBCL using current WHO criteria. Additional clinical patient characteristics for the R-CHOP cohort are described in Table 2. Additional analysis used a second “MMMNLP CHOP” cohort of 177 patients studied by the Molecular Mechanisms of Non-Hodgkin's Lymphoma Network Project (Hummel et al., N. Engl. J. Med., 354: 2419-30 (2006)).
  • TABLE 2
    Clinical characteristics of DLBCL patients treated with R-CHOP
    % Germinal % Activated %
    % center B cell- B cell-like Unclassified
    Total like DLBCL DLBCL DLBCL
    Characteristic (N = 233) (N = 107) (N = 93) (N = 33) P-value
    Age >60 yr 52 47 63 39 0.02
    Ann Arbor stage > II 54 48 62 50 0.06
    Lactate 48 43 58 41 0.06
    Dehydrogenase >1x
    Normal
    No. of extranodal 15 14 15 14 0.8
    sites >1
    Eastern Cooperative 25 17 33 27 0.02
    Oncology Group
    (ECOG) performance
    status
    International <0.001
    Prognostic Index
    (IPI) Score
    0 or 1 41 55 21 50
    2 or 3 46 33 63 38
    4 or 5 13 12 15 12
    Revised IPI Score <0.001
    0 19 27 5 28
    1 or 2 56 52 64 48
    3-5 25 21 31 24
  • Gene expression profiling was performed using Affymetrix U133+2.0 microarrays. Gene expression profiling data are available through the National Center for Biotechnology Information web site as described in Lenz et al., New Engl. J. Med, 359: 2313-23 (2008), at page 2314. All gene expression array data were normalized using MAS 5.0 software, and were log 2 transformed. To account for technical differences in the microarray processing between the R-CHOP cohort data and the LLMPP CHOP cohort data, the expression values of each gene in the R-CHOP cohort data were adjusted so that its median matched the median of the LLMPP CHOP data.
  • Gene expression signature identification and survival predictor model development were based solely on the data from the LLMPP CHOP training set. No prior survival analysis or subgroup analysis was performed with the test sets (MMMLNP CHOP and R-CHOP cohorts). The Cox model was used to identify genes associated with survival in the CHOP training set and to build multivariate survival models. The models and their associated scaling coefficients were fixed based on the CHOP training set and then evaluated on the test sets. The P-values of survival effects of continuous variables such as gene expression or signature expression were calculated with the Cox likelihood ratio test. The significance of survival effects based on discrete variables such as lymphoma subtype or International Prognostic Index (IPI) was calculated using the log rank test. Validation P-values presented are one-sided in the direction observed in the training set. All other P-values were two sided. Survival curves were estimated using the Kaplan-Meier method.
  • All aspects of gene expression signature identification and survival predictor model development were based solely on the data from the CHOP training set. No prior survival analysis or subgroup analysis was performed with the test sets (MMMLNP CHOP and R-CHOP cohorts). The Cox model was used to identify genes associated with survival in the CHOP training set and to build multivariate survival models. The models and their associated scale factors were fixed based on the CHOP training set, and then evaluated on the test sets.
  • Since ABC and GCB DLBCL subtypes have distinct overall survival rates with CHOP chemotherapy (Rosenwald et al., N. Engl. J. Med., 346: 1937-47 (2002); Alizadeh et al., Nature, 403:503-11(2000); Hummel et al., N. Engl. J. Med., 354:2419-30 (2006); Monti, Blood, 105:1851-61(2005)), whether this distinction remains prognostically significant among patients treated with R-CHOP was tested (Coiffier et al, N. Engl. J. Med., 346: 235-42 (2002)). Gene expression profiles were determined for pre-treatment biopsy samples from a “training set” of 181 patients treated with CHOP or CHOP-like chemotherapy alone and from a “test set” of 233 patients treated with R-CHOP. The patients in these two cohorts were comparable with respect to age range and distribution of the clinical prognostic variables that constitute the International Prognostic Index (IPI) (Table 2). In the R-CHOP cohort, patients with GCB DLBCL had better survival rates than those with ABC DLBCL. Specifically, R-CHOP treated GCB DLBCL and ABC DLBCL patients had 3-year overall survival rates of 84% and 56%, respectively, and 3-year progression-free survival rates of 74% and 40%, respectively (FIGS. 1A and 1B). In the CHOP training set, and in a second “MMMLMP” CHOP cohort (Hummel et al., supra), the overall survival rates for ABC DLBCL and GCB DLBCL were lower than in the R-CHOP cohort (FIG. 6). Multivariate analysis indicated that the relative benefit (i.e., change in survival outcome) due to R-CHOP therapy (as compared to CHOP) was not significantly different between ABC and GCB DLBCL.
  • Four gene expression signatures have been previously shown to have prognostic significance in DLBCL patients treated with CHOP (Rosenwald et al., supra). Of these, the GCB signature and lymph node signature were associated with favorable survival, and the proliferation signature was associated with inferior survival within the CHOP training set, in the MMMLNP CHOP cohort (see the corresponding signature panels in FIG. 7), and in the R-CHOP cohort (see corresponding signature panels in FIG. 1C). Thus, the biological differences among DLBCL tumors reflected by these three signatures remain prognostically important in Rituximab treated patients, even though Rituximab treatment generally improved survival in DLBCL.
  • The remaining fourth gene expression signature, the MHC class II signature, which was associated with survival in the CHOP training set when treated as a continuous variable, was not associated with survival in the R-CHOP cohort (see MHC class II signature panel in FIG. 1C). Moreover, tumors with extremely low “outlier” expression of this signature were associated with inferior survival in both CHOP cohorts (see FIGS. 8A and 8B), but not in the R-CHOP cohort (see FIG. 8C).
  • The foregoing results indicate that Rituximab immunotherapy combined with chemotherapy (R-CHOP) benefits both the ABC and GCB subtypes of DLBCL and that gene expression signatures that predicted survival in the context of CHOP chemotherapy retained their prognostic power among R-CHOP-treated patients.
  • The foregoing results also indicate that the biological variation among DLBCL tumors, as measured by gene expression signatures, has a consistent relationship to therapeutic response regardless of the treatment regimen used. There is a striking difference in 3-year progression-free survival between ABC DLBCL patients and GCB DLBCL patients treated with R-CHOP (40% vs. 74%). This difference is likely due to genetic and biological differences between these DLBCL subtypes (Staudt et al., Adv. Immunol., 87: 163-208 (2005)).
  • Hence, future clinical trials in DLBCL should incorporate quantitative methods to discern these biological differences so that patient cohorts in different trials can be compared and treatment responses can be related to defined tumor phenotypes.
    • EXAMPLE 2
  • This example demonstrates the development of GCB, stromal-1, and stromal-2 survival signatures and a related multivariate model of survival for R-CHOP-treated DLBCL.
  • Unless otherwise indicated, patient cohorts and methods of gene expression analysis are as described in Example 1.
  • In the LLMPP CHOP cohort data, 936 genes were identified as associated with poor prognosis p<0.01 (1-sided). For genes having multiple array probe sets associated with survival, only the probe set with the strongest association with survival was used. The expression values of the probe sets in the LLMPP CHOP cohort data were then clustered. The largest cluster with an average correlation of >0.6 and containing myc was identified as the proliferation survival signature. 1396 genes were identified as associated with favorable outcome. The largest cluster with average correlation of >0.6 and containing BCL6 was identified as the germinal center B cell (GCB) survival signature. A cluster with average correlation of >0.6 and containing FM was identified as the stromal-1 survival signature, whereas another cluster with average correlation of >0.6 containing HLADRA was identified as the MHC class II survival signature. The expression levels of genes within each signature were then averaged to create a “signature average” for each biopsy specimen. For the MMMLNP CHOP data set, the average was calculated for those array elements represented on the Affymetrix U133A microarray.
  • From the four prognostic clusters or signatures, two signatures, the stromal-1 and the GCB signatures were used to create the best two variable survival model. Neither the proliferation nor the MHC class II signatures added to the prognostic value of this two variable model. This bivariate model performed well in the MMMLNP CHOP cohort (FIG. 9A) and in the R-CHOP cohort (FIG. 2A).
  • The CHOP training set was used to discover and refine signatures that added to the prognostic significance of this bivariate model, and the resulting multivariate models were tested in the R-CHOP cohort. 563 genes were identified as adding to the model in the direction of adverse prognosis. These genes were clustered by hierarchical clustering, and three clusters of more than 10 genes with an average correlation of >0.6 were identified. In addition, 542 genes were identified which added to the stromal-1 and GCB signature model in the direction of favorable prognosis. These genes were clustered, and two clusters of more than 10 genes with an average correlation of >0.6 were identified. Signature averages were determined for these clusters, and three variable models containing the stromal-1 and GCB signature and each of the cluster averages were formed on the MMMLNP CHOP and R-CHOP data sets. Of the five cluster averages, two were found to add statistical significance (p<0.02) in the MMMLNP CHOP data as compared to a model containing the stromal-1 and GCB signatures alone. By contrast, in the R-CHOP data, three of the five cluster averages were found to add significance (p<0.02) to the bivariate model. One of these cluster averages added significantly to the bivariate model in both the MMMLNP CHOP and R-CHOP data. This signature, designated Signature 122, was also found to add to the stromal-1 and GCB signature far more significantly than any of the four other signatures on the LLMPP CHOP data and, thus, was retained for further analysis.
  • Signature 122 added significantly to the bivariate model in both the MMMLNP CHOP cohort (p=0.011) and in the R-CHOP cohort (p=0.001) (FIGS. 9B and 9C). This Signature 122 positively correlated with the stromal-1 signature, although it was associated with adverse survival when added to the bivariate model. To further refine our model, we identified genes that were more correlated with Signature 122 than with the stromal-1 signature (p<0.02). These genes were organized by hierarchical clustering, and three sets of correlated genes (r>0.6) were observed. One of these clusters, the stromal-2 signature, added to the significance of the bivariate model in both the MMMLNP CHOP cohort (p=0.002) and the R-CHOP cohort (p<0.001) (FIGS. 2B and 9D).
  • A multivariate survival model was formed by fitting a Cox model with the GCB, stromal-1, and stomal-2 signatures to the LLMPP CHOP cohort data shown in Table 3. This final multivariate model with its associated scaling coefficients was then evaluated on the MMLLMPP CHOP and R-CHOP cohort data sets. Survival predictor scores from the final model were used to divide the R-CHOP cohort into quartile groups with 3-year overall survival rates of 89%, 82%, 74%, and 48%, and 3-year progression-free survival rates of 84%, 69%, 61% and 33% (FIG. 2B). The survival predictor scores from the final model are illustrated in FIG. 3 along with the three component signatures and representative genes of each signature.
  • TABLE 3
    Time to Status at Time to death, Status at last Germinal
    death or last last follow up progression, or follow up Center Stromal-1 Stromal-2
    follow up (1 = dead, last follow up (1 = progressed or died, Signature Signature Signature Model
    Patient (years) 0 = alive) (years) 0 = no progression) Average Average Average Score
    2 2.75 0 2.75 0 9.238 8.778 7.475 0.376
    3 2.67 0 2.67 0 9.942 8.227 7.102 0.387
    5 1.27 1 0.72 1 8.859 9.033 8.716 1.113
    21 2.39 0 2.40 0 10.573 8.519 6.959 −0.270
    22 2.38 0 2.38 0 8.737 8.686 7.598 0.761
    23 2.52 0 2.52 0 10.694 10.322 8.817 −0.897
    24 5.11 0 5.11 0 11.376 7.854 7.598 0.500
    26 4.01 0 4.01 0 9.829 9.956 8.507 −0.372
    28 3.96 0 3.96 0 10.957 9.277 8.248 −0.330
    41 0.52 1 0.52 1 9.273 9.437 8.202 0.183
    47 1.53 1 0.77 1 9.548 8.802 8.061 0.617
    48 0.37 1 0.12 1 8.660 8.279 6.891 0.729
    49 2.37 0 2.35 1 10.915 8.988 6.847 −0.965
    53 3.89 0 2.23 1 9.530 9.792 9.693 0.721
    61 0.90 1 0.46 1 8.649 8.038 8.104 1.798
    65 4.04 0 4.04 0 10.744 9.330 7.930 −0.508
    66 4.04 0 4.04 0 10.714 10.016 7.536 −1.459
    95 0.62 1 0.44 1 9.244 9.197 8.105 0.373
    96 5.37 0 5.37 0 10.107 8.723 7.608 0.157
    97 5.07 0 5.07 0 9.777 9.192 7.359 −0.349
    98 0.94 1 0.59 1 8.794 7.711 7.367 1.571
    99 0.40 1 0.40 1 9.024 9.272 9.160 1.101
    103 0.03 1 0.02 1 8.883 8.190 7.742 1.301
    104 3.76 0 3.76 0 9.785 9.866 7.929 −0.652
    106 2.95 0 2.95 0 10.585 7.797 6.824 0.367
    107 2.94 0 2.94 0 11.535 8.358 6.660 −0.711
    108 2.73 0 2.73 0 9.653 8.495 7.550 0.539
    109 0.16 1 0.11 1 9.301 9.376 7.994 0.092
    110 2.46 0 2.46 0 10.254 8.980 7.324 −0.357
    111 2.44 0 2.44 0 10.137 10.691 8.948 −0.949
    113 2.12 0 2.12 0 10.746 8.555 6.942 −0.390
    114 1.98 0 0.88 1 8.562 8.159 7.120 1.047
    115 1.92 0 1.92 0 10.313 9.385 8.157 −0.231
    118 1.64 0 1.64 0 10.209 10.194 8.231 −0.959
    119 1.60 0 1.60 0 11.059 8.852 7.479 −0.461
    1087 0.05 1 0.05 1 8.756 8.491 7.949 1.188
    1089 5.12 0 1.27 1 9.863 9.135 8.034 0.129
    1091 5.15 0 5.15 0 10.454 9.918 8.742 −0.437
    1092 5.06 0 5.07 0 9.452 9.467 8.912 0.556
    1093 3.83 1 1.62 1 9.915 9.138 7.747 −0.090
    1096 4.02 0 4.02 0 8.887 9.236 7.795 0.274
    1097 1.26 1 1.08 1 11.219 9.234 8.321 −0.347
    1098 3.53 0 3.53 0 9.117 9.236 7.655 0.082
    1099 3.07 0 0.91 1 9.284 8.798 7.741 0.515
    1101 5.64 0 5.64 0 9.803 9.466 8.156 −0.101
    1108 3.30 0 3.30 0 9.195 10.456 9.065 −0.237
    1109 3.78 0 3.78 0 11.008 10.051 8.273 −1.120
    1164 0.19 1 0.16 1 9.242 10.307 10.548 0.896
    1167 1.49 1 0.45 1 9.809 9.105 8.784 0.687
    1168 0.42 1 0.30 1 8.718 8.368 7.149 0.790
    1169 1.71 1 1.22 1 11.512 8.108 7.507 0.125
    1172 2.82 0 2.82 0 11.137 8.871 8.153 −0.057
    1173 0.87 1 0.79 1 11.324 9.914 8.514 −0.950
    1175 1.06 1 0.56 1 9.107 10.310 9.063 −0.053
    1179 2.53 0 2.53 0 9.506 9.437 8.461 0.260
    1181 1.72 0 1.72 0 10.688 9.018 7.647 −0.360
    1184 4.74 0 2.97 1 10.812 8.979 7.922 −0.187
    1185 3.71 0 3.71 0 10.431 8.397 7.317 0.156
    1186 3.43 0 3.43 0 8.688 8.944 8.552 1.164
    1187 5.23 0 5.23 0 10.072 10.192 8.667 −0.604
    1189 5.13 0 5.13 0 10.109 9.212 7.967 −0.097
    1190 3.66 0 3.66 0 10.713 10.409 8.910 −0.930
    1192 0.16 1 0.16 1 8.825 9.903 8.061 −0.199
    1195 4.36 0 4.36 0 11.539 7.567 6.873 0.234
    1197 3.13 0 3.13 0 10.287 10.365 9.549 −0.275
    1200 0.31 1 0.31 1 9.432 8.950 9.805 1.692
    1206 6.51 0 6.51 0 10.410 9.946 8.925 −0.323
    1211 6.25 0 6.25 0 11.596 7.908 6.524 −0.372
    1215 5.35 0 5.35 0 10.504 9.061 7.550 −0.392
    1216 0.46 1 0.29 1 10.017 9.010 7.794 0.028
    1219 0.51 1 0.51 1 10.614 10.014 8.619 −0.683
    1220 2.24 1 2.25 1 8.850 9.400 8.036 0.286
    1221 3.94 0 3.95 0 8.777 7.489 6.672 1.334
    1222 3.53 0 3.53 0 10.463 9.310 7.019 −0.986
    1224 3.22 0 2.11 1 9.751 9.505 8.453 0.082
    1225 2.95 0 2.95 0 8.613 8.313 7.668 1.240
    1226 0.08 1 0.08 1 9.229 8.851 7.950 0.625
    1228 2.78 0 0.99 1 11.532 8.261 6.932 −0.428
    1230 0.59 1 0.54 1 9.369 6.951 6.956 1.825
    1231 1.41 0 1.41 0 10.248 8.788 8.011 0.303
    1232 2.49 0 0.68 1 10.362 8.528 7.975 0.495
    1233 2.50 0 2.50 0 9.239 10.581 8.470 −0.784
    1236 2.56 0 2.56 0 9.156 10.000 7.805 −0.608
    1238 0.16 1 0.16 1 9.488 9.055 8.256 0.517
    1239 2.24 0 2.24 0 8.886 8.978 7.838 0.564
    1240 1.48 0 1.48 0 10.474 9.073 7.702 −0.288
    1241 1.41 1 1.17 1 9.044 9.054 7.451 0.160
    1251 2.72 0 2.72 0 8.410 8.687 7.082 0.549
    1252 0.01 1 0.01 1 11.167 8.070 7.358 0.206
    1255 5.17 0 5.17 0 9.501 9.411 7.887 −0.099
    1271 4.72 0 4.73 0 10.718 8.452 7.060 −0.194
    1272 5.68 0 5.68 0 9.161 9.080 7.668 0.231
    1275 1.89 1 1.48 1 9.257 8.559 8.607 1.354
    1277 5.06 0 5.07 0 11.091 9.938 8.274 −1.038
    1279 4.87 0 4.87 0 9.309 10.085 9.676 0.504
    1281 3.36 0 not available (n/a) n/a 9.535 9.969 9.090 0.132
    1284 3.51 0 3.51 0 10.922 9.680 8.481 −0.567
    1288 1.54 0 n/a n/a 9.430 8.896 8.037 0.554
    1289 0.03 1 0.03 1 8.915 9.052 8.002 0.589
    1290 5.23 0 5.23 0 10.432 10.426 8.154 −1.340
    1291 0.04 1 0.04 1 11.319 8.246 7.323 −0.059
    1292 0.10 1 0.10 1 8.667 8.764 8.110 1.058
    1293 4.81 0 4.81 0 11.116 9.842 8.083 −1.081
    1294 0.53 1 0.53 1 10.138 10.181 8.501 −0.733
    1295 5.16 0 5.17 0 9.445 9.694 7.739 −0.463
    1296 4.79 0 4.79 0 10.228 9.064 8.852 0.600
    1297 4.24 0 4.24 0 9.524 7.990 7.008 0.740
    1298 4.56 0 4.56 0 9.022 9.000 7.695 0.389
    1331 3.29 0 3.29 0 11.004 9.488 8.289 −0.536
    1334 2.87 0 2.87 0 11.434 9.509 8.109 −0.859
    1335 1.38 1 0.90 1 9.586 8.545 7.423 0.431
    1336 2.44 0 2.44 0 10.844 9.704 7.706 −1.082
    1337 0.02 1 0.02 1 8.521 7.788 7.860 1.941
    1449 1.62 0 1.62 0 9.604 8.463 8.030 0.917
    1450 1.30 0 0.53 1 8.571 8.112 7.241 1.173
    1451 1.84 0 1.85 0 10.637 9.205 7.759 −0.452
    1453 1.71 0 1.71 0 10.964 9.089 8.226 −0.157
    1454 0.62 0 0.62 0 11.106 8.514 7.604 −0.052
    1553 2.93 0 1.92 1 8.975 9.284 7.475 −0.029
    1612 5.37 0 5.37 0 10.526 9.471 7.809 −0.643
    1613 5.81 0 n/a n/a 10.868 9.695 7.730 −1.067
    1614 4.36 1 4.36 1 10.358 9.226 8.765 0.322
    1617 0.52 0 0.52 0 10.332 8.723 7.180 −0.227
    1618 1.70 0 0.98 1 11.233 8.956 7.852 −0.387
    1619 0.25 1 0.25 1 8.646 8.028 7.123 1.146
    1620 2.17 0 2.17 0 11.647 8.385 7.343 −0.325
    1623 2.80 0 2.80 0 9.611 9.484 8.249 0.024
    1626 1.76 0 1.76 0 11.236 9.495 8.108 −0.763
    1628 3.13 0 1.23 1 8.714 7.972 7.149 1.192
    1645 2.85 0 2.85 0 10.146 9.476 8.914 0.258
    1647 2.79 0 2.80 0 10.485 10.495 8.707 −1.058
    1650 0.75 1 0.75 1 8.830 7.346 6.486 1.333
    1651 1.66 0 1.66 0 9.190 7.949 6.829 0.801
    1652 1.64 0 n/a n/a 8.798 8.943 8.331 0.969
    1702 1.05 0 1.05 1 9.008 8.217 8.078 1.447
    1703 0.70 1 0.70 1 9.499 8.637 7.790 0.621
    1704 3.14 0 3.14 0 9.908 9.231 7.503 −0.347
    1705 3.94 0 3.94 0 8.933 8.445 8.187 1.321
    1707 2.80 0 2.80 0 10.610 9.348 7.872 −0.510
    1742 3.27 0 n/a n/a 10.033 8.715 7.412 0.063
    1746 1.91 0 1.55 1 9.249 8.705 8.205 0.937
    1747 1.48 0 1.48 0 10.162 8.866 7.602 −0.016
    1756 3.47 0 3.47 0 10.815 9.638 7.248 −1.312
    1761 0.23 1 0.23 1 9.842 10.192 8.664 −0.511
    1762 5.20 0 5.20 0 10.583 9.333 7.445 −0.772
    1763 5.51 0 5.51 0 8.917 8.925 8.084 0.771
    1766 1.59 0 1.59 0 10.919 10.037 8.389 −0.990
    1782 1.09 0 1.09 0 10.753 9.600 8.332 −0.516
    1788 0.39 1 0.24 1 10.364 8.738 8.914 0.915
    1861 0.56 1 0.19 1 9.728 8.604 7.594 0.427
    1867 1.17 1 0.38 1 8.903 11.501 10.559 −0.166
    1916 1.41 0 n/a n/a 9.295 11.197 11.508 0.619
    1920 1.32 0 1.32 0 10.165 9.630 8.789 0.009
    1927 1.53 0 1.53 0 9.195 10.261 9.791 0.451
    1928 0.72 0 0.72 0 9.769 8.510 7.330 0.328
    1939 0.47 1 0.47 1 9.097 9.363 7.647 −0.043
    2002 1.29 0 1.30 0 9.469 9.542 8.600 0.262
    2006 1.23 0 1.23 0 10.434 8.223 7.162 0.227
    2067 2.18 0 2.18 0 10.244 11.186 9.391 −1.197
    2070 0.31 0 0.12 1 10.486 10.680 10.353 −0.135
    2162 0.38 1 0.38 1 10.934 10.020 7.960 −1.268
    2270 1.59 0 1.59 0 10.117 9.904 8.506 −0.440
    2271 1.60 0 1.60 0 8.995 9.349 8.261 0.428
    2274 0.41 0 0.41 0 8.863 7.623 7.222 1.533
    2283 1.19 0 1.19 0 10.501 8.361 6.741 −0.226
    2291 0.87 1 0.85 1 10.732 10.184 9.436 −0.353
    2299 0.93 0 0.93 0 10.661 9.905 8.189 −0.883
    2301 0.61 0 0.61 0 9.852 9.903 8.352 −0.432
    2306 0.68 0 0.68 0 8.586 8.759 8.191 1.151
    2309 0.43 0 0.43 0 10.839 7.671 6.860 0.413
    2311 0.80 0 0.80 0 10.901 7.797 6.912 0.294
    2318 0.99 0 0.99 0 10.283 9.403 8.655 0.100
    2321 0.82 0 0.82 0 9.691 8.956 7.404 −0.044
    2411 0.67 0 0.67 0 8.986 8.383 7.854 1.137
    2415 0.62 0 0.62 0 9.296 10.509 9.551 −0.005
    2444 3.99 0 3.99 0 10.154 9.871 9.026 −0.071
    2445 3.36 0 3.36 0 8.788 8.184 7.964 1.497
    2479 0.51 0 0.51 0 11.151 9.023 8.199 −0.186
    2482 4.54 0 4.54 0 10.373 9.847 8.208 −0.691
    2483 3.89 1 3.89 1 9.241 8.902 7.742 0.428
    2484 2.69 1 1.90 1 10.279 9.619 8.312 −0.349
    2485 4.43 0 4.43 0 9.957 9.865 8.439 −0.378
    2486 4.37 0 n/a n/a 10.698 10.203 8.041 −1.301
    2487 4.34 0 4.34 0 11.227 9.909 8.260 −1.076
    2488 4.20 0 4.21 0 9.510 8.709 7.615 0.426
    2490 4.02 0 4.02 0 10.510 10.961 8.956 −1.374
    2491 0.50 1 0.25 1 9.047 8.554 7.624 0.784
    2492 3.96 0 3.96 0 9.904 10.901 9.140 −0.935
    2497 3.44 0 3.44 0 9.221 9.438 8.065 0.111
    2498 3.37 0 3.37 0 9.318 9.427 8.003 0.040
    2500 3.31 0 3.31 0 11.014 9.406 7.375 −1.074
    2501 3.28 0 n/a n/a 8.822 8.551 7.750 0.966
    2503 2.99 0 2.99 0 8.301 7.967 6.929 1.222
    2504 2.78 0 2.78 0 10.145 8.004 7.017 0.472
    2505 2.76 0 2.76 0 11.036 8.442 7.136 −0.266
    2507 0.86 1 0.54 1 9.737 9.475 8.988 0.480
    2508 2.58 0 2.58 0 8.678 9.389 8.230 0.498
    2509 0.96 1 0.76 1 8.895 10.441 9.088 −0.081
    2511 1.55 1 1.06 1 9.225 9.267 9.191 1.042
    2512 2.45 0 2.45 0 11.047 10.465 9.337 −0.838
    2513 0.61 1 0.61 1 10.855 10.378 8.395 −1.305
    2514 2.18 0 2.18 0 10.477 9.832 7.498 −1.198
    2515 2.13 0 2.13 0 9.295 10.519 9.788 0.145
    2516 2.07 0 2.07 0 10.575 10.592 8.642 −1.238
    2517 2.04 0 0.76 1 9.385 9.163 8.328 0.498
    2584 0.68 0 0.68 0 10.759 9.356 8.135 −0.404
    2599 4.05 0 4.05 0 10.629 9.158 7.724 −0.425
    2600 1.01 1 0.54 1 9.785 8.619 7.291 0.184
    2601 1.22 1 0.88 1 9.385 8.044 7.178 0.859
    2603 4.43 0 4.43 0 9.582 10.707 9.803 −0.156
    2604 0.84 0 0.36 1 9.844 10.511 8.382 −1.026
    2609 8.89 0 2.55 1 8.981 8.775 7.506 0.507
    2610 0.74 0 0.74 0 10.793 8.964 7.421 −0.502
    2611 0.66 0 0.66 0 10.353 10.233 9.032 −0.518
    2612 1.17 1 1.13 1 10.290 9.028 8.287 0.230
    2613 1.66 0 1.66 0 10.997 9.089 7.749 −0.493
    2614 0.21 1 0.21 1 8.768 7.850 7.100 1.261
    2615 0.48 0 0.48 0 11.359 9.470 7.647 −1.100
    2639 10.29 0 10.30  0 11.085 10.385 8.003 −1.674
    2641 1.38 0 1.38 0 9.199 8.818 7.340 0.259
    2642 3.67 0 3.67 0 10.731 8.777 7.167 −0.458
    2643 5.49 0 5.49 0 10.236 10.578 8.473 −1.197
    2645 0.19 0 n/a n/a 11.130 9.997 8.254 −1.129
    2646 0.18 1 0.18 1 8.893 7.648 6.871 1.260
    2648 0.25 0 0.25 0 8.855 7.745 7.060 1.303
    2649 2.13 0 2.13 0 9.688 10.354 9.885 0.214
    2650 2.43 0 n/a n/a 10.007 10.052 8.861 −0.305
    2651 1.61 0 n/a n/a 10.660 9.452 7.831 −0.665
    2652 1.84 0 1.84 0 11.378 9.247 7.684 −0.856
    2653 1.88 0 1.88 0 11.182 9.638 7.781 −1.106
    2654 1.43 0 1.43 0 8.791 9.395 8.905 0.902
    2813 3.97 0 3.97 0 10.701 9.366 8.258 −0.306
    2814 0.81 1 0.70 1 10.561 9.176 9.275 0.632
  • The International Prognostic Index (IPI), which is based on 5 clinical variables, predicts survival in both CHOP-treated and R-CHOP-treated patients (Shipp et al., N. Engl. J. Med., 329:987-94 (1993); Sehn et al., Blood, 109: 1857-61 (2007)). The inventive gene expression-based survival model retained its prognostic significance among R-CHOP-treated patients segregated according to IPI into high, intermediate and low IPI risk groups, both as originally defined (Shipp et al., supra) (p<0.001) (FIG. 2C) and as recently modified for R-CHOP-treated DLBCL (Sehn et al., supra) (p<0.001) (FIG. 10).
  • The foregoing results indicate that the gene expression-based multivariate model can be used to identify large disparities in survival among patients with different DLBCL gene signature profiles. Thus, survival predictor scores were used to divide patients into least and most favorable quartile groups having 3-year progression-free survival rates of 33% and 84%, respectively. Given its statistical independence from the IPI, the gene expression-based survival predictor provides a complementary view of DLBCL variation that can be considered when analyzing data from DLBCL clinical trials. Additionally, the foregoing results indicate that whole-genome gene expression profiles in conjunction with the survival model described herein can be used to provide optimal predictions of expected survival outcomes for subjects suffering from DLBCL.
    • EXAMPLE 3
  • This example demonstrates the use of a survival predictor score to predict the probability of progression free and overall survival outcomes at a period of time t following R-CHOP treatment in accordance with the invention.
  • RNA is isolated from a patient's DLBCL biopsy and hybridized to a U133+ array from Affymetrix (Santa Clara, Calif.). The array is scanned, and MAS 5.0 algorithm is applied to obtain signal values normalized to a target intensity of 500. Signal values are log 2 transformed to intensity values. For genes of interest with multiple probe sets, the intensity value of the multiple probe sets are averaged to obtain a single intensity value for each gene. The single intensity values of genes in the GCB signature are averaged to obtain a GCB signature average of 9.2. The single intensity values of genes in the stromal-1 signature are averaged to obtain a stromal-1 signature average of 8.5. The single intensity values of genes in the stromal-2 signature are averaged to obtain a stromal-2 signature average of 7.2.
  • The patient's survival predictor score is calculated using the following equation 8.11−[0.419*(GCB signature average)]−[1.015*(stromal-1 signature average)]+[0.675*(stromal-2 signature average)], such that the survival predictor score=8.11−[0.419*(9.2)]−[1.015*(8.5)]+[0.675*(7.2)]=0.389
  • Table 4 includes values from a progression free survival curve generated using baseline hazard functions calculated from the R-CHOP patient data described in Table 3. The curve was generated in accordance with the methods of Kalbfleisch and Prentice, Biometrika, 60: 267-279 (1973), which involves maximizing the full likelihood, under the assumption that the true scaling coefficients were equal to prior estimates. In Table 4, F0(t) is the probability of progression free survival for each indicated time period following R-CHOP treatment (t-RCHOP).
  • TABLE 4
    t-RCHOP (years) F0 (t)
    0.000 1.000
    0.008 0.997
    0.016 0.993
    0.025 0.990
    0.030 0.987
    0.036 0.983
    0.049 0.980
    0.082 0.977
    0.096 0.973
    0.107 0.970
    0.118 0.967
    0.120 0.963
    0.156 0.960
    0.156 0.956
    0.159 0.953
    0.178 0.950
    0.192 0.946
    0.211 0.943
    0.233 0.939
    0.241 0.936
    0.246 0.932
    0.252 0.928
    0.290 0.925
    0.298 0.921
    0.307 0.918
    0.364 0.914
    0.381 0.910
    0.381 0.907
    0.400 0.903
    0.441 0.899
    0.446 0.895
    0.463 0.891
    0.468 0.887
    0.515 0.884
    0.517 0.880
    0.531 0.876
    0.534 0.872
    0.537 0.868
    0.537 0.864
    0.539 0.860
    0.561 0.856
    0.586 0.852
    0.611 0.848
    0.679 0.843
    0.698 0.839
    0.698 0.834
    0.720 0.830
    0.747 0.826
    0.756 0.821
    0.761 0.816
    0.767 0.812
    0.786 0.807
    0.849 0.803
    0.879 0.798
    0.884 0.793
    0.898 0.789
    0.912 0.784
    0.977 0.779
    0.986 0.774
    1.046 0.770
    1.057 0.765
    1.076 0.760
    1.128 0.755
    1.166 0.750
    1.216 0.745
    1.227 0.740
    1.270 0.735
    1.481 0.729
    1.547 0.724
    1.624 0.718
    1.900 0.711
    1.919 0.705
    2.105 0.699
    2.231 0.692
    2.245 0.685
    2.352 0.678
    2.546 0.671
    2.968 0.662
    3.890 0.648
    4.364 0.623
  • The patient's probability of 2 year progression free survival is calculated using the equation: P(PFS)=F0(t)(exp(0.976*survival predictor score)), where F0(t) is the F0(t) value that corresponds to the largest time value smaller than 2 years in the progression free survival curve. In Table 4, the largest time value smaller than 2 is 1.919, and the corresponding PF0(t) value is 0.705. Accordingly, the patient's probability of 2 year progression free survival P(PFS)=0.705(exp(0.976*survival predictor score))=0.7051.462=0.600 or about 60%.
  • Table 5 includes values from an overall survival curve generated using baseline hazard functions calculated from the R-CHOP patient data described in Table 3. The curve was made according to the method of Kalbfleisch and Prentice, Biometrika, 60: 267-279 (1973), which involves maximizing the full likelihood, under the assumption that the true scaling coefficients were equal to our estimates. In Table 5, OS0(t) is the probability of overall survival for each indicated time period following R-CHOP treatment (t-RCHOP).
  • TABLE 5
    t-RCHOP (years) OS0 (t)
    0.000 1.000
    0.008 0.997
    0.016 0.994
    0.030 0.991
    0.033 0.988
    0.036 0.984
    0.049 0.981
    0.082 0.978
    0.096 0.975
    0.156 0.972
    0.156 0.969
    0.159 0.965
    0.178 0.962
    0.192 0.959
    0.211 0.956
    0.233 0.952
    0.246 0.949
    0.307 0.946
    0.367 0.942
    0.380 0.939
    0.386 0.935
    0.402 0.932
    0.416 0.928
    0.463 0.925
    0.468 0.921
    0.504 0.918
    0.515 0.914
    0.517 0.910
    0.531 0.907
    0.556 0.903
    0.586 0.900
    0.610 0.896
    0.619 0.892
    0.698 0.888
    0.747 0.885
    0.807 0.881
    0.862 0.877
    0.868 0.873
    0.873 0.869
    0.895 0.864
    0.944 0.860
    0.963 0.856
    1.010 0.852
    1.057 0.848
    1.169 0.843
    1.169 0.839
    1.215 0.835
    1.262 0.830
    1.273 0.826
    1.382 0.821
    1.412 0.817
    1.492 0.812
    1.527 0.807
    1.552 0.802
    1.708 0.796
    1.889 0.791
    2.244 0.784
    2.693 0.777
    3.826 0.763
    3.889 0.749
    4.363 0.724
  • The patient's probability of 2 year overall survival is calculated using the equation: P(OS)=OS0(t)(exp(survival predictor score)), where OS0(t) is the value that corresponds to the largest time value in the overall survival curve which is smaller than 2 years. In Table 5, the largest time value smaller than 2 is 1.889, and the corresponding OS0(t) value is 0.791. Accordingly, the patient's probability of 2 year overall survival is P(PFS)=0.791(exp(0.389))=0.7911.4476=0.707 or 70.7%.
    • EXAMPLE 4
  • This example demonstrates the biological basis for DLBCL prognostic signatures.
  • Unless otherwise indicated, cohorts and methods of gene expression analysis are described in Examples 1 and 2. Furthermore, cell suspensions from three biopsies were separated by flow cytometry into a CD19+ malignant subpopulation and a CD19− non-malignant subpopulation. Gene expression profiling was performed following two rounds of linear amplification from total RNA (Dave et al., N. Engl. J. Med., 351: 2159-69 (2004)). After MAS5.0 normalization, genes were selected that had a log 2 signal value greater than 7 in either the CD19+ or CD19− fractions in at least two of the sorted samples.
  • To assess whether the gene expression signatures in the final survival model of Example 2 were derived from the malignant lymphoma cells or from the host microenvironment, three DLBCL biopsy samples were fractionated into CD19+ malignant cells and CD19− non-malignant cells by flow sorting. Most germinal center B cell signature genes were more highly expressed in the malignant fraction, whereas genes from the stromal-1 and stromal-2 signatures were more highly expressed in the non-malignant stromal fraction (FIG. 4A), hence their name. Since these two signatures were synergistic in predicting survival, they were combined into a “stromal score” (FIG. 3), high values of which were associated with adverse outcome.
  • The germinal center B cell signature relates to the distinction between the ABC and GCB DLBCL subtypes (FIG. 3). By contrast, the genes defining the stromal-1 signature encodes components of the extracellular matrix, including fibronectin, osteonectin, various collagen and laminin isoforms, and the anti-angiogenic factor thrombospondin (FIG. 3 and Table 1). This signature also encodes modifiers of collagen synthesis (LOXL1, SERPINHI), proteins that remodel the extracellular matrix (MMP2, MMP9, MMP14, PLAU, TIMP2), and CTGF, a secreted protein that can initiate fibrotic responses (Frazier et al., J. Invest. Dermatol., 107(3): 404-11 (1996)). In addition, the stromal-1 signature includes genes characteristically expressed in cells of the monocytic lineage, such as CEBPA and CSF2RA.
  • The stromal-1 signature is significantly related to several previously curated gene expression signatures (Shaffer et al., Immunol. Rev., 210: 67-85 (2006)) based on gene set enrichment analysis (Subramanian et al., Proc. Nat'l. Acad. Sci. USA, 102(43): 15545-50 (2005)). Two of these signatures include genes that are coordinately expressed in normal mesenchymal tissues but not in hematopoietic subsets, many of which encode extracellular matrix proteins (false discovery rate (FDR)<0.001) (FIGS. 4B and 11) (Su et al., Proc. Nat'l. Acad. Sci. USA, 101: 6062-7 (2004)). Also enriched was a “monocyte” signature, comprised of genes that are more highly expressed in CD14+ blood monocytes than in B cells, T cells, or NK cells (FDR=0.014) (FIG. 4B). By contrast, a pan-T cell signature was not related to the stromal-1 signature (FIG. 4B). These findings suggest that high expression of the stromal-1 signature identifies tumors with vigorous extracellular matrix deposition and infiltration by cells in the monocytic lineage.
  • In this regard, the stromal-1 signature gene product fibronectin was prominently localized by immunohistochemistry to fibrous strands running between the malignant cells in DLBCL biopsy samples, in keeping with its role in extracellular matrix formation. By contrast, the protein products of three other stromal-1 gene—MMP9, SPARC, and CTGF—were localized primarily in histiocytic cells that infiltrated the DLBCL biopsies. By immunofluorescence, SPARC and CTGF colocalized with CD68, which is a marker for cells in the monocytic lineage. As expected for a stromal-1 gene product, SPARC protein levels were associated with favorable overall survival (FIG. 5A).
  • The stromal-1 signature includes genes that are coordinately expressed in many normal mesenchymal tissues, most of which encode proteins that form or modify the extracellular matrix. The localization of fibronectin to fibrous strands insinuated between the malignant lymphoma cells suggests that the stromal-1 signature reflects the fibrotic nature of many DLBCL tumors. This fibrotic reaction may be related to another stromal-1 signature component, CTGF, which participates in many fibrotic responses and diseases, and promotes tumor growth and metastasis of epithelial cancers (Shi-Wen et al., Cytokine Growth Factor Rev., 19: 133-44 (2008)).
  • The foregoing results also indicate that the stromal-1 signature reflects a monocyte-rich host reaction to the lymphoma that is associated with the abundant deposition of extracellular matrix. Tumors with high expression of the stromal-1 signature were infiltrated by cells of the myeloid lineage, which include cells that have been implicated in the pathogenesis of epithelial cancers, including tumor-associated macrophages, myeloid-derived suppressor cells, and Tie2-expressing monocytes (reviewed in Wels et al., Genes Dev., 22: 559-74 (2008)). In animal models, these myeloid lineage cells promote tumor cell invasion by secreting matrix metalloproteinases such as MMP9, suppress T cell immune responses, and initiate angiogenesis.
  • Several stromal-2 signature genes encode well-known markers of endothelial cells. These include von-Willebrand factor (VWF) and CD31 (PECAM1), as well as other genes specifically expressed in endothelium such as EGFL7, MMRN2, GPR116, and SPARCL (Table 1). This signature also includes genes encoding key regulators of angiogenesis, such as, for example, KDR (VEGF receptor-2); Grb10, which mediates KDR signaling; integrin alpha 9, which enhances VEGF signaling; TEK, the receptor tyrosine kinase for the cytokine angiopoietin; ROBO4, an endothelial-specific molecular guidance molecule that regulates angiogenesis; and ERG, a transcription factor required for endothelial tube formation. The stromal-2 signature genes CAV1, CAV2, and EHD2 encode components of caveolae, which are specialized plasma membrane structures that are abundant in endothelial cells and required for angiogenesis (Frank et al., Arterioscler. Thromb. Vasc. Biol., 23: 1161-8 (2003); Woodman et al., Am. J. Pathol., 162: 2059-68 (2003)). Although the stromal-2 signature includes a large number of genes expressed in endothelial cells, other genes are expressed exclusively in adipocytes, including ADIPOQ, FABP4, RBP4, and PLIN.
  • Quantitative tests were done to determine whether expression of the stromal-2 signature relative to the stromal-1 signature (i.e., high stromal score) is related to high tumor blood vessel density, given the connection between many stromal-2 signature genes and angiogenesis. More specifically, the stromal-1 signature averages were subtracted from the stromal-2 signature average to thereby obtain a stromal score for each biopsy. Tests showed a quantitative measure of blood vessel density correlated significantly with the stromal score (r=0.483, p=0.019) (see FIGS. 5B and 5C), such that higher blood vessel densities correlated with higher stromal scores.
  • Thus, the stromal-1 and stromal-2 gene expression signatures reflect the character of the non-malignant cells in DLBCL tumors, and the stromal-2 signature may represent an “angiogenic switch” in which the progression of a hyperplastic lesion to a fully malignant tumor is accompanied by new blood vessel formation (Hanahan et al., Cell, 86: 353-64 (1996)). DLBCL tumors with high relative expression of the stomal-2 signature were associated with increased tumor blood vessel density and adverse survival. Significant macrophage infiltration in some DLBCL tumors may predispose to angiogenesis since, in experimental models, tumor-associated macrophages accumulate prior to the angiogenic switch and are required for the switch to occur (Lin et al., Cancer Res., 66: 11238-46 (2006)). Additionally, CXCL12 (SDF-1), a stromal-2 signature component, is a chemokine secreted either by fibroblasts or endothelial cells that can promote angiogenesis by recruiting CXCR4+ endothelial precursor cells from the bone marrow (Orimo et al., Cell, 121: 335-48 (2005)). Moreover, an antagonist of angiogenesis, thrombospondin-2 (Kazerounian et al., Cell Mol. Life Sci., 65: 700-12 (2008)), is a stromal-1 signature component, which may explain why tumors with low relative expression of this signature had an elevated blood vessel density. Furthermore, the expression of adipocyte-associated genes in DLBCL tumors with high stromal-2 signature expression may play a role in angiogenesis since some cells in adipose tissue may have the potential to differentiate into endothelial cells (Planat-Benard et al., Circulation, 109: 656-63 (2004)). Alternatively, the expression of adipose-associated genes may reflect the recruitment of bone marrow-derived mesenchymal stem cells, which home efficiently to tumors (Karnoub et al., Nature, 449: 557-63 (2007)) and can stabilize newly formed blood vessels (Au et al., Blood, 111: 4551-4558 (2008)).
  • The foregoing results indicate that the stromal-1 and stromal-2 gene signatures can be used to generate a stromal score that correlates with increased blood vessel density. Thus, the stromal score can be used to determine if a DLBCL patient is likely to benefit from administration of antiangiogenic therapy (alone, or in conjunction with another DLBCL therapeutic regimen).
  • All references, including publications, patent applications, and patents, cited herein are hereby incorporated by reference to the same extent as if each reference were individually and specifically indicated to be incorporated by reference and were set forth in its entirety herein.
  • The use of the terms “a” and “an” and “the” and similar referents in the context of describing the invention (especially in the context of the following claims) are to be construed to cover both the singular and the plural, unless otherwise indicated herein or clearly contradicted by context. The terms “comprising,” “having,” “including,” and “containing” are to be construed as open-ended terms (i.e., meaning “including, but not limited to,”) unless otherwise noted. Recitation of ranges of values herein are merely intended to serve as a shorthand method of referring individually to each separate value falling within the range, unless otherwise indicated herein, and each separate value is incorporated into the specification as if it were individually recited herein. All methods described herein can be performed in any suitable order unless otherwise indicated herein or otherwise clearly contradicted by context. The use of any and all examples, or exemplary language (e.g., “such as”) provided herein, is intended merely to better illuminate the invention and does not pose a limitation on the scope of the invention unless otherwise claimed. No language in the specification should be construed as indicating any non-claimed element as essential to the practice of the invention.
  • Preferred embodiments of this invention are described herein, including the best mode known to the inventors for carrying out the invention. Variations of those preferred embodiments may become apparent to those of ordinary skill in the art upon reading the foregoing description. The inventors expect skilled artisans to employ such variations as appropriate, and the inventors intend for the invention to be practiced otherwise than as specifically described herein. Accordingly, this invention includes all modifications and equivalents of the subject matter recited in the claims appended hereto as permitted by applicable law. Moreover, any combination of the above-described elements in all possible variations thereof is encompassed by the invention unless otherwise indicated herein or otherwise clearly contradicted by context.

Claims (21)

1-32. (canceled)
33. A method of predicting the survival outcome of a subject suffering from diffuse large B cell lymphoma (DLBCL), which method comprises:
a) isolating gene expression product from one or more DLBCL biopsy samples from a subject;
b) obtaining a gene expression profile from the gene expression product, wherein the expression profile comprises an expression level for each gene in a germinal center B cell (GCB) gene expression signature and a stromal-1 gene expression signature;
c) determining a GCB signature value and a stromal-1 signature value from the gene expression profile; and
d) calculating a survival predictor score using an equation that includes subtracting [(x)*(the GCB signature value)] and subtracting [(y)*(the stromal-1 signature value)], wherein (x) and (y) are scale factors and wherein a lower survival predictor score indicates a more favorable survival outcome and a higher survival predictor score indicates a less favorable survival outcome for the subject.
34. The method of claim 33, wherein the GCB signature value corresponds to the average of the expression levels of the genes in the GCB gene expression signature and the stromal-1 signature value corresponds to the average of the expression levels of the genes in the stromal-1 gene expression signature.
35. The method of claim 33, wherein the method comprises:
b) obtaining a gene expression profile from the gene expression product, wherein the expression profile comprises an expression level for each gene in a GCB expression signature, a stromal-1 gene expression signature, and a stromal-2 gene expression signature;
c) determining a GCB signature value, a stromal-1 signature value, and a stromal-2 signature value from the gene expression profile; and
d) calculating a survival predictor score using an equation that includes subtracting [(x)*(the GCB signature value)] and subtracting [(y)*(the stromal-1 signature value)], and adding [(z)*(the stromal-2 signature value)], wherein (x), (y), and (z) are scale factors and wherein a lower survival predictor score indicates a more favorable survival outcome and a higher survival predictor score indicates a less favorable survival outcome for the subject.
36. The method of claim 35, wherein the the GCB signature value corresponds to the average of the expression levels of the genes in the GCB gene expression signature, the stromal-1 signature value corresponds to the average of the expression levels of the genes in the stromal-1 gene expression signature, and the stromal-2 signature value corresponds to the average of the expression levels of the genes in the stromal-2 gene expression signature.
37. The method of claim 35, wherein the method comprises:
d) calculating a survival predictor score using the equation: survival predictor score=8.11−[0.419*(the GCB signature value)]−[1.015*(the stromal-1 signature value)]+[0.675*(the stromal-2 signature value)], wherein a lower survival predictor score indicates a more favorable survival outcome and a higher survival predictor score indicates a less favorable outcome for the subject.
38. A method of evaluating a therapeutic regimen for a DLBCL patient based on survival outcome, wherein the method comprises:
a) isolating gene expression product from one or more DLBCL biopsy samples from a subject;
b) obtaining a gene expression profile from the gene expression product, wherein the expression profile comprises an expression level for each gene in a germinal center B cell (GCB) gene expression signature and a stromal-1 gene expression signature;
c) determining a GCB signature value and a stromal-1 signature value from the gene expression profile; and
d) calculating a survival predictor score using an equation that includes subtracting [(x)*(the GCB signature value)] and subtracting [(y)*(the stromal-1 signature value)], wherein (x) and (y) are scale factors and wherein (i) a lower survival predictor score indicates a more favorable survival outcome and a therapeutic regimen that includes chemotherapy and Rituximab (R-CHOP) and (ii) a higher survival predictor score indicates a less favorable survival outcome and a therapeutic regimen other than R-CHOP.
39. The method of claim 38, wherein the DCLBCL patient suffered relapse from R-CHOP treatment.
40. The method of claim 38, wherein the GCB signature value corresponds to the average of the expression levels of the genes in the GCB gene expression signature and the stromal-1 signature value corresponds to the average of the expression levels of the genes in the stromal-1 gene expression signature.
41. The method of claim 38, wherein the method comprises:
b) obtaining a gene expression profile from the gene expression product, wherein the expression profile comprises an expression level for each gene in a GCB expression signature, a stromal-1 gene expression signature, and a stromal-2 gene expression signature;
c) determining a GCB signature value, a stromal-1 signature value, and a stromal-2 gene signature value from the gene expression profile; and
d) calculating a survival predictor score using an equation that includes subtracting [(x)*(the GCB signature value)] and subtracting [(y)*(the stromal-1 signature value)], and adding [(z)*(the stromal-2 signature value)], wherein (x), (y), and (z) are scale factors and wherein (i) a lower survival predictor score indicates a more favorable survival outcome and a therapeutic regimen that includes chemotherapy and Rituximab (R-CHOP) and (ii) a higher survival predictor score indicates a less favorable survival outcome and a therapeutic regimen other than R-CHOP.
42. The method of claim 41, wherein the the GCB signature value corresponds to the average of the expression levels of the genes in the GCB gene expression signature, the stromal-1 signature value corresponds to the average of the expression levels of the genes in the stromal-1 gene expression signature, and the stromal-2 signature value corresponds to the average of the expression levels of the genes in the stromal-2 gene expression signature.
43. The method of claim 41, wherein the method comprises:
d) calculating a survival predictor score using the equation: survival predictor score=8.11−[0.419*(the GCB signature value)]−[1.015*(the stromal-1 signature value)]+[0.675*(the stromal-2 signature value)] and wherein (i) a lower survival predictor score indicates a more favorable survival outcome and a therapeutic regimen that includes chemotherapy and Rituximab (R-CHOP) and (ii) a higher survival predictor score indicates a less favorable survival outcome and a therapeutic regimen other than R-CHOP.
44. A method of treating a subject with DLBCL, the method comprising evaluating a therapeutic regimen for a DLBCL patient according to the method of claim 38 and providing a therapeutic regimen based on the indication of the survival predictor score, wherein a lower survival predictor indicates treatment with a therapeutic regimen that includes chemotherapy and Rituximab (R-CHOP) and a higher survival predictor score indicates a less favorable survival outcome and a therapeutic regimen other than R-CHOP.
45. The method of claim 44, wherein evaluating a therapeutic regimen includes the method of claim 41.
46. A method of predicting the survival outcome of a subject suffering from diffuse large B cell lymphoma (DLBCL), which method comprises:
a) obtaining one or more DLBCL biopsy samples from a subject;
b) isolating gene expression product from the one or more DLBCL biopsy samples;
c) obtaining a gene expression profile from the gene expression product, wherein the expression profile comprises an expression level for each gene in a germinal center B-cell gene (GCB) expression signature, a stromal-1 gene expression signature, and a stromal-2 gene expression signature;
c) determining a GCB signature value, a stromal-1 signature value, and a stromal-2 signature value from the gene expression profile; and
d) calculating a survival predictor score using the equation: survival predictor score=A−[(x)*(the GCB signature value)]−[(y)*(the stromal-1 signature value)]+[(z)*(the stromal-2 signature value)], wherein A is an offset term and (x), (y), and (z) are scale factors; and
e) calculating the probability of a survival outcome for the subject beyond an amount of time t following treatment for DLBCL, wherein the subject's probability of the survival outcome P(SO) is calculated using the equation: P(SO)=SO0(t)(exp((s)*survival predictor score)), wherein SO0(t) is the probability of the survival outcome, which corresponds to the largest time value smaller than t in a survival outcome curve, and wherein (s) is a scale factor.
47. The method of claim 46, wherein the survival outcome is overall survival and the method comprises:
d) calculating a survival predictor score using the equation: survival predictor score=[0.419*(the GCB signature value)]−[1.015*(the stromal-1 signature value)]+[0.675*(the stromal-2 signature value)]; and
e) calculating the probability of overall survival after time t for the subject, wherein the subject's probability of overall survival P(OS) is calculated using the equation: P(OS)=OS0(t)(exp(survival predictor score)), wherein OS0(t) is the probability of overall survival, which corresponds to the largest time value smaller than t in an overall survival curve, and wherein scale factor (s)=1.
48. The method of claim 46, wherein the survival outcome is progression free survival and the method comprises:
d) calculating a survival predictor score using the equation: survival predictor score=8.11−[0.419*(the GCB signature value)]−[1.015*(the stromal-1 signature value)]+[0.675*(the stromal-2 signature value)]; and
e) calculating the probability of progression free survival after time t for the subject, wherein the subject's probability of progression free survival P(PFS) is calculated using the equation P(PFS)=F0(t)(exp(0.976*survival predictor score)), wherein F0(t) is the probability of progression free survival, which corresponds to the largest time smaller than t in a survival curve, and wherein wherein scale factor (s)=0.976.
49. The method of claim 46, wherein the the GCB signature value corresponds to the average of the expression levels of the genes in the GCB gene expression signature, the stromal-1 signature value corresponds to the average of the expression levels of the genes in the stromal-1 gene expression signature, and the stromal-2 signature value corresponds to the average of the expression levels of the genes in the stromal-2 gene expression signature.
50. The method of claim 46, wherein the treatment for DLCBL includes the administration Rituximab.
51. The method of claim 46, wherein the method further includes providing the subject with the calculated probability of the survival outcome after time t.
52. A method of evaluating a subject for antiangiogenic therapy of DLBCL, which method comprises:
a) isolating gene expression product from one or more DLBCL biopsy samples from a subject;
b) obtaining a gene expression profile from the gene expression product, wherein the profile includes an expression level for each gene in a stromal-2 signature;
c) determining the subject's stromal-2 signature value from the gene expression profile; and
d) determining whether the subject's stromal-2 signature value is higher or lower than a standard stromal-2 value, wherein antiangiogenic therapy is indicated by a stromal-2 signature value that is higher than the standard stromal-2 value and antiangiogenic therapy is not indicated by a stromal-2 signature value that is not higher than the standard stromal-2 value.
US12/996,489 2008-06-06 2009-06-05 Survival predictor for diffuse large b cell lymphoma Abandoned US20110195064A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US12/996,489 US20110195064A1 (en) 2008-06-06 2009-06-05 Survival predictor for diffuse large b cell lymphoma

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US5967808P 2008-06-06 2008-06-06
PCT/US2009/046421 WO2009149359A2 (en) 2008-06-06 2009-06-05 Survival predictor for diffuse large b cell lymphoma
US12/996,489 US20110195064A1 (en) 2008-06-06 2009-06-05 Survival predictor for diffuse large b cell lymphoma

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2009/046421 A-371-Of-International WO2009149359A2 (en) 2008-06-06 2009-06-05 Survival predictor for diffuse large b cell lymphoma

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US14/540,302 Continuation US9970059B2 (en) 2008-06-06 2014-11-13 Survival predictor for diffuse large B cell lymphoma

Publications (1)

Publication Number Publication Date
US20110195064A1 true US20110195064A1 (en) 2011-08-11

Family

ID=41165407

Family Applications (3)

Application Number Title Priority Date Filing Date
US12/996,489 Abandoned US20110195064A1 (en) 2008-06-06 2009-06-05 Survival predictor for diffuse large b cell lymphoma
US14/540,302 Active 2031-01-14 US9970059B2 (en) 2008-06-06 2014-11-13 Survival predictor for diffuse large B cell lymphoma
US15/965,510 Active 2030-11-19 US11028444B2 (en) 2008-06-06 2018-04-27 Survival predictor for diffuse large B cell lymphoma

Family Applications After (2)

Application Number Title Priority Date Filing Date
US14/540,302 Active 2031-01-14 US9970059B2 (en) 2008-06-06 2014-11-13 Survival predictor for diffuse large B cell lymphoma
US15/965,510 Active 2030-11-19 US11028444B2 (en) 2008-06-06 2018-04-27 Survival predictor for diffuse large B cell lymphoma

Country Status (5)

Country Link
US (3) US20110195064A1 (en)
EP (1) EP2294420B8 (en)
CA (1) CA2726811C (en)
ES (1) ES2552937T3 (en)
WO (1) WO2009149359A2 (en)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20160117467A1 (en) * 2012-10-01 2016-04-28 True Health Diagnostics, Llc System and method for automatically generating a historical health trend graph for a patient
US20170091642A1 (en) * 2015-09-24 2017-03-30 Sas Institute Inc. Techniques to provide real-time processing enhancements and modeling for data anomaly detection pertaining to medical events using decision trees
US10607717B2 (en) 2013-11-06 2020-03-31 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Method for subtyping lymphoma types by means of expression profiling
CN114045339A (en) * 2021-11-05 2022-02-15 山东第一医科大学附属省立医院(山东省立医院) Application of iron death related gene in prognosis evaluation of diffuse large B cell lymphoma

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2715348B1 (en) * 2011-06-02 2019-04-10 Almac Diagnostic Services Limited Molecular diagnostic test for cancer
MX2015006955A (en) 2012-12-03 2016-01-25 Almac Diagnostics Ltd Molecular diagnostic test for cancer.
CA2930305A1 (en) 2013-11-19 2015-05-28 Brandeis University Multiplex target detection assay
GB201409479D0 (en) 2014-05-28 2014-07-09 Almac Diagnostics Ltd Molecular diagnostic test for cancer
CA3021569A1 (en) 2016-04-20 2017-10-26 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Evaluation of mantle cell lymphoma and methods related thereto
WO2019065901A1 (en) * 2017-09-29 2019-04-04 国立大学法人九州大学 Method and kit for predicting therapeutic effectiveness of chemotherapy for diffuse large b-cell lymphoma patients

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5445934A (en) * 1989-06-07 1995-08-29 Affymax Technologies N.V. Array of oligonucleotides on a solid substrate
US5744305A (en) * 1989-06-07 1998-04-28 Affymetrix, Inc. Arrays of materials attached to a substrate
US6020198A (en) * 1998-09-25 2000-02-01 Isis Pharmaceuticals Inc. Antisense modulation of RIP-1 expression
US6410229B1 (en) * 1995-09-15 2002-06-25 Affymetrix, Inc. Expression monitoring by hybridization to high density nucleic acid arrays
US20020110820A1 (en) * 2000-09-19 2002-08-15 Sridhar Ramaswamy Genetic markers for tumors
US20030194701A1 (en) * 2000-11-20 2003-10-16 Golub Todd R. Diffuse large cell lymphoma diagnosis and outcome prediction by expression analysis
US20030219760A1 (en) * 2001-09-05 2003-11-27 The Brigham And Women's Hospital, Inc. Diagnostic and prognostic tests
US20050164231A1 (en) * 2003-09-03 2005-07-28 Staudt Louis M. Methods for identifying, diagnosing, and predicting survival of lymphomas

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5527681A (en) 1989-06-07 1996-06-18 Affymax Technologies N.V. Immobilized molecular synthesis of systematically substituted compounds
US5800992A (en) 1989-06-07 1998-09-01 Fodor; Stephen P.A. Method of detecting nucleic acids
US5242974A (en) 1991-11-22 1993-09-07 Affymax Technologies N.V. Polymer reversal on solid surfaces
US5424186A (en) 1989-06-07 1995-06-13 Affymax Technologies N.V. Very large scale immobilized polymer synthesis
US5252743A (en) 1989-11-13 1993-10-12 Affymax Technologies N.V. Spatially-addressable immobilization of anti-ligands on surfaces
EP0834576B1 (en) 1990-12-06 2002-01-16 Affymetrix, Inc. (a Delaware Corporation) Detection of nucleic acid sequences
AU669489B2 (en) 1991-09-18 1996-06-13 Affymax Technologies N.V. Method of synthesizing diverse collections of oligomers
US5324633A (en) 1991-11-22 1994-06-28 Affymax Technologies N.V. Method and apparatus for measuring binding affinity
AU675054B2 (en) 1991-11-22 1997-01-23 Affymetrix, Inc. Combinatorial strategies for polymer synthesis
US5384261A (en) 1991-11-22 1995-01-24 Affymax Technologies N.V. Very large scale immobilized polymer synthesis using mechanically directed flow paths
US5550215A (en) 1991-11-22 1996-08-27 Holmes; Christopher P. Polymer reversal on solid surfaces
US5491074A (en) 1993-04-01 1996-02-13 Affymax Technologies Nv Association peptides
US5858659A (en) 1995-11-29 1999-01-12 Affymetrix, Inc. Polymorphism detection
US5837832A (en) 1993-06-25 1998-11-17 Affymetrix, Inc. Arrays of nucleic acid probes on biological chips
US5578832A (en) 1994-09-02 1996-11-26 Affymetrix, Inc. Method and apparatus for imaging a sample on a device
US5631734A (en) 1994-02-10 1997-05-20 Affymetrix, Inc. Method and apparatus for detection of fluorescently labeled materials
US6090555A (en) 1997-12-11 2000-07-18 Affymetrix, Inc. Scanned image alignment systems and methods
DE69503126T2 (en) 1994-05-05 1998-11-12 Beckman Instruments Inc REPETITIVE OLIGONUCLEOTIDE MATRIX
US5571639A (en) 1994-05-24 1996-11-05 Affymax Technologies N.V. Computer-aided engineering system for design of sequence arrays and lithographic masks
US5795716A (en) 1994-10-21 1998-08-18 Chee; Mark S. Computer-aided visualization and analysis system for sequence evaluation
US5599695A (en) 1995-02-27 1997-02-04 Affymetrix, Inc. Printing molecular library arrays using deprotection agents solely in the vapor phase
US5624711A (en) 1995-04-27 1997-04-29 Affymax Technologies, N.V. Derivatization of solid supports and methods for oligomer synthesis
US5856174A (en) 1995-06-29 1999-01-05 Affymetrix, Inc. Integrated nucleic acid diagnostic device
US5968740A (en) 1995-07-24 1999-10-19 Affymetrix, Inc. Method of Identifying a Base in a Nucleic Acid
JP2000512744A (en) 1996-05-16 2000-09-26 アフィメトリックス，インコーポレイテッド System and method for detecting label material
US6033860A (en) 1997-10-31 2000-03-07 Affymetrix, Inc. Expression profiles in adult and fetal organs
US5936324A (en) 1998-03-30 1999-08-10 Genetic Microsystems Inc. Moving magnet scanner
WO2003021229A2 (en) 2001-09-05 2003-03-13 The Brigham And Women's Hospital, Inc. Diagnostic and prognostic tests
US7309788B2 (en) 2001-09-21 2007-12-18 Boryung Pharmaceutical Co., Ltd. Method for preparing pyrimidinone compound and pharmaceutically acceptable salts thereof
US8131475B2 (en) 2003-09-03 2012-03-06 The United States Of America As Represented By The Secretary, Department Of Health And Human Services Methods for identifying, diagnosing, and predicting survival of lymphomas
US20080051379A1 (en) * 2004-12-01 2008-02-28 Trustees Of Boston University Compositions and Methods for the Treatment of Peripheral B-Cell Neoplasms
US8445198B2 (en) * 2005-12-01 2013-05-21 Medical Prognosis Institute Methods, kits and devices for identifying biomarkers of treatment response and use thereof to predict treatment efficacy
AU2007294575B2 (en) * 2006-09-08 2013-06-27 Viela Bio, Inc. Humanized anti-CD19 antibodies and their use in treatment of oncology, transplantation and autoimmune disease
US20090280493A1 (en) * 2006-09-08 2009-11-12 Siemens Healthcare Diagnostics Inc. Methods and Compositions for the Prediction of Response to Trastuzumab Containing Chemotherapy Regimen in Malignant Neoplasia

Patent Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5445934A (en) * 1989-06-07 1995-08-29 Affymax Technologies N.V. Array of oligonucleotides on a solid substrate
US5744305A (en) * 1989-06-07 1998-04-28 Affymetrix, Inc. Arrays of materials attached to a substrate
US6410229B1 (en) * 1995-09-15 2002-06-25 Affymetrix, Inc. Expression monitoring by hybridization to high density nucleic acid arrays
US6020198A (en) * 1998-09-25 2000-02-01 Isis Pharmaceuticals Inc. Antisense modulation of RIP-1 expression
US20020110820A1 (en) * 2000-09-19 2002-08-15 Sridhar Ramaswamy Genetic markers for tumors
US20030194701A1 (en) * 2000-11-20 2003-10-16 Golub Todd R. Diffuse large cell lymphoma diagnosis and outcome prediction by expression analysis
US20030219760A1 (en) * 2001-09-05 2003-11-27 The Brigham And Women's Hospital, Inc. Diagnostic and prognostic tests
US20050164231A1 (en) * 2003-09-03 2005-07-28 Staudt Louis M. Methods for identifying, diagnosing, and predicting survival of lymphomas
US7711492B2 (en) * 2003-09-03 2010-05-04 The United States Of America As Represented By The Department Of Health And Human Services Methods for diagnosing lymphoma types

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20160117467A1 (en) * 2012-10-01 2016-04-28 True Health Diagnostics, Llc System and method for automatically generating a historical health trend graph for a patient
US10607717B2 (en) 2013-11-06 2020-03-31 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Method for subtyping lymphoma types by means of expression profiling
US11574704B2 (en) 2013-11-06 2023-02-07 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Method for subtyping lymphoma types by means of expression profiling
US20170091642A1 (en) * 2015-09-24 2017-03-30 Sas Institute Inc. Techniques to provide real-time processing enhancements and modeling for data anomaly detection pertaining to medical events using decision trees
US9646258B2 (en) * 2015-09-24 2017-05-09 Sas Institute Inc. Techniques to provide real-time processing enhancements and modeling for data anomaly detection pertaining to medical events using decision trees
CN114045339A (en) * 2021-11-05 2022-02-15 山东第一医科大学附属省立医院(山东省立医院) Application of iron death related gene in prognosis evaluation of diffuse large B cell lymphoma

Also Published As

Publication number Publication date
US20150132297A1 (en) 2015-05-14
US20180245165A1 (en) 2018-08-30
WO2009149359A8 (en) 2011-07-14
EP2294420B8 (en) 2015-10-21
US9970059B2 (en) 2018-05-15
CA2726811A1 (en) 2009-12-10
ES2552937T3 (en) 2015-12-03
EP2294420B1 (en) 2015-08-12
CA2726811C (en) 2019-11-26
WO2009149359A3 (en) 2010-02-25
US11028444B2 (en) 2021-06-08
WO2009149359A2 (en) 2009-12-10
EP2294420A2 (en) 2011-03-16

Similar Documents

Publication Publication Date Title
US11028444B2 (en) Survival predictor for diffuse large B cell lymphoma
US10329624B2 (en) Grading of breast cancer
Badea et al. Combined gene expression analysis of whole-tissue and microdissected pancreatic ductal adenocarcinoma identifies genes specifically overexpressed in tumor epithelia-the authors reported a combined gene expression analysis of whole-tissue and microdissected pancreatic ductal adenocarcinoma identifies genes specifically overexpressed in tumor epithelia
JP5179177B2 (en) Urine marker for detecting bladder cancer
DK2591363T3 (en) DIAGNOSIS AND TREATMENT OF BREAST CANCER
US20090258002A1 (en) Biomarkers for Tissue Status
Hedvat et al. Insights into extramedullary tumour cell growth revealed by expression profiling of human plasmacytomas and multiple myeloma
PT2138848E (en) Method for the diagnosis and/or prognosis of cancer of the bladder
US20120196761A1 (en) Diagnosis of in situ and invasive breast cancer
US20090005258A1 (en) Diagnosis of Metastases in Hnscc Tumours
CA2699434A1 (en) Stroma derived predictor of breast cancer
CA2674211A1 (en) Methods and kits for diagnosis and/or prognosis of the tolerant state in liver transplantation
US10233502B2 (en) Compositions for and methods of detecting, diagnosing, and prognosing thymic cancer
US20070275404A1 (en) Gene expression signatures associated with tumor stromal cells
WO2006019037A1 (en) Method of judging liver fibrosis stage
JP2012527895A (en) Characteristics of B cells associated with immune tolerance in transplant recipients
KR101182974B1 (en) Pellino 1 as a marker for the diagnosis or prognosis of lymphoma
US20120201750A1 (en) Serum biomarkers for melanoma metastasis
US20210054464A1 (en) Methods for subtyping of bladder cancer
JP2008072952A (en) Marker gene for detecting intrahepatic cholangiocarcinoma
KR102163550B1 (en) Urine markers for detection of bladder cancer
WO2015105191A1 (en) Method for assessing lymphadenopathy lesions
WO2023195931A2 (en) Method for detecting high-risk nasopharyngeal cancer
WO2014009798A1 (en) Gene expression profiling using 5 genes to predict prognosis in breast cancer
JPWO2015115545A1 (en) Methods for assessing the risk of breast cancer metastasis or recurrence

Legal Events

Date Code Title Description
AS Assignment

Owner name: BRITISH COLOMBIA CANCER AGENCY BRANCH, CANADA

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:RIMSZA, LISA;LISTER, ANDREW T.;WEISENBURGER, DENNIS;AND OTHERS;SIGNING DATES FROM 20101229 TO 20110207;REEL/FRAME:026037/0117

Owner name: ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSI

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:RIMSZA, LISA;LISTER, ANDREW T.;WEISENBURGER, DENNIS;AND OTHERS;SIGNING DATES FROM 20101229 TO 20110207;REEL/FRAME:026037/0117

Owner name: HOSPITAL CLINIC, SPAIN

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:RIMSZA, LISA;LISTER, ANDREW T.;WEISENBURGER, DENNIS;AND OTHERS;SIGNING DATES FROM 20101229 TO 20110207;REEL/FRAME:026037/0117

Owner name: QUEEN MARY AND WESTFIELD COLLEGE, UNIVERSITY OF LO

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:RIMSZA, LISA;LISTER, ANDREW T.;WEISENBURGER, DENNIS;AND OTHERS;SIGNING DATES FROM 20101229 TO 20110207;REEL/FRAME:026037/0117

Owner name: OREGON HEALTH & SCIENCE UNIVERSITY, OREGON

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:RIMSZA, LISA;LISTER, ANDREW T.;WEISENBURGER, DENNIS;AND OTHERS;SIGNING DATES FROM 20101229 TO 20110207;REEL/FRAME:026037/0117

Owner name: JULIUS-MAXIMILIANS-UNIVERSITY OF WUERZBURG, GERMAN

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:RIMSZA, LISA;LISTER, ANDREW T.;WEISENBURGER, DENNIS;AND OTHERS;SIGNING DATES FROM 20101229 TO 20110207;REEL/FRAME:026037/0117

Owner name: THE UNITED STATES OF AMERICA, AS REPRESENTED BY TH

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:STAUDT, LOUIS M.;REEL/FRAME:026036/0850

Effective date: 20110126

Owner name: UNIVERSITY OF ROCHESTER, NEW YORK

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:RIMSZA, LISA;LISTER, ANDREW T.;WEISENBURGER, DENNIS;AND OTHERS;SIGNING DATES FROM 20101229 TO 20110207;REEL/FRAME:026037/0117

Owner name: UNIVERSITAT DE BARCELONA, SPAIN

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:RIMSZA, LISA;LISTER, ANDREW T.;WEISENBURGER, DENNIS;AND OTHERS;SIGNING DATES FROM 20101229 TO 20110207;REEL/FRAME:026037/0117

Owner name: THE UNITED STATES OF AMERICA, AS REPRESENTED BY TH

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:RIMSZA, LISA;LISTER, ANDREW T.;WEISENBURGER, DENNIS;AND OTHERS;SIGNING DATES FROM 20101229 TO 20110207;REEL/FRAME:026037/0117

Owner name: BOARD OF REGENTS OF THE UNIVERSITY OF NEBRASKA, NE

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:RIMSZA, LISA;LISTER, ANDREW T.;WEISENBURGER, DENNIS;AND OTHERS;SIGNING DATES FROM 20101229 TO 20110207;REEL/FRAME:026037/0117

Owner name: OSLO UNIVERSITY HOSPITAL HF, NORWAY

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:RIMSZA, LISA;LISTER, ANDREW T.;WEISENBURGER, DENNIS;AND OTHERS;SIGNING DATES FROM 20101229 TO 20110207;REEL/FRAME:026037/0117

AS Assignment

Owner name: THE UNITED STATES OF AMERICA, AS REPRESENTED BY TH

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:CHAN, WING C.;REEL/FRAME:027417/0306

Effective date: 20111101

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION